



(51) International Patent Classification:

A61K 38/18 (2006.01) *C07K 14/50* (2006.01)
A61P 3/00 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:

PCT/US2016/060944

(22) International Filing Date:

8 November 2016 (08.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/252,939 9 November 2015 (09.11.2015) US

(71) Applicant: NGM BIOPHARMACEUTICALS, INC.
[US/US]; 333 Oyster Point Blvd., South San Francisco,
CA 94080 (US).

(72) Inventors: LING, Lei; 411 Nantucket Street, Foster City,
CA 94404 (US). LUO, Jian; 992 Ventura Avenue, Al-
bany, CA 94796 (US). TIAN, Hui; 266 Surfbird Isle,
Foster City, CA 94404 (US).


(74) Agents: WEISSER, Tamera, M. et al.; JONES DAY, 250
Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS

**FIG.1**

(57) Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS**Cross-Reference to Related Applications**

This application claims the benefit of priority to U.S. Serial No. 62/252,939 filed November 9, 2015, which is incorporated herein by reference in its entirety.

1. Field

[0001] Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.

2. Summary

[0002] The invention is based, in part, on variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities. In one embodiment, the activity is glucose lowering activity. In another embodiment, the activity is bile acid homeostasis modulating activity. Such variants and fusions (chimeras) of FGF19 and/or FGF21 peptide sequences include sequences that do not substantially or significantly increase or induce hepatocellular carcinoma (HCC) formation or HCC tumorigenesis. Such variants and fusions (chimeras) of FGF19 and/or FGF21 peptide sequences further include sequences that do not induce a substantial elevation or increase in lipid profile.

[0003] In one embodiment, provided herein is a method of modulating bile acid homeostasis, comprising administering a chimeric peptide sequence provided herein. Also provided herein is a method of treating a bile acid-related disorder, comprising administering a chimeric peptide sequence provided herein. In another embodiment, provided herein is a method of treating a bile acid-associated disorder comprising administering a chimeric peptide sequence provided herein. In specific embodiments, an effective amount of the chimeric peptide sequence is administered.

[0004] In one embodiment, a chimeric peptide sequence comprises or consists of: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL

(SEQ ID NO:121) or DASPH (SEQ ID NO:122); and b) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 (FGF19) (WGDPIRLRHLTYTSG; SEQ ID NO:169), wherein the W residue corresponds to the first amino acid position of the C-terminal region.

[0005] In another embodiment, the treatment peptide, comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122); and b) a C-terminal region comprising a portion of SEQ ID NO:99 [FGF19], the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises (i) a first C-terminal region sequence comprising WGDPIRLRHLTYTSG (amino acids 16 to 29 of SEQ ID NO:99 [FGF19]), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and (ii) a second C-terminal region sequence comprising
PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRTVAIKGVHVSRYLCMGADGKMQGL
LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFEEK (amino acid residues 30 to 194 of SEQ ID NO:99 [FGF19]).

In certain embodiments, the peptide (i) binds to fibroblast growth factor receptor 4 (FGFR4) with an affinity equal to or greater than FGF19 binding affinity for FGFR4; (ii) activates FGFR4 to an extent or amount equal to or greater than FGF19 activates FGFR4; (iii) has at least one of reduced hepatocellular carcinoma (HCC) formation; greater glucose lowering activity, less lipid increasing activity, less triglyceride activity, less cholesterol activity, less non-HDL activity or less HDL increasing activity, as compared to FGF19, or as compared to an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19 (SEQ ID NO:99); and/or (iv) has less lean mass reducing activity as compared to FGF21.

[0006] In some embodiments, the second C-terminal region sequence of the treatment peptide comprises from 1 to 5 amino acid substitutions, deletions or insertions. In some embodiments, the treatment peptide is less than about 250 amino acids in length.

[0007] In one embodiment, the treatment peptide has an amino acid sequence comprising or consisting of

MRDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (SEQ ID NO:70). In certain embodiments, the treatment peptide has an amino acid sequence comprising SEQ ID NO:70. In other embodiments, the treatment peptide has an amino acid sequence consisting of SEQ ID NO:70. In some embodiments, the treatment peptide is fused with an immunoglobulin Fc region.

[0008] In another embodiment, the treatment peptide has an amino acid sequence comprising or consisting of

RDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (SEQ ID NO:69). In certain embodiments, the treatment peptide has an amino acid sequence comprising SEQ ID NO:69. In other embodiments, the treatment peptide has an amino acid sequence consisting of SEQ ID NO:69. In some embodiments, the treatment peptide is fused with an immunoglobulin Fc region.

[0009] In another embodiment, a chimeric peptide sequence comprises or consists of: a) an N-terminal region comprising a portion of SEQ ID NO:100 (FGF21), the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises amino acid residues GQV, and wherein the V residue corresponds to the last amino acid position of the N-terminal region; and b) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 21-29 of SEQ ID NO:99 (FGF19), RLRHLTYTSG (SEQ ID NO:185), and wherein the R residue corresponds to the first position of the C-terminal region.

[0010] In a further embodiment, a chimeric peptide sequence comprises or consists of any of: a) an N-terminal region comprising a portion of SEQ ID NO:100 (FGF21), the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises at least 5 contiguous amino acids of SEQ ID NO:100 (FGF21) including the amino acid residues GQV, and wherein the V residue corresponds to the last amino acid position of the N-terminal region; and b) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-

terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 21-29 of SEQ ID NO:99 (FGF19), RLRHLYTSG (SEQ ID NO:185), and wherein the R residue corresponds to the first position of the C-terminal region.

[0011] In an additional embodiment, a peptide sequence comprises or consists of any of: a) a FGF19 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19; b) a FGF21 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF21; c) a portion of an FGF19 sequence fused to a portion of an FGF21 sequence; or d) a portion of an FGF19 sequence fused to a portion of an FGF21 sequence, wherein the FGF19 and/or FGF21 sequence portion(s) have one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19 and/or FGF21.

[0012] In particular aspects, the N-terminal region comprises at least 6 contiguous amino acids (or more, *e.g.*, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-40, 40-50, 50-75, 75-100 contiguous amino acids) of SEQ ID NO:100 (FGF21), including the amino acid residues GQ; or has an N-terminal region with at least 7 contiguous amino acids (or more, *e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-40, 40-50, 50-75, 75-100 contiguous amino acids) of SEQ ID NO:100 (FGF21), including the amino acid residues GQV.

[0013] In some embodiments, the peptide comprises i) a FGF19 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19; ii) a FGF21 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF21; iii) a portion of a FGF19 sequence fused to a portion of a FGF21 sequence; or iv) a portion of a FGF19 sequence fused to a portion of a FGF21 sequence, wherein the FGF19 and/or FGF21 sequence portion(s) have one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19 and/or FGF21.

[0014] In still further embodiments, a peptide sequence or a chimeric peptide sequence comprises or consists of amino-terminal amino acids 1-16 of SEQ ID NO:100 (FGF21) fused to carboxy-terminal amino acids 21-194 of SEQ ID NO:99 (FGF19), or the peptide sequence has amino-terminal amino acids 1-147 of SEQ ID NO:99 (FGF19) fused to carboxy-terminal amino acids 147-181 of SEQ ID NO:100 (FGF21) (M41), or the peptide sequence has amino-terminal amino acids 1-20 of SEQ ID NO:99 (FGF19) fused to carboxy-terminal amino acids 17-181 of SEQ ID

NO:100 (FGF21) (M44), or the peptide sequence has amino-terminal amino acids 1-146 of SEQ ID NO:100 (FGF21) fused to carboxy-terminal amino acids 148-194 of SEQ ID NO:99 (FGF19) (M45), or the peptide sequence has amino-terminal amino acids 1-20 of SEQ ID NO:99 (FGF19) fused to internal amino acids 17-146 of SEQ ID NO:100 (FGF21) or fused to carboxy-terminal amino acids 148-194 of SEQ ID NO:99 (FGF19) (M46).

[0015] In various further embodiments, a peptide sequence has at least one amino acid substitution to amino acid residues 125-129 of SEQ ID NO:99 (FGF19), EIRPD; at least one amino acid substitution to amino acid residues 126-128 of SEQ ID NO:99 (FGF19), IRP; or at least one amino acid substitution to amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP, or at least one amino acid substitution to amino acid residues 1-124 of SEQ ID NO:99 (FGF19) and/or to amino acid residues 130-194 of SEQ ID NO:99 (FGF19). More specifically, for example, a peptide sequence with a substitution to one of amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP, wherein at least one amino acid substitution is R127L or P128E. Said substitutions within a corresponding FGF19 sequence (*e.g.*, EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated. In certain embodiments, the peptide comprises both a R127L and P128E substitution to amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP, or the corresponding FGF19 sequence thereof in a variant peptide provided herein. In certain embodiments, the amino acid sequence of the peptide comprises at least one amino acid substitution in the Loop-8 region of FGF19, or the corresponding FGF19 sequence thereof in a variant peptide provided herein. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises four amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises five amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the IRP (amino acids 3-5 of

SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution. In other embodiments, the substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is a Pro (P) to Glu (E) substitution. In some embodiments, the substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution and a Pro (P) to Glu (E) substitution. In specific embodiments, the foregoing substitution(s) in the Loop-8 region of FGF19 is in the corresponding FGF19 sequence thereof in a variant peptide provided herein. That is, said substitutions within a corresponding FGF19 sequence (*e.g.*, EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated.

[0016] Methods and uses provided herein can be practiced using a peptide or chimeric sequence, as set forth herein. For example, a sequence that comprises or consists of any peptide sequence set forth herein as M1 to M98, M101 to M160, or M200 to M207 or SEQ ID NOs:1 to 98, 101 to 135, 138 to 205 a peptide sequence that comprises or consists of any sequence set forth in Tables 1-11, or a peptide sequence that comprises or consists of any sequence set forth in the Sequence Listing herein.

[0017] In some embodiments, the peptide is a variant peptide designated M139. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:193. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:193. In some embodiments, the peptide is a variant peptide designated M140. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:194. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:194. In some embodiments, the peptide is a variant peptide designated M141. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:195. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:195. In some embodiments, the peptide is a variant peptide designated M160. In some embodiments, the peptide comprises an amino acid sequence set forth in

SEQ ID NO:196. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:196. In some embodiments, the peptide is a variant peptide designated M200. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:197. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:197. In some embodiments, the peptide is a variant peptide designated M201. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide is a variant peptide designated M202. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:199. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:199. In certain embodiments, the peptide is a variant peptide designated M203. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:200. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:200. In some embodiments, the peptide is a variant peptide designated M204. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:201. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:201. In another embodiment, the peptide is a variant peptide designated M205. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide is a variant peptide designated M206. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:203. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:203. In yet other embodiments, the peptide is a variant peptide designated M207. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:204. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:204.

[0018] In some embodiments, the N-terminal R residue is deleted. In other embodiments, the peptide comprises at least one (*e.g.*, from 1 to 20, from 1 to 15, from 1 to 10 or from 1 to 5) amino acid substitution(s). In another embodiment, the peptide comprises at least one (*e.g.*, from 1 to 20, from 1 to 15, from 1 to 10 or from 1 to 5) amino acid deletion(s). In other embodiments, the peptide comprises at least one (*e.g.*, from 1 to 20, from 1 to 15, from 1 to 10 or from 1 to 5) amino acid insertion(s).

[0019] Methods and uses provided herein can be practiced using a peptide or chimeric sequence of any suitable length. In particular embodiments, the N-terminal or C-terminal region of the peptide or chimeric sequence is from about 20 to about 200 amino acid residues in length. In other particular

aspects, a peptide or chimeric sequence has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid deletions from the amino terminus, the carboxy-terminus or internally. In further particular embodiments, a peptide or chimeric sequence has an N-terminal region, or a C-terminal region that comprises or consists of an amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino acids. In additional more particular embodiments, a peptide or chimeric sequence has an FGF19 sequence portion, or an FGF21 sequence portion that comprises or consists of an amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino acids of FGF19 or FGF21.

[0020] In yet additional embodiments, a peptide sequence or a chimeric peptide sequence has a WGDPI (SEQ ID NO:170) sequence motif corresponding to the WGDPI sequence of amino acids 16-20 of SEQ ID NO:99 (FGF19); has a substituted, mutated or absent WGDPI (SEQ ID NO:170) sequence motif corresponding to FGF19 WGDPI (SEQ ID NO:170) sequence of amino acids 16-20 of FGF19; has a WGDPI (SEQ ID NO:170) sequence with one or more amino acids substituted, mutated or absent. In various other further aspects, the peptide sequence is distinct from an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the FGF19 WGDPI (SEQ ID NO:170) sequence at amino acids 16-20.

[0021] In yet further embodiments, a peptide sequence or a chimeric peptide sequence has N-terminal region comprises amino acid residues VHYG (SEQ ID NO:101), wherein the N-terminal region comprises amino acid residues DASPHVHYG (SEQ ID NO:102), or the N-terminal region comprises amino acid residues DSSPLVHYG (SEQ ID NO:103). More particularly, in one aspect the G corresponds to the last position of the N-terminal region.

[0022] In various additional aspects, the N-terminal region comprises amino acid residues DSSPLLQ (SEQ ID NO:104), where the Q residue is the last amino acid position of the N-terminal region, or comprises amino acid residues DSSPLLQFGGQV (SEQ ID NO:105), where the V residue corresponds to the last position of the N-terminal region.

[0023] In certain embodiments, an N-terminal region comprises or consists of (or further comprises or consists of): RHPIP (SEQ ID NO:106), where R is the first amino acid position of the N-terminal region; or HPIP (SEQ ID NO:107), where H is the first amino acid position of the N-

terminal region; or RPLAF (SEQ ID NO:108), where R is the first amino acid position of the N-terminal region; or PLAF (SEQ ID NO:109), where P is the first amino acid position of the N-terminal region; or R, where R is the first amino acid position of the N-terminal region.

[0024] In various other aspects, a peptide or chimeric sequence has: amino acid residues HPIP (SEQ ID NO:107), which are the first 4 amino acid residues of the N-terminal region. In various still further aspects, a peptide or chimeric sequence has: an R residue at the first position of the N-terminal region, or the first position of the N-terminal region is an M residue, or the first and second positions of the N-terminal region is an MR sequence, or the first and second positions of the N-terminal region is an RM sequence, or the first and second positions of the N-terminal region is an RD sequence, or the first and second positions of the N-terminal region is an DS sequence, or the first and second positions of the N-terminal region is an MD sequence, or the first and second positions of the N-terminal region is an MS sequence, or the first through third positions of the N-terminal region is an MDS sequence, or the first through third positions of the N-terminal region is an RDS sequence, or the first through third positions of the N-terminal region is an MSD sequence, or the first through third positions of the N-terminal region is an MSS sequence, or the first through third positions of the N-terminal region is an DSS sequence, or the first through fourth positions of the N-terminal region is an RDSS (SEQ ID NO:115), sequence, or the first through fourth positions of the N-terminal region is an MDSS (SEQ ID NO:116), sequence, or the first through fifth positions of the N-terminal region is an MRDSS (SEQ ID NO:117), sequence, or the first through fifth positions of the N-terminal region is an MSSPL (SEQ ID NO:113) sequence, or the first through sixth positions of the N-terminal region is an MDSSPL (SEQ ID NO:110) sequence, or the first through seventh positions of the N-terminal region is an MSDSSPL (SEQ ID NO:111) sequence.

[0025] In various other particular aspects, a peptide or chimeric sequence has at the N-terminal region first amino acid position an “M” residue, an “R” residue, a “S” residue, a “H” residue, a “P” residue, a “L” residue or an “D” residue. In various alternative particular aspects, a peptide or chimeric sequence peptide sequence does not have a “M” residue or an “R” residue at the first amino acid position of the N-terminal region.

[0026] In further various other aspects, a peptide or chimeric sequence has an N-terminal region with any one of the following sequences: MDSSPL (SEQ ID NO:110), MSDSSPL (SEQ ID NO:111), SDSSPL (SEQ ID NO:112), MSSPL (SEQ ID NO:113) or SSPL (SEQ ID NO:114).

[0027] In some embodiments, a peptide sequence or a chimeric peptide sequence has a residue at the last position of the C-terminal region that corresponds to about residue 194 of SEQ ID NO:99 (FGF19). In still other embodiments, a peptide sequence or a chimeric peptide sequence an addition

of amino acid residues 30-194 of SEQ ID NO:99 (FGF19) at the C-terminus, resulting in a chimeric polypeptide having a residue at the last position of the C-terminal region that corresponds to about residue 194 of SEQ ID NO:99 (FGF19). In further other embodiments, a chimeric peptide sequence or peptide sequence comprises all or a portion of an FGF19 sequence (*e.g.*, SEQ ID NO:99), positioned at the C-terminus of the peptide, or where the amino terminal “R” residue is deleted from the peptide.

[0028] In more particular embodiments, a chimeric peptide sequence or peptide sequence comprises or consists of any of M1 to M98, M101 to M160, or M200 to M207 variant peptide sequences, or a subsequence or fragment of any of the M1 to M98, M101 to M160, or M200 to M207 variant peptide sequences. Methods and uses provided herein can also be practiced using a peptide or chimeric sequence, as set forth herein. For example, a sequence that comprises or consists of any peptide sequence set forth herein as M1 to M98, M101 to M160, or M200 to M207 or SEQ ID NOs: 1 to 98, 101 to 135, 138 to 205 a peptide sequence that comprises or consists of any sequence set forth in Tables 1-11 or a peptide sequence that comprises or consists of any sequence set forth in the Sequence Listing herein.

[0029] In various more particular aspects, a peptide sequence comprises or consists of any one of the following sequences:

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M3) (SEQ ID NO:3);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIREDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M140) (SEQ ID NO:194);

RPLAFSDAGPHVHYGWGDPIRQRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M160) (SEQ ID NO:196);

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRT
VAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQ

RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M69) (SEQ ID NO:69);

RDSSPLLQWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K (M52) (SEQ ID NO:52);

RHIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M5) (SEQ ID NO:5);

HPIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M5-R) (SEQ ID NO:160);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGS LHFDPEACSFRELLEDGYNVYQSEAHSLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (M71) (SEQ
ID NO:71);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGS LHFDPEACSFRELLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPAPPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (M72) (SEQ
ID NO:72);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGS LHFDPEACSFRELLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVVQDELQGVGGEGCHMHPE
NCKTLLTDIDRTHTEKPVWDGITGE (M73) (SEQ ID NO:73);

RPLAFSDASPHVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M1) (SEQ ID NO:1 or 139);

RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSL S
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSF EK (M2) (SEQ ID NO:2 or 140);

RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTVAI
KGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K (M48) (SEQ ID NO:48 or 6 or 148);

RPLAFSDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV AL
RTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSA
KQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVR
SPSF EK (M49) (SEQ ID NO:49 or 7 or 149);

RHIPDSSPLLQFGDQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALR
TVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEILEDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M50) (SEQ ID NO:50);

RHIPDSSPLLQFGGNVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALR
TVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M51) (SEQ ID NO:51 or 36 or 155);

MDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTVA
IKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K (M53) (SEQ ID NO:192);

MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALR
TVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M70) (SEQ ID NO:70);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEILPDGYNVYRSEKHRLPVSL

SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M139) (SEQ ID NO:193); or

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE EEEILCDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M141) (SEQ ID NO:195);

or a subsequence or fragment of any of the foregoing peptide sequences. In certain embodiments of any of the foregoing peptide sequences, the R terminal residue (R residue at the N-terminus) is deleted.

[0030] In other embodiments, the peptide comprises or consists of:

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRT
VAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M200) (SEQ ID NO:197); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0031] In some embodiments, the peptide comprises or consists of:

RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSL
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSFEK (M201) (SEQ ID NO:198); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0032] In certain embodiments, the peptide comprises or consists of:

RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M202) (SEQ ID NO:199); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0033] In other embodiments, the peptide comprises or consists of:

RDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTVAI
KGVH SVRYLCMGADGKMQLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE

K (M203) (SEQ ID NO:200); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0034] In some embodiments, the peptide comprises or consists of:

RHPIPDSSPLLQFGDQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEILEDGYNVYRSEKHRLPVSLSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M204) (SEQ ID NO:201); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0035] In certain embodiments, the peptide comprises or consists of:

RDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEILEDGYNVYRSEKHRLPVSLSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K (M205) (SEQ ID NO:202); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0036] In some embodiments, the peptide comprises or consists of:

RHPIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEILEDGYNVYRSEKHRLPVSLSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M206) (SEQ ID NO:203); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0037] In other embodiments, the peptide comprises or consists of:

MRDSSPLVHYGWGDIPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEILEDGYNVYRSEKHRLPVSLSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M207) (SEQ ID NO:204); or a subsequence or fragment thereof.

[0038] In some embodiments, the peptide is a variant peptide designated M139. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:193. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:193. In some embodiments, the peptide is a variant peptide designated M140. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:194. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:194. In some embodiments, the peptide is a variant peptide designated M141. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:195. In other embodiments, the peptide consists of an amino acid

sequence set forth in SEQ ID NO:195. In some embodiments, the peptide is a variant peptide designated M160. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:196. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:196. In some embodiments, the peptide is a variant peptide designated M200. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:197. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:197. In some embodiments, the peptide is a variant peptide designated M201. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide is a variant peptide designated M202. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:199. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:199. In certain embodiments, the peptide is a variant peptide designated M203. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:200. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:200. In some embodiments, the peptide is a variant peptide designated M204. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:201. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:201. In another embodiment, the peptide is a variant peptide designated M205. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide is a variant peptide designated M206. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:203. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:203. In yet other embodiments, the peptide is a variant peptide designated M207. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:204. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:204.

[0039] In various additional particular aspects, the N-terminus of the peptide sequence includes or consists of any of:

HPIPDSSPLLQFGGQVRLRHLTYTSG (M5-R) (amino acids 1-25 of SEQ ID NO:160);

DSSPLLQFGGQVRLRHLTYTSG (M6-R) (amino acids 2-22 of SEQ ID NO:6);

RPLAFSDSSPLLQFGGQVRLRHLTYTSG (M7) (amino acids 1-27 of SEQ ID NO:7);

HPIPDSSPLLQWGDPIRLRHLTYTSG (M8-R) (amino acids 2-26 of SEQ ID NO:8);

HPIPDSSPLLQFGWGDPIRLRHLTYTSG (M9-R) (amino acids 2-28 of SEQ ID NO:9);

HPIPDSSPHVHYGWGDPIRLRHLYTSG (M10-R) (amino acids 2-28 of SEQ ID NO:10);
RPLAFSDAGPLLQWGDPIRLRHLYTSG (M11) (amino acids 1-27 of SEQ ID NO:11);
RPLAFSDAGPLLQFGWGDPIRLRHLYTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
RPLAFSDAGPLLQFGGQVRLRHLYTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
HPIPDSSPHVHYGGQVRLRHLYTSG (M14-R) (amino acids 2-26 of SEQ ID NO:14);
RPLAFSDAGPHVHYGGQVRLRHLYTSG (M15) (amino acids 1-27 of SEQ ID NO:15);
RPLAFSDAGPHVHWGDPIRLRHLYTSG (M16) (amino acids 1-27 of SEQ ID NO:16);
RPLAFSDAGPHVGWGDPIRLRHLYTSG (M17) (amino acids 1-27 of SEQ ID NO:17);
RPLAFSDAGPHYGWGDPIRLRHLYTSG (M18) (amino acids 1-27 of SEQ ID NO:18);
RPLAFSDAGPVYGWGDPIRLRHLYTSG (M19) (amino acids 1-27 of SEQ ID NO:19);
RPLAFSDAGPVHGWGDPIRLRHLYTSG (M20) (amino acids 1-27 of SEQ ID NO:20);
RPLAFSDAGPVHYWGDPIRLRHLYTSG (M21) (amino acids 1-27 of SEQ ID NO:21);
RPLAFSDAGPHVHWGDPIRLRHLYTSG (M22) (amino acids 1-27 of SEQ ID NO:22);
RPLAFSDAGPHHWGDPIRLRHLYTSG (M23) (amino acids 1-27 of SEQ ID NO:23);
RPLAFSDAGPHHYWGDPIRLRHLYTSG (M24) (amino acids 1-27 of SEQ ID NO:24);
RPLAFSDAGPHVYWGDPIRLRHLYTSG (M25) (amino acids 1-27 of SEQ ID NO:25);
RPLAFSDSSPLVHWGDPIRLRHLYTSG (M26) (amino acids 1-27 of SEQ ID NO:26);
RPLAFSDSSPHVHWGDPIRLRHLYTSG (M27) (amino acids 1-27 of SEQ ID NO:27);
RPLAFSDAGPHVWGDPIRLRHLYTSG (M28) (amino acids 1-26 of SEQ ID NO:28);
RPLAFSDAGPHVHYWGDPIRLRHLYTSG (M29) (amino acids 1-28 of SEQ ID NO:29);
RPLAFSDAGPHVHYAWGDPIRLRHLYTSG (M30) (amino acids 1-29 of SEQ ID NO:30);
RHPIPDSSPLLQFGAQVRLRHLYTSG (M31) (amino acids 1-26 of SEQ ID NO:31);
RHPIPDSSPLLQFGDQVRLRHLYTSG (M32) (amino acids 1-26 of SEQ ID NO:32);
RHPIPDSSPLLQFGPQVRLRHLYTSG (M33) (amino acids 1-26 of SEQ ID NO:33);
RHPIPDSSPLLQFGGAVRLRHLYTSG (M34) (amino acids 1-26 of SEQ ID NO:34);
RHPIPDSSPLLQFGGEVRLRHLYTSG (M35) (amino acids 1-26 of SEQ ID NO:35);
RHPIPDSSPLLQFGGNVRLRHLYTSG (M36) (amino acids 1-26 of SEQ ID NO:36);
RHPIPDSSPLLQFGGQARLRHLYTSG (M37) (amino acids 1-26 of SEQ ID NO:37);
RHPIPDSSPLLQFGGQIRLRHLYTSG (M38) (amino acids 1-26 of SEQ ID NO:38);
RHPIPDSSPLLQFGGQTRLRHLYTSG (M39) (amino acids 1-26 of SEQ ID NO:39);
RHPIPDSSPLLQFGWGQPVRLRHLYTSG (M40) (amino acids 1-28 of SEQ ID NO:40);
DAGPHVHYGWGDPIRLRHLYTSG (M74-R) (amino acids 2-24 of SEQ ID NO:74);
VHYGWGDPIRLRHLYTSG (M75-R) (amino acids 2-19 of SEQ ID NO:75);

RLRHLYTSG (M77-R) (amino acids 2-10 of SEQ ID NO:77);
 RHPIPDSSPLLQFGWGDPIRLRHLYTSG (M9) (amino acids 1-28 of SEQ ID NO:9);
 RHPIPDSSPLLQWGDPIRLRHLYTSG (M8) (amino acids 1-26 of SEQ ID NO:8);
 RPLAFSDAGPLLQFGWGDPIRLRHLYTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
 RHPIPDSSPHVHYGWGDPIRLRHLYTSG (M10) (amino acids 1-28 of SEQ ID NO:10);
 RPLAFSDAGPLLQFGGQVRLRHLYTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 RHPIPDSSPHVHYGGQVRLRHLYTSG (M14) (amino acids 1-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGDIRLRHLYTSG (M43) (amino acids 1-27 of SEQ ID NO:43); or
 RDSSPLLQFGGQVRLRHLYTSG (M6) (amino acids 1-22 of SEQ ID NO:6). In certain
 embodiments, the peptide comprises or consists of any of:

[0040] HPIPDSSPLLQFGGQVRLRHLYTSG (M5-R) (amino acids 1-25 of SEQ ID NO:160);
 DSSPLLQFGGQVRLRHLYTSG (M6-R) (amino acids 2-22 of SEQ ID NO:6);
 RPLAFSDSSPLLQFGGQVRLRHLYTSG (M7) (amino acids 1-27 of SEQ ID NO:7);
 HPIPDSSPLLQWGDPIRLRHLYTSG (M8-R) (amino acids 2-26 of SEQ ID NO:8);
 HPIPDSSPLLQFGWGDPIRLRHLYTSG (M9-R) (amino acids 2-28 of SEQ ID NO:9);
 HPIPDSSPHVHYGWGDPIRLRHLYTSG (M10-R) (amino acids 2-28 of SEQ ID NO:10);
 RPLAFSDAGPLLQWGDPIRLRHLYTSG (M11) (amino acids 1-27 of SEQ ID NO:11);
 RPLAFSDAGPLLQFGWGDPIRLRHLYTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
 RPLAFSDAGPLLQFGGQVRLRHLYTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 HPIPDSSPHVHYGGQVRLRHLYTSG (M14-R) (amino acids 2-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGQVRLRHLYTSG (M15) (amino acids 1-27 of SEQ ID NO:15);
 RPLAFSDAGPHVHWGDPIRLRHLYTSG (M16) (amino acids 1-27 of SEQ ID NO:16);
 RPLAFSDAGPHVGWGDPIRLRHLYTSG (M17) (amino acids 1-27 of SEQ ID NO:17);
 RPLAFSDAGPHYGWGDPIRLRHLYTSG (M18) (amino acids 1-27 of SEQ ID NO:18);
 RPLAFSDAGPVYGWGDPIRLRHLYTSG (M19) (amino acids 1-27 of SEQ ID NO:19);
 RPLAFSDAGPVHGWGDPIRLRHLYTSG (M20) (amino acids 1-27 of SEQ ID NO:20);
 RPLAFSDAGPVHYWGDPIRLRHLYTSG (M21) (amino acids 1-27 of SEQ ID NO:21);
 RPLAFSDAGPHVHWGDPIRLRHLYTSG (M22) (amino acids 1-27 of SEQ ID NO:22);
 RPLAFSDAGPHHWGDPIRLRHLYTSG (M23) (amino acids 1-27 of SEQ ID NO:23);
 RPLAFSDAGPHHYWGDPIRLRHLYTSG (M24) (amino acids 1-27 of SEQ ID NO:24);
 RPLAFSDAGPHVYWGDPIRLRHLYTSG (M25) (amino acids 1-27 of SEQ ID NO:25);
 RPLAFSDSSPLVHWGDPIRLRHLYTSG (M26) (amino acids 1-27 of SEQ ID NO:26);
 RPLAFSDSSPHVHWGDPIRLRHLYTSG (M27) (amino acids 1-27 of SEQ ID NO:27);

RPLAFSDAGPHVWGDPIRLRHLTYTSG (M28) (amino acids 1-26 of SEQ ID NO:28);
 RPLAFSDAGPHVHYWGDPIRLRHLTYTSG (M29) (amino acids 1-28 of SEQ ID NO:29);
 RPLAFSDAGPHVHYAWGDPIRLRHLTYTSG (M30) (amino acids 1-29 of SEQ ID NO:30);
 RHPIPDSSPLLQFGAQVRLRHLTYTSG (M31) (amino acids 1-26 of SEQ ID NO:31);
 RHPIPDSSPLLQFGDQVRLRHLTYTSG (M32) (amino acids 1-26 of SEQ ID NO:32);
 RHPIPDSSPLLQFGPQVRLRHLTYTSG (M33) (amino acids 1-26 of SEQ ID NO:33);
 RHPIPDSSPLLQFGGAVRLRHLTYTSG (M34) (amino acids 1-26 of SEQ ID NO:34);
 RHPIPDSSPLLQFGGEVRLRHLTYTSG (M35) (amino acids 1-26 of SEQ ID NO:35);
 RHPIPDSSPLLQFGGNVRLRHLTYTSG (M36) (amino acids 1-26 of SEQ ID NO:36);
 RHPIPDSSPLLQFGGQARLRHLTYTSG (M37) (amino acids 1-26 of SEQ ID NO:37);
 RHPIPDSSPLLQFGGQIRLRHLTYTSG (M38) (amino acids 1-26 of SEQ ID NO:38);
 RHPIPDSSPLLQFGGQTRLRHLTYTSG (M39) (amino acids 1-26 of SEQ ID NO:39);
 RHPIPDSSPLLQFGWGQPVRLRHLTYTSG (M40) (amino acids 1-28 of SEQ ID NO:40);
 DAGPHVHYGWGDPIRLRHLTYTSG (M74-R) (amino acids 2-24 of SEQ ID NO:74);
 VHYGWGDPIRLRHLTYTSG (M75-R) (amino acids 2-19 of SEQ ID NO:75);
 LLRHLTYTSG (M77-R) (amino acids 2-10 of SEQ ID NO:77);
 RHPIPDSSPLLQFGWGDPIRLRHLTYTSG (M9) (amino acids 1-28 of SEQ ID NO:9);
 RHPIPDSSPLLQWGDPIRLRHLTYTSG (M8) (amino acids 1-26 of SEQ ID NO:8);
 RPLAFSDAGPLLQFGWGDPIRLRHLTYTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
 RHPIPDSSPHVHYGWGDPIRLRHLTYTSG (M10) (amino acids 1-28 of SEQ ID NO:10);
 RPLAFSDAGPLLQFGGQVRLRHLTYTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 RHPIPDSSPHVHYGGQVRLRHLTYTSG (M14) (amino acids 1-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGDIRLRHLTYTSG (M43) amino acids 1-27 of SEQ ID NO:43); or
 RDSSPLLQFGGQVRLRHLTYTSG (M6) (amino acids 1-22 of SEQ ID NO:6). In some
 embodiments, the peptide comprises a C-terminal region comprising a portion of SEQ ID NO:99
 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position,
 wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 (FGF19),
 WGDPIRLRHLTYTSG (SEQ ID NO:169), wherein the W residue corresponds to the first amino acid
 position of the C-terminal region.

[0041] In various further particular aspects, a peptide sequence includes or consists of:
 HPIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLSLEIKAVLRT
 VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ

RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (SEQ ID NO:160);

DSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA VALRTVAI
KGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K (SEQ ID NO:138 or 161);

RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (SEQ ID NO:1 or 139);

RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSL
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSFEK (SEQ ID NO:2 or 140); or

DSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTV
AIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQR
QLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF
EK (SEQ ID NO:141);

or a subsequence or fragment thereof of any of the foregoing peptide sequences. In certain embodiments of any of the foregoing peptide sequences, the R terminal residue is deleted.

[0042] In certain embodiments, a peptide sequence includes the addition of amino acid residues 30-194 of SEQ ID NO:99 (FGF19) at the C-terminus, resulting in a chimeric polypeptide. In some embodiments, a peptide sequence has at least one amino acid substitution to amino acid residues 125-129 of SEQ ID NO:99 (FGF19), EIRPD. In other embodiments, the peptide sequence has at least one amino acid substitution to amino acid residues 126-128 of SEQ ID NO:99 (FGF19), IRP. In other embodiments, the peptide sequence has at least one amino acid substitution to amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP. In other embodiments, the peptide sequence has at least one amino acid substitution to amino acid residues 1-124 of SEQ ID NO:99 (FGF19) and/or to amino acid residues 130-194 of SEQ ID NO:99 (FGF19). For example, in certain embodiments, a peptide sequence comprises substitution to one of amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP, wherein at least one amino acid substitution is R127L or P128E. Said substitutions

within a corresponding FGF19 sequence (*e.g.*, EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated. In certain embodiments, the peptide comprises both a R127L and P128E substitution to amino acid residues 127-128 of SEQ ID NO:99 (FGF19), RP, or the corresponding FGF19 sequence thereof in a variant peptide provided herein. . In certain embodiments, the amino acid sequence of the peptide comprises at least one amino acid substitution in the Loop-8 region of FGF19, or the corresponding FGF19 sequence thereof in a variant peptide provided herein. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises four amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises five amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution. In other embodiments, the substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is a Pro (P) to Glu (E) substitution. In some embodiments, the substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution and a Pro (P) to Glu (E) substitution. In

specific embodiments, the foregoing substitution(s) in the Loop-8 region of FGF19 is in the corresponding FGF19 sequence thereof in a variant peptide provided herein. That is, said substitutions within a corresponding FGF19 sequence (*e.g.*, EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated.

[0043] Methods and uses provided herein can be practiced using a peptide or chimeric sequence of any suitable length. In particular embodiments, the N-terminal or C-terminal region of the peptide or chimeric sequence is from about 20 to about 200 amino acid residues in length. In further particular embodiments, a chimeric peptide sequence or peptide sequence has at least one amino acid deletion. In other particular aspects, a peptide or chimeric sequence has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid deletions from the amino terminus, the carboxy-terminus or internally. In one embodiment, the amino acid substitution, or deletion is at any of amino acid positions 8-20 of FGF19 (AGPHVHYGWGDPI) (SEQ ID NO:187). In further particular embodiments, a peptide or chimeric sequence has an N-terminal region, or a C-terminal region that comprises or consists of an amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino acids. In additional more particular embodiments, a peptide or chimeric sequence has an FGF19 sequence portion, or an FGF21 sequence portion that comprises or consists of an amino acid sequence of about 5 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90, 90 to 100 or more amino acids of FGF19 or FGF21.

[0044] In various further embodiments, a peptide or chimeric sequence has an amino acid substitution, an addition, insertion or is a subsequence that has at least one amino acid deleted. Such amino acid substitutions, additions, insertions and deletions of a peptide sequence can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues (10-20, 20-30, 30-40, 40-50, *etc.*), for example, at the N- or C-terminus, or internal. For example, a subsequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid deletions from the amino terminus, the carboxy-terminus or internally. In a particular aspect, the amino acid substitution, or deletion is at any of amino acid positions 8-20 of FGF19 (AGPHVHYGWGDPI) (SEQ ID NO:187).

[0045] In various still more particular aspects, a peptide or chimeric sequence includes all or a portion of an FGF19 sequence set forth as:

PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGL
LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:188) positioned at
the C-terminus of the peptide, or the amino terminal “R” residue is deleted from the sequence.

[0046] In various embodiments, a peptide or chimeric sequence has a function or activity greater or less than a comparison sequence. In further particular embodiments, chimeric peptide sequences and peptide sequences have particular functions or activities. In one aspect, a chimeric peptide sequence or peptide sequence maintains or increases a fibroblast growth factor receptor 4 (FGFR4) mediated activity. In additional aspects, a chimeric peptide sequence or peptide sequence binds to FGFR4 or activates FGFR4, or does not detectably bind to FGFR4 or activate FGFR4, or binds to FGFR4 with an affinity less than, comparable to or greater than FGF19 binding affinity for FGFR4, or activates FGFR4 to an extent or amount less than, comparable to or greater than FGF19 activates FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein activates FGFR4 to an extent or amount less than the extent or amount that FGF19 activates FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein activates FGFR4 to an extent or amount comparable to the extent or amount that FGF19 activates FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein activates FGFR4 to an extent or amount greater than the extent or amount that FGF19 activates FGFR4.

[0047] In one embodiment, a chimeric peptide sequence or peptide sequence provided herein maintains an FGFR4 mediated activity. In one embodiment, a chimeric peptide sequence or peptide sequence provided herein increases an FGFR4 mediated activity. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein binds to FGFR4 with an affinity less than FGF19 binding affinity for FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein binds to FGFR4 with an affinity comparable to FGF19 binding affinity for FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein binds to FGFR4 with an affinity greater than FGF19 binding affinity for FGFR4. In some embodiments, a chimeric peptide sequence or peptide sequence provided herein does not detectably bind to FGFR4.

[0048] In further aspects, a chimeric peptide sequence or peptide sequence has reduced HCC formation compared to FGF19, or an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDPI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPI (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDPI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; or has greater glucose lowering activity compared to FGF19, or an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDPI (SEQ ID NO:173), GDPI

(SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; has less lipid increasing activity compared to FGF19, or an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; or has less triglyceride, cholesterol, non-HDL or HDL increasing activity compared to FGF19, or an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; or the peptide sequence has less lean mass reducing activity compared to FGF21. Such functions and activities can be ascertained *in vitro* or *in vivo*, for example, in a *db/db* mouse.

[0049] In one embodiment, a peptide or chimeric sequence has a function or activity greater or less than a comparison sequence. In some embodiments, the comparison sequence is FGF19. In another embodiment, the comparison sequence is FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19. In one embodiment, a peptide or chimeric peptide sequence provided herein has greater glucose lowering activity compared to a comparison sequence. In another embodiment, a peptide or chimeric peptide sequence provided herein has less lipid increasing activity compared to a comparison sequence. In other embodiment, a peptide or chimeric peptide sequence provided herein has lower or reduced lipid (*e.g.*, triglyceride, cholesterol, non-HDL) activity compared to a comparison sequence. In other embodiments, a peptide or chimeric peptide sequence provided herein has more HDL increasing

activity as compared to a comparison sequence. In other embodiment, a peptide or chimeric peptide sequence provided herein has less lean mass reducing activity compared to a comparison sequence or FGF21.

[0050] In further additional various embodiments, a peptide or chimeric sequence includes one or more L-amino acids, D-amino acids, non-naturally occurring amino acids, or amino acid mimetic, derivative or analogue. In still further various embodiments, a peptide or chimeric sequence has an N-terminal region, or a C-terminal region, or a FGF19 sequence portion, or an FGF21 sequence portion, joined by a linker or spacer.

[0051] In still additional embodiments, chimeric peptide sequences and peptide sequences isolated or purified, and/or chimeric peptide sequences and peptide sequences can be included in compositions. In one embodiment, a chimeric peptide sequence or peptide sequence is included in a pharmaceutical composition. Such compositions include combinations of inactive or other active ingredients. In one embodiment, a compositions, such as a pharmaceutical composition includes chimeric peptide sequence or peptide sequence and a glucose lowering agent.

[0052] In still additional embodiments, a chimeric peptide or peptide sequence is included in a pharmaceutical composition, which in turn can be used for practicing the methods and uses provided herein. Such compositions include combinations of inactive or other active ingredients. In one embodiment, a composition, such as a pharmaceutical composition includes chimeric peptide sequence or peptide sequence and a glucose lowering agent. In one embodiment, a composition, such as a pharmaceutical composition includes chimeric peptide sequence or peptide sequence and an agent that improves bile acid homeostasis.

[0053] In yet further embodiments, nucleic acid molecules encoding the chimeric peptide sequence or peptide sequence are provided. Such molecules can further include an expression control element in operable linkage that confers expression of the nucleic acid molecule encoding the peptide *in vitro*, in a cell or *in vivo*, or a vector comprising the nucleic acid molecule (*e.g.*, a viral vector). Transformed and host cells that express the chimeric peptide sequences and peptide sequences are also provided.

[0054] Uses and methods of treatment that include administration or delivery of any chimeric peptide sequence or peptide sequence are also provided. In particular embodiments, a use or method of treatment of a subject includes administering a chimeric peptide or peptide sequence provided herein to a subject, such as a subject having, or at risk of having, a disease or disorder treatable by a peptide sequence provided herein, in an amount effective for treating the disease or disorder.

[0055] In one embodiment, provided herein is a method of preventing a disease or disorder in a subject having, or at risk of having, a disease or disorder preventable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for preventing the disease or disorder. In another embodiment, provided herein is a method of treating a disease or disorder in a subject having, or at risk of having, a disease or disorder treatable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for treating the disease or disorder. In yet another embodiment, provided herein is a method of managing a disease or disorder in a subject having, or at risk of having, a disease or disorder manageable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for managing the disease or disorder. In one embodiment, the disease or disorder is a bile acid-related disease or associated disorder.

[0056] Non-limiting exemplary bile acid-related or associated disorders preventable, treatable or manageable according to the methods and uses provided herein include: cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, primary biliary cirrhosis (PBC), primary familial intrahepatic cholestasis (PFIC) (*e.g.*, progressive PFIC), primary sclerosing cholangitis (PSC), pregnancy intrahepatic cholestasis (PIC), neonatal cholestasis, and drug-induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile duct compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), short bowel syndrome, disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, bile acid diarrhea (BAD)) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to non-alcoholic steatohepatitis (NASH), cirrhosis and portal hypertension; *e.g.*, in mammals, such as humans. Additional bile acid-related or associated disorders include metabolic syndrome; a lipid or glucose disorder; cholesterol or triglyceride metabolism; type 2 diabetes.

[0057] In one particular embodiment, the bile acid-related or associated disorder is bile acid malabsorption. In another particular embodiment, the bile acid-related or associated disorder is diarrhea. In another particular embodiment, the bile acid-related or associated disorder is bile

acid diarrhea. In a still further particular embodiment, the bile acid-related or associated disorder is cholestasis. In one embodiment, the cholestasis is intrahepatic cholestasis. In another embodiment, the cholestasis is extrahepatic cholestasis. In another, further particular embodiment, the bile acid-related or associated disorder is an error in bile acid synthesis. In another further particular embodiment, the bile acid-related or associated disorder is primary biliary cirrhosis (PBC). In other particular embodiments, the bile acid-related or associated disorder is primary sclerosing cholangitis (PSC). In another embodiment, the bile acid-related or associated disorder is PFIC (*e.g.*, progressive PFIC). In another embodiment, the bile acid-related or associated disorder is NASH. In another embodiment, the bile acid-related or associated disorder is a hyperglycemic condition. In a specific embodiment, the bile acid-related or associated disorder is type 2 diabetes.

[0058] In some embodiments, the pharmaceutical composition further comprises at least one additional agent effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder, wherein the additional agent is: a glucocorticoid; CDCA; UDCA; insulin, an insulin secretagogues, an insulin mimetic, a sulfonylurea and a meglitinide; a biguanide; an alpha-glucosidase inhibitors; a DPP-IV inhibitor, GLP-1, a GLP-1 agonists and a GLP-1 analog; a DPP-IV-resistant analogue; a PPAR gamma agonist, a dual-acting PPAR agonist, a pan-acting PPAR agonist; a PTP1B inhibitor; an SGLT inhibitor; an RXR agonist; a glycogen synthase kinase-3 inhibitor; an immune modulator; a beta-3 adrenergic receptor agonist; an 11beta-HSD1 inhibitor; amylin and an amylin analogue; a bile acid sequestrant; or an SGLT-2 inhibitor. In certain embodiments, the at least one additional agent effective in modulating PBC is UDCA, an FXR agonist, OCA, an ASBT inhibitor, an autoimmune agent, an anti-IL-12 agent, an anti-CD80 agent, an anti-CD20 agent, a CXCL10 neutralizing antibody, a ligand for CXCR3, a fibrate, fish oil, colchicine, methotrexate, azathioprine, cyclosporine, or an anti-retroviral therapy. In particular embodiments, the at least one additional agent effective in modulating PBC is UDCA, OCA, an ASBT inhibitor, an anti-IL-12 agent, an anti-CD20 agent, or a fibrate.

[0059] Non-limiting exemplary disorders or conditions preventable, treatable or manageable with the peptide formulations, methods and uses thereof provided herein, include metabolic diseases and disorders. Non-limiting examples of diseases and disorders include: metabolic syndrome; a lipid- or glucose-related disorder; cholesterol or triglyceride metabolism; type 2 diabetes; cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, PBC,

PFIC, PSC, PIC, neonatal cholestasis, and drug induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile cut compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, BAD) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to NASH, cirrhosis and portal hypertension. For treatment, peptide provided herein can be administered to subjects in need of modulation of bile acid homeostasis or having a bile-acid related or associated disorder. Peptides provided herein may also be useful in other hyperglycemic-related disorders, including kidney damage (*e.g.*, tubule damage or nephropathy), liver degeneration, eye damage (*e.g.*, diabetic retinopathy or cataracts), and diabetic foot disorders; dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary artery disease, cerebrovascular disorders and the like.

[0060] Other conditions which may be associated with metabolic syndrome, such as obesity and elevated body mass (including the co-morbid conditions thereof such as, but not limited to, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS)), and also include thromboses, hypercoagulable and prothrombotic states (arterial and venous), hypertension (including portal hypertension (defined as a hepatic venous pressure gradient (HVPG) greater than 5 mm Hg), cardiovascular disease, stroke and heart failure; disorders or conditions in which inflammatory reactions are involved, including atherosclerosis, chronic inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), asthma, lupus erythematosus, arthritis, or other inflammatory rheumatic disorders; Disorders of cell cycle or cell differentiation processes such as adipose cell tumors, lipomatous carcinomas including, for example, liposarcomas, solid tumors, and neoplasms; Neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, progressive multifocal leukoencephalopathy and Guillian-Barre syndrome; Skin and dermatological disorders and/or disorders of wound healing processes, including erythemato-

squamous dermatoses; and other disorders such as syndrome X, osteoarthritis, and acute respiratory distress syndrome.

[0061] In one embodiment, of the various methods provided herein, the subject is a human. In certain embodiments, the subject is a subject in need thereof.

[0062] In some embodiments, the chimeric peptide sequence or a peptide sequence described herein, either alone or in combination with at least one additional therapeutic agent or treatment modality, is assessed to ensure that it does not cause untoward adverse effects in the subject. In a particular aspect, the combination of a chimeric peptide sequence or a peptide sequence described herein and at least one additional therapeutic agent or treatment modality is assessed to ensure that it does not induce HCC in the subject. Such assessments may be performed before initiation of therapy (*e.g.*, in a dose escalation study), during therapy, (*e.g.*, by evaluating a marker correlating with HCC activity), or subsequent to termination of therapy (*e.g.*, by performing a liver biopsy). In some aspects, the assessment is performed in a suitable test environment (*e.g.*, a validated animal model). One of ordinary skill in the art is familiar with additional means for ensuring that the combination therapy described herein is suitable for the particular subject, or a subject population representative of the particular subject, taking into consideration all relevant factors including, for example, the severity of the subject's bile acid-related or associated disorder (*e.g.*, PBC) and the other medications be taken by the subject.

[0063] In one embodiment, a method includes administering a chimeric peptide or peptide sequence provided herein to a subject, such as a subject having a hyperglycemic condition (*e.g.*, diabetes, such as insulin-dependent (type I) diabetes, type II diabetes, or gestational diabetes), insulin resistance, hyperinsulinemia, glucose intolerance or metabolic syndrome, or is obese or has an undesirable body mass. In particular aspects of the methods and uses, a chimeric peptide sequence or peptide sequence is administered to a subject in an amount effective to improve glucose metabolism in the subject. In more particular aspects, a subject has a fasting plasma glucose level greater than 100 mg/dl or has a hemoglobin A1c (HbA1c) level above 6%, prior to administration. In further embodiments, a use or method of treatment of a subject is intended to or results in reduced glucose levels, increased insulin sensitivity, reduced insulin resistance, reduced glucagon, an improvement in glucose tolerance, or glucose metabolism or homeostasis, improved pancreatic function, or reduced triglyceride, cholesterol, IDL, LDL or VLDL levels, or a decrease in blood pressure, a decrease in intimal thickening of the blood vessel, or a decrease in body mass or weight gain.

[0064] In particular aspects of the invention methods and uses, a chimeric peptide sequence or peptide sequence is administered to a subject in an amount effective to improve or provide bile acid homeostasis. Non-limiting exemplary bile acid related or associated disorders treatable according to the invention methods and uses include: metabolic syndrome; a lipid- or glucose-related disorder; cholesterol or triglyceride metabolism; type 2 diabetes; cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, PBC, PFIC, PSC, PIC, neonatal cholestasis, and drug induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile duct compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, BAD) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to NASH, cirrhosis and portal hypertension. In one embodiment, the bile acid related or associated disorder is bile acid malabsorption. In another embodiment, the bile acid related or associated disorder is diarrhea. In another embodiment, the bile acid related or associated disorder is cholestasis (*e.g.*, intrahepatic or extrahepatic cholestasis). In another embodiment, the bile acid related or associated disorder is primary biliary cirrhosis. In another embodiment, the bile acid related or associated disorder is primary sclerosing cholangitis. In another embodiment, the bile acid related or associated disorder is PFIC (*e.g.*, progressive PFIC).

3. Description of Drawings

[0065] **FIG. 1** shows cyp7a1 expression in *db/db* mice dosed intraperitoneally with the indicated concentrations of FGF19 and FGF21 (SEQ ID NOs:99 and 100).

[0066] **FIG. 2A-2D** show cyp7a1 expression in human primary hepatocytes following dosing of A) variant M1 (SEQ ID NO:1); B) variant M2 (SEQ ID NO:2); C) variant M5 (SEQ ID NO:5); and D) variant M32 (SEQ ID NO:32).

[0067] **FIG. 3A-3D** show cyp7a1 expression in human primary hepatocytes following dosing of A) variant M69 (SEQ ID NO:69); B) variant M75 (SEQ ID NO:75); C) variant M70 (SEQ ID NO:70); and D) variant M76 (SEQ ID NO:76).

[0068] **FIG. 4A-4D** show cyp7a1 expression in human primary hepatocytes following dosing of A) variant M85 (SEQ ID NO:85); B) variant M96 (SEQ ID NO:96); C) variant M90 (SEQ ID NO:90); and D) variant M98 (SEQ ID NO:98).

[0069] **FIG. 5** is a table showing the cyp7a1 IC₅₀ (pM), relative cyp7a1 expression and HCC core of the indicated variants: M1, M2, M5, M32, M69, M70, M75, M76, M85, M90, M96 and M98.

[0070] **FIG. 6** depicts the results of a human clinical trial, showing administration of M70 is able to suppress 7 α -hydroxy-4-cholsten-3-one (C4), a marker of bile acid synthesis, as compared to a placebo.

[0071] **FIG. 7** depicts that the expression of FGFR4/ β -klotho complex in L6 cells potentiates activation of intracellular signaling pathways by FGF19, M3 and M70.

[0072] **FIG. 8** depicts that administration of M70 is able to suppress C4 as compared to a placebo.

[0073] **FIG. 9** depicts that mice treated with M70 showed a statistically significant improvement in biochemical markers of liver damage, such as alkaline phosphatase (ALP), alkaline aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT), following bile duct ligation (BDL) surgery.

[0074] **FIG. 10** depicts that continuous expression of M70 in *Mdr2* knockout mouse normalized liver enzymes such as ALP, ALT, and AST.

[0075] **FIG. 11** depicts the results of a human clinical trial, showing administration of M70 was able to promote body weight loss and to reduce serum triglycerides in type 2 diabetes patients.

4. Detailed Description

[0076] Before the present disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments set forth herein, and it is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

4.1 Definitions

[0077] The terms “patient” or “subject” are used interchangeably to refer to a human or a non-human animal (*e.g.*, a mammal).

[0078] The terms “treat”, “treating”, “treatment” and the like refer to a course of action (such as administering a polypeptide or a pharmaceutical composition comprising a polypeptide) initiated after a disease, disorder or condition, or a symptom thereof, has been diagnosed, observed, and the like so as to eliminate, reduce, suppress, mitigate, or ameliorate, either temporarily or permanently, at least one of the underlying causes of a disease, disorder, or condition afflicting a subject, or at least one of the symptoms associated with a disease, disorder, condition afflicting a subject. Thus,

treatment includes inhibiting (*i.e.*, arresting the development or further development of the disease, disorder or condition or clinical symptoms association therewith) an active disease.

[0079] The term “in need of treatment” as used herein refers to a judgment made by a physician or other medical professional that a subject requires or will benefit from treatment.

[0080] The terms “prevent”, “preventing”, “prevention” and the like refer to a course of action (such as administering a polypeptide or a pharmaceutical composition comprising a polypeptide) initiated in a manner (*e.g.*, prior to the onset of a disease, disorder, condition or symptom thereof) so as to prevent, suppress, inhibit or reduce, either temporarily or permanently, a subject’s risk of developing a disease, disorder, condition or the like (as determined by, for example, the absence of clinical symptoms) or delaying the onset thereof, generally in the context of a subject predisposed to having a particular disease, disorder or condition. In certain instances, the terms also refer to slowing the progression of the disease, disorder or condition or inhibiting progression thereof to a harmful or otherwise undesired state.

[0081] The term “in need of prevention” as used herein refers to a judgment made by a physician or other medical professional that a subject requires or will benefit from preventative care.

[0082] The phrase “therapeutically effective amount” refers to the administration of an agent to a subject, either alone or as a part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount that is capable of having any detectable, positive effect on any symptom, aspect, or characteristics of a disease, disorder or condition when administered to a patient. The therapeutically effective amount can be ascertained by measuring relevant physiological effects. For example, in the case of a hyperglycemic condition, a lowering or reduction of blood glucose or an improvement in glucose tolerance test can be used to determine whether the amount of an agent is effective to treat the hyperglycemic condition. For example, a therapeutically effective amount is an amount sufficient to reduce or decrease any level (*e.g.*, a baseline level) of fasting plasma glucose (FPG), wherein, for example, the amount is sufficient to reduce a FPG level greater than 200 mg/dl to less than 200 mg/dl, wherein the amount is sufficient to reduce a FPG level between 175 mg/dl and 200 mg/dl to less than the starting level, wherein the amount is sufficient to reduce a FPG level between 150 mg/dl and 175 mg/dl to less than the starting level, wherein the amount is sufficient to reduce a FPG level between 125 mg/dl and 150 mg/dl to less than the starting level, and so on (*e.g.*, reducing FPG levels to less than 125 mg/dl, to less than 120 mg/dl, to less than 115 mg/dl, to less than 110 mg/dl, *etc.*). Moreover, in the case of HbA1c levels, the effective amount is an amount sufficient to reduce or decrease levels by more than about 10% to 9%, by more than about 9% to 8%, by more than about 8% to 7%, by more than about 7% to 6%, by more than about 6% to 5%, and so

on. More particularly, a reduction or decrease of HbA1c levels by about 0.1%, 0.25%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, or more is contemplated by the present disclosure. The therapeutically effective amount can be adjusted in connection with the dosing regimen and diagnostic analysis of the subject's condition and the like.

[0083] The phrase “in a sufficient amount to effect a change” means that there is a detectable difference between a level of an indicator measured before (*e.g.*, a baseline level) and after administration of a particular therapy. Indicators include any objective parameter (*e.g.*, level of glucose or insulin) or subjective parameter (*e.g.*, a subject's feeling of well-being).

[0084] The phrase “glucose tolerance”, as used herein, refers to the ability of a subject to control the level of plasma glucose and/or plasma insulin when glucose intake fluctuates. For example, glucose tolerance encompasses the subject's ability to reduce, within about 120 minutes, the level of plasma glucose back to a level determined before the intake of glucose.

[0085] Broadly speaking, the terms “diabetes” and “diabetic” refer to a progressive disease of carbohydrate metabolism involving inadequate production or utilization of insulin, frequently characterized by hyperglycemia and glycosuria. The terms “pre-diabetes” and “pre-diabetic” refer to a state wherein a subject does not have the characteristics, symptoms and the like typically observed in diabetes, but does have characteristics, symptoms and the like that, if left untreated, can progress to diabetes. The presence of these conditions can be determined using, for example, either the fasting plasma glucose (FPG) test or the oral glucose tolerance test (OGTT). Both usually require a subject to fast for at least 8 hours prior to initiating the test. In the FPG test, a subject's blood glucose is measured after the conclusion of the fasting; generally, the subject fasts overnight and the blood glucose is measured in the morning before the subject eats. A healthy subject would generally have a FPG concentration between about 90 and about 100 mg/dl, a subject with “pre-diabetes” would generally have a FPG concentration between about 100 and about 125 mg/dl, and a subject with “diabetes” would generally have a FPG level above about 126 mg/dl. In the OGTT, a subject's blood glucose is measured after fasting and again two hours after drinking a glucose-rich beverage. Two hours after consumption of the glucose-rich beverage, a healthy subject generally has a blood glucose concentration below about 140 mg/dl, a pre-diabetic subject generally has a blood glucose concentration about 140 to about 199 mg/dl, and a diabetic subject generally has a blood glucose concentration about 200 mg/dl or above. While the aforementioned glycemic values pertain to human subjects, normoglycemia, moderate hyperglycemia and overt hyperglycemia are scaled differently in murine subjects. A healthy murine subject after a four-hour fast would generally have a FPG

concentration between about 100 and about 150 mg/dl, a murine subject with “pre-diabetes” would generally have a FPG concentration between about 175 and about 250 mg/dl and a murine subject with “diabetes” would generally have a FPG concentration above about 250 mg/dl.

[0086] The term “insulin resistance” as used herein refers to a condition where a normal amount of insulin is unable to produce a normal physiological or molecular response. In some cases, a hyper-physiological amount of insulin, either endogenously produced or exogenously administered, is able to overcome the insulin resistance, in whole or in part, and produce a biologic response.

[0087] The term “metabolic syndrome” refers to an associated cluster of traits that includes, but is not limited to, hyperinsulinemia, abnormal glucose tolerance, obesity, redistribution of fat to the abdominal or upper body compartment, hypertension, dysfibrinolysis, and dyslipidemia characterized by high triglycerides, low high density lipoprotein (HDL)-cholesterol, and high small dense low density lipoprotein (LDL) particles. Subjects having metabolic syndrome are at risk for development of type 2 diabetes and/or other disorders (*e.g.*, atherosclerosis).

[0088] The phrase “glucose metabolism disorder” encompasses any disorder characterized by a clinical symptom or a combination of clinical symptoms that is associated with an elevated level of glucose and/or an elevated level of insulin in a subject relative to a healthy individual. Elevated levels of glucose and/or insulin can be manifested in the following diseases, disorders and conditions: hyperglycemia, type II diabetes, gestational diabetes, type I diabetes, insulin resistance, impaired glucose tolerance, hyperinsulinemia, impaired glucose metabolism, pre-diabetes, other metabolic disorders (such as metabolic syndrome, which is also referred to as syndrome X), and obesity, among others. The polypeptides of the present disclosure, and compositions thereof, can be used, for example, to achieve and/or maintain glucose homeostasis, *e.g.*, to reduce glucose level in the bloodstream and/or to reduce insulin level to a range found in a healthy subject.

[0089] The term “hyperglycemia”, as used herein, refers to a condition in which an elevated amount of glucose circulates in the blood plasma of a subject relative to a healthy individual. Hyperglycemia can be diagnosed using methods known in the art, including measurement of fasting blood glucose levels as described herein.

[0090] The term “hyperinsulinemia”, as used herein, refers to a condition in which there are elevated levels of circulating insulin when, concomitantly, blood glucose levels are either elevated or normal. Hyperinsulinemia can be caused by insulin resistance which is associated with dyslipidemia, such as high triglycerides, high cholesterol, high low-density lipoprotein (LDL) and low high-density lipoprotein (HDL); high uric acids levels; polycystic ovary syndrome; type II diabetes and obesity. Hyperinsulinemia can be diagnosed as having a plasma insulin level higher than about 2 μ U/mL.

[0091] As used herein, the phrase “body weight disorder” and similar terms refer to conditions associated with excessive body weight and/or enhanced appetite. Various parameters are used to determine whether a subject is overweight compared to a reference healthy individual, including the subject’s age, height, sex and health status. For example, a subject can be considered overweight or obese by assessment of the subject’s Body Mass Index (BMI), which is calculated by dividing a subject’s weight in kilograms by the subject’s height in meters squared. An adult having a BMI in the range of ~18.5 to ~24.9 kg/m² is considered to have a normal weight; an adult having a BMI between ~25 and ~29.9 kg/m² can be considered overweight (pre-obese); and an adult having a BMI of ~30 kg/m² or higher can be considered obese. Enhanced appetite frequently contributes to excessive body weight. There are several conditions associated with enhanced appetite, including, for example, night eating syndrome, which is characterized by morning anorexia and evening polyphagia often associated with insomnia, but which can be related to injury to the hypothalamus.

[0092] The terms “polypeptide,” “peptide,” and “protein”, used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified polypeptide backbones. The terms include fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusion proteins with heterologous and homologous leader sequences, with or without N-terminus methionine residues; immunologically tagged proteins; and the like. It will be appreciated that throughout this disclosure reference is made to amino acids according to the single letter or three letter codes.

[0093] As used herein, the term “variant” encompasses naturally-occurring variants (*e.g.*, homologs and allelic variants) and non-naturally-occurring variants (*e.g.*, muteins). Naturally-occurring variants include homologs, *i.e.*, nucleic acids and polypeptides that differ in nucleotide or amino acid sequence, respectively, from one species to another. Naturally-occurring variants include allelic variants, *i.e.*, nucleic acids and polypeptides that differ in nucleotide or amino acid sequence, respectively, from one individual to another within a species. Non-naturally-occurring variants include nucleic acids and polypeptides that comprise a change in nucleotide or amino acid sequence, respectively, where the change in sequence is artificially introduced, *e.g.*, the change is generated in the laboratory or other facility by human intervention (“hand of man”).

[0094] The term “native”, in reference to FGF19, refers to biologically active, naturally-occurring FGF19, including biologically active, naturally-occurring FGF19 variants. The term includes the 194 amino acid human FGF19 mature sequence.

[0095] The terms “label”, “labeling” and the like, when use in the context of a polypeptide or nucleic acid (or antibody, as appropriate) of the present disclosure are meant to refer broadly to any means useful in, for example, polypeptide purification, identification, isolation and synthesis. Labels are generally covalently bound to the polypeptide of interest and can be introduced in any manner known in the art, including attachment to a mature polypeptide (generally at the N- or C-terminus), incorporation during solid-phase peptide synthesis, or through recombinant means. Examples include, but are not limited to, fluorescence, biotinylation, and radioactive isotopes. Polypeptide and nucleic acid molecules can be labeled by both *in vitro* and *in vivo* methods. Labeling reagents and kits can be obtained from a number of commercial sources (*e.g.*, Thermo Fischer Scientific, Rockford, IL; and Molecular Probes/Life Technologies; Grand Island, NY).

[0096] The term “muteins” as used herein refers broadly to mutated recombinant proteins, *i.e.*, a polypeptide comprising an artificially introduced change in amino acid sequence, *e.g.*, a change in amino acid sequence generated in the laboratory or other facility by human intervention (“hand of man”). These proteins usually carry single or multiple amino acid substitutions and are frequently derived from cloned genes that have been subjected to site-directed or random mutagenesis, or from completely synthetic genes.

[0097] As used herein in reference to native human FGF19 or a FGF19 mutein, the terms “modified”, “modification” and the like refer to one or more changes that enhance a desired property of human FGF19, a naturally-occurring FGF19 variant, or a FGF19 mutein, wherein the change(s) does not alter the primary amino acid sequence of the FGF19. Such desired properties include, for example, enhancing solubility, prolonging the circulation half-life, increasing the stability, reducing the clearance, altering the immunogenicity or allergenicity, improving aspects of manufacturability (*e.g.*, cost and efficiency), and enabling the raising of particular antibodies (*e.g.*, by introduction of unique epitopes) for use in detection assays. Changes to human FGF19, a naturally-occurring FGF19 variant, or a FGF19 mutein that can be carried out include, but are not limited to, pegylation (covalent attachment of one or more molecules of polyethylene glycol (PEG), or derivatives thereof); glycosylation (*e.g.*, N-glycosylation), polysialylation and hesylation; albumin fusion; albumin binding through, for example, a conjugated fatty acid chain (acylation); Fc-fusion; and fusion with a PEG mimetic. Some particular embodiments entail modifications involving polyethylene glycol, other particular embodiments entail modifications involving albumin, and still other particular modifications entail modifications involving glycosylation.

[0098] The terms “DNA”, “nucleic acid”, “nucleic acid molecule”, “polynucleotide” and the like are used interchangeably herein to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include linear and circular nucleic acids, messenger RNA (mRNA), complementary DNA (cDNA), recombinant polynucleotides, vectors, probes, primers and the like.

[0099] The term “probe” refers to a fragment of DNA or RNA corresponding to a gene or sequence of interest, wherein the fragment has been labeled radioactively (*e.g.*, by incorporating ³²P or ³⁵S) or with some other detectable molecule, such as biotin, digoxigenin or fluorescein. As stretches of DNA or RNA with complementary sequences will hybridize, a probe can be used, for example, to label viral plaques, bacterial colonies or bands on a gel that contain the gene of interest. A probe can be cloned DNA or it can be a synthetic DNA strand; the latter can be used to obtain a cDNA or genomic clone from an isolated protein by, for example, microsequencing a portion of the protein, deducing the nucleic acid sequence encoding the protein, synthesizing an oligonucleotide carrying that sequence, radiolabeling the sequence and using it as a probe to screen a cDNA library or a genomic library.

[0100] The term “heterologous” refers to two components that are defined by structures derived from different sources. For example, in the context of a polypeptide, a “heterologous” polypeptide can include operably linked amino acid sequences that are derived from different polypeptides. Similarly, in the context of a polynucleotide encoding a chimeric polypeptide, a “heterologous” polynucleotide can include operably linked nucleic acid sequences that can be derived from different genes. Exemplary “heterologous” nucleic acids include expression constructs in which a nucleic acid comprising a coding sequence is operably linked to a regulatory element (*e.g.*, a promoter) that is from a genetic origin different from that of the coding sequence (*e.g.*, to provide for expression in a host cell of interest, which can be of different genetic origin than the promoter, the coding sequence or both). In the context of recombinant cells, “heterologous” can refer to the presence of a nucleic acid (or gene product, such as a polypeptide) that is of a different genetic origin than the host cell in which it is present.

[0101] The term “operably linked” refers to linkage between molecules to provide a desired function. For example, “operably linked” in the context of nucleic acids refers to a functional linkage between nucleic acid sequences. By way of example, a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) can be operably linked to a second polynucleotide, wherein the expression control sequence affects transcription and/or translation of the second polynucleotide. In the context of a polypeptide, “operably linked”

refers to a functional linkage between amino acid sequences (*e.g.*, different domains) to provide for a described activity of the polypeptide.

[0102] As used herein in the context of the structure of a polypeptide, “N-terminus” (or “amino terminus”) and “C-terminus” (or “carboxyl terminus”) refer to the extreme amino and carboxyl ends of the polypeptide, respectively, while the terms “N-terminal” and “C-terminal” refer to relative positions in the amino acid sequence of the polypeptide toward the N-terminus and the C-terminus, respectively, and can include the residues at the N-terminus and C-terminus, respectively.

“Immediately N-terminal” or “immediately C-terminal” refers to a position of a first amino acid residue relative to a second amino acid residue where the first and second amino acid residues are covalently bound to provide a contiguous amino acid sequence.

[0103] “Derived from”, in the context of an amino acid sequence or polynucleotide sequence (*e.g.*, an amino acid sequence “derived from” a FGF19 polypeptide), is meant to indicate that the polypeptide or nucleic acid has a sequence that is based on that of a reference polypeptide or nucleic acid (*e.g.*, a naturally occurring FGF19 polypeptide or a FGF19-encoding nucleic acid), and is not meant to be limiting as to the source or method in which the protein or nucleic acid is made. By way of example, the term “derived from” includes homologues or variants of reference amino acid or DNA sequences.

[0104] In the context of a polypeptide, the term “isolated” refers to a polypeptide of interest that, if naturally occurring, is in an environment different from that in which it can naturally occur.

“Isolated” is meant to include polypeptides that are within samples that are substantially enriched for the polypeptide of interest and/or in which the polypeptide of interest is partially or substantially purified. Where the polypeptide is not naturally occurring, “isolated” indicates the polypeptide has been separated from an environment in which it was made by either synthetic or recombinant means.

[0105] “Enriched” means that a sample is non-naturally manipulated (*e.g.*, by a scientist or a clinician) so that a polypeptide of interest is present in a) a greater concentration (*e.g.*, at least 3-fold greater, at least 4-fold greater, at least 8-fold greater, at least 64-fold greater, or more) than the concentration of the polypeptide in the starting sample, such as a biological sample (*e.g.*, a sample in which the polypeptide naturally occurs or in which it is present after administration), or b) a concentration greater than the environment in which the polypeptide was made (*e.g.*, as in a bacterial cell).

[0106] “Substantially pure” indicates that a component (*e.g.*, a polypeptide) makes up greater than about 50% of the total content of the composition, and typically greater than about 60% of the total polypeptide content. More typically, “substantially pure” refers to compositions in which at

least 75%, at least 85%, at least 90% or more of the total composition is the component of interest. In some cases, the polypeptide will make up greater than about 90%, or greater than about 95% of the total content of the composition.

[0107] The terms “measuring” or “assaying” and grammatical variations thereof are used interchangeably herein and refer to either qualitative or quantitative determinations, or both qualitative and quantitative determinations. When the terms are used in reference to detection, any means of assessing the relative amount is contemplated, including the various methods set forth herein and known in the art. For example, gene expression can be assayed or measured by a Northern blot, Western blot, immunoprecipitation assay, or by measuring activity, function or amount of the expressed protein.

[0108] The terms “antibodies” (Abs) and “immunoglobulins” (Igs) refer to glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity.

[0109] The term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations, which can include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

[0110] In the context of an antibody, the term “isolated” refers to an antibody that has been separated and/or recovered from contaminant components of its natural environment; such contaminant components include materials which might interfere with diagnostic or therapeutic uses for the antibody, and can include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.

[0111] As used herein, the term “FGF19-dependent” and similar terms, as used in the context of a disease, disorder or condition, refers to a disease, disorder or other condition that is caused all, or in part, by the expression of FGF19. In certain embodiments, the expression of FGF19 is amplified as compared to a control. In some embodiments, the expression of FGF19 is amplified 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, or any numerical range thereof. In some embodiments, the amplified expression of FGF19 directly results in the disease, disorder or condition, or a symptom thereof. In other embodiments, the

amplified expression of FGF19 indirectly results in the disease disorder or condition, or a symptom thereof.

4.2 Peptides

[0112] In certain embodiments, the pharmaceutical compositions, formulations and dosage forms provided herein comprise one or more peptides or peptide sequences provided herein. In certain embodiments, the pharmaceutical compositions, formulations and dosage forms provided herein comprise one or more variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities associated with the treatment and/or prevention of a bile acid-related or associated disorder (*e.g.*, PBC), a metabolic disorder or a cancer or tumor. In certain embodiments, the activity is a glucose lowering activity. Such variants and fusions (chimeras) of FGF19 and/or FGF21 peptide sequences include sequences that do not substantially increase or induce HCC formation or HCC tumorigenesis and/or do not induce a substantial elevation or increase in lipid profile.

[0113] In one embodiment, a chimeric peptide sequence includes or consists of an N-terminal region having at least seven amino acid residues and the N-terminal region having a first amino acid position and a last amino acid position, where the N-terminal region has a DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122) sequence; and a C-terminal region having a portion of FGF19 and the C-terminal region having a first amino acid position and a last amino acid position, where the C-terminal region includes amino acid residues 16-29 of FGF19 (WGDPIRLRHLTYTSG; SEQ ID NO:169) and the W residue corresponds to the first amino acid position of the C-terminal region. In particular embodiments, the variant is M70:

MRDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPV
SLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDS16MDPFG
LVTGLEAVRSPSFEK (SEQ ID NO:70). In other particular embodiments, the variant is M69:
RDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVA
LRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVS
LSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDS16MDPFG
LVTGLEAVRSPSFEK (SEQ ID NO:69).

[0114] In another embodiment, the treatment peptide, comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position; and b) a C-terminal region comprising a portion of SEQ ID NO:99 [FGF19], the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises (i) a first C-terminal region sequence comprising WGDPIRLRHLTYTSG (amino acids 16 to 29 of SEQ ID NO:99 [FGF19]), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and (ii) a second C-terminal region sequence comprising
 PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVLRRTVAIKGVHVSRYLCMGADGKMQGL
 LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPE
 EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (amino acid residues 30 to 194 of SEQ ID NO:99 [FGF19]).

[0115] In another embodiment, the treatment peptide, comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122); and b) a C-terminal region comprising a portion of SEQ ID NO:99 [FGF19], the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises (i) a first C-terminal region sequence comprising WGDPIRLRHLTYTSG (amino acids 16 to 29 of SEQ ID NO:99 [FGF19]), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and (ii) a second C-terminal region sequence comprising
 PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVLRRTVAIKGVHVSRYLCMGADGKMQGL
 LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPE
 EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (amino acid residues 30 to 194 of SEQ ID NO:99 [FGF19]). In certain embodiments, the peptide (i) binds to FGFR4 with an affinity equal to or greater than FGF19 binding affinity for FGFR4; (ii) activates FGFR4 to an extent or amount equal to or greater than FGF19 activates FGFR4; (iii) has at least one of reduced HCC formation; greater glucose lowering activity, less lipid increasing activity, less triglyceride activity, less cholesterol activity, less non-HDL activity or less HDL increasing activity, as compared to FGF19, or as compared to an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAIP (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181),

WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19 (SEQ ID NO:99); and/or (iv) has less lean mass reducing activity as compared to FGF21.

[0116] In certain embodiments, the second C-terminal region sequence comprises at least one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) sequence. In some embodiments, the at least one amino acid substitution is to the IRP sequence of the EIRPD (amino acids 2-6 of SEQ ID NO:190) sequence. In some embodiments, the at least one amino acid substitution is to the RP sequence of the EIRPD sequence (amino acids 2-6 of SEQ ID NO:190). In some embodiments, the at least one amino acid substitution is R to L substitution. In other embodiments, the at least one amino acid substitution is P to E substitution. In yet other embodiments, the at least one amino acid substitution is RP to LE substitution.

[0117] In some embodiments, the second C-terminal region sequence comprises from 2 to 5 amino acid substitutions, deletions or insertions. In other embodiments, the peptide is less than about 250 amino acids in length.

[0118] In one embodiment, the treatment peptide has an amino acid sequence comprising or consisting of

MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLR
TVAIKGVHVSRYLCMGADGKMQLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (SEQ ID NO:70). In certain embodiments, the treatment peptide has an amino acid sequence comprising SEQ ID NO:70. In other embodiments, the treatment peptide has an amino acid sequence consisting of SEQ ID NO:70. In some embodiments, the treatment peptide is fused with an immunoglobulin Fc region.

[0119] In another embodiment, the treatment peptide has an amino acid sequence comprising or consisting of

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLR
VAIKGVHVSRYLCMGADGKMQLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (SEQ ID NO:69). In certain embodiments, the treatment peptide has an amino acid sequence comprising SEQ ID NO:69. In other embodiments, the treatment peptide has an amino acid sequence consisting of SEQ ID NO:69. In some embodiments, the treatment peptide is fused with an immunoglobulin Fc region.

[0120] In another embodiment, the treatment peptide, comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position,; and b) a C-terminal region comprising a first amino acid position and a last amino acid position, wherein the C-terminal region comprises (i) a first C-terminal region sequence comprising WGDPIRQRHLYTSG (SEQ ID NO:169 with a L7Q substitution), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and (ii) a second C-terminal region sequence comprising

PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGL
LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (SEQ ID NO:188).

[0121] In another embodiment, the treatment peptide, comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121), DASPH (SEQ ID NO:122), or DAGPH (amino acids 7 to 11 of SEQ ID NO:99 [FGF19]); and b) a C-terminal region comprising a first amino acid position and a last amino acid position, wherein the C-terminal region comprises (i) a first C-terminal region sequence comprising WGDPIRQRHLYTSG (SEQ ID NO:169 with a L7Q substitution), wherein the W residue corresponds to the first amino acid position of the C-terminal region; and (ii) a second C-terminal region sequence comprising

PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGL
LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (SEQ ID NO:188). In some embodiments, the peptide (i) binds to FGFR4 with an affinity equal to or greater than FGF19 binding affinity for FGFR4; (ii) activates FGFR4 to an extent or amount equal to or greater than FGF19 activates FGFR4; (iii) has at least one of reduced hepatocellular carcinoma (HCC) formation; greater glucose lowering activity, less lipid increasing activity, less triglyceride activity, less cholesterol activity, less non-HDL activity or less HDL increasing activity, as compared to FGF19, or as compared to an FGF19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPIV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the

FGF19 WGDPI (SEQ ID NO:170) sequence at amino acids 16-20; and/or (iv) has less lean mass reducing activity as compared to FGF21.

[0122] In certain embodiments, the second C-terminal region sequence comprises at least one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) sequence. In some embodiments, the at least one amino acid substitution is to the IRP sequence of the EIRPD (amino acids 2-6 of SEQ ID NO:190) sequence. In some embodiments, the at least one amino acid substitution is to the RP sequence of the EIRPD sequence (amino acids 2-6 of SEQ ID NO:190). In some embodiments, the at least one amino acid substitution is R to L substitution. In other embodiments, the at least one amino acid substitution is P to E substitution. In yet other embodiments, the at least one amino acid substitution is RP to LE substitution.

[0123] In some embodiments, the second C-terminal region sequence comprises from 2 to 5 amino acid substitutions, deletions or insertions. In other embodiments, the peptide is less than about 250 amino acids in length.

[0124] In another embodiment, a chimeric peptide sequence includes or consists of an N-terminal region having a portion of FGF21 and the N-terminal region having a first amino acid position and a last amino acid position, where the N-terminal region has a GQV sequence and the V residue corresponds to the last amino acid position of the N-terminal region; and a C-terminal region having a portion of FGF19 and the C-terminal region having a first amino acid position and a last amino acid position where the C-terminal region includes amino acid residues 21-29 of FGF19 (RLRHLYTSG; SEQ ID NO: 185) and the R residue corresponds to the first position of the C-terminal region.

[0125] In particular aspects, modifications to the Loop-8 region of FGF19 are disclosed herein that possess favorable metabolic parameters without exhibiting substantial tumorigenicity. Herein, FGF19 residues 127-129 are defined as constituting the Loop-8 region, although in the literature the Loop-8 region is sometimes defined as including or consisting of other residues (*e.g.*, residues 125-129). Certain combinations of R127L and P128E substitutions to the FGF19 framework had an unexpectedly positive effect on HCC formation. Even more surprisingly, a combination of R127L and P128E substitutions and a substitution of Gln (Q) for Leu (L) in the FGF19 core region had an even more significant effect on preventing HCC formation.

[0126] Accordingly, variants of FGF19 Loop-8 region are included since they can reduce or eliminate substantial, measurable or detectable HCC formation. Furthermore, the effect of reducing HCC formation may be enhanced by modifications to amino acid residues outside of

the Loop-8 region (*e.g.*, substitutions of amino acid residues in the core region, such as the region corresponding to amino acids 21-29 of SEQ ID NO:99). In some embodiments, the Loop-8 modified variant comprises a substitution in the FGF19 Loop-8 region corresponding to amino acids 127-129 of SEQ ID NO:99. In certain embodiments, the Loop-8 modified variant comprises a substitution in the FGF19 Loop-8 region corresponding to (i) a R127L substitution, (ii) a P128E substitution, or (iii) a R127L substitution and a P128E substitution.

[0127] In certain embodiments, the amino acid sequence of the peptide comprises at least one amino acid substitution in the Loop-8 region of FGF19, or the corresponding FGF19 sequence thereof in a variant peptide provided herein. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises four amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises five amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution. In other embodiments, the substitution to the

RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is a Pro (P) to Glu (E) substitution. In some embodiments, the substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution and a Pro (P) to Glu (E) substitution. In specific embodiments, the foregoing substitution(s) in the Loop-8 region of FGF19 is in the corresponding FGF19 sequence thereof in a variant peptide provided herein. That is, said substitutions within a corresponding FGF19 sequence (e.g., EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated.

[0128] In some embodiments, the FGF19 variant comprises or further comprises a substitution in the core region corresponding to amino acids 21-29 of SEQ ID NO:99. In certain embodiments, the FGF19 variant comprises or further comprises a substitution in the core region corresponding to a L22Q substitution.

[0129] In some embodiments, the Loop-8 modified variant is M70:

MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE~~EE~~IRPDGYNVYRSEKHRLPV
SLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDS16MDPFG
LVTGLEAVRSPSF EK (SEQ ID NO:70), comprising a substitution in the FGF19 Loop-8 region (underlined). In certain embodiments, the Loop-8 modified M70 variant comprises a substitution in the FGF19 Loop-8 region (RPD; underlined) corresponding to (i) an R to L substitution, (ii) a P to E substitution, or (iii) an R to L substitution and a P to E substitution (SEQ. ID NO:204). In certain embodiments, the Loop-8 modified M70 variant further comprises or further comprises a substitution in the FGF19 core region. In some embodiments, the Loop-8 modified M70 variant comprises a L18Q substitution (*i.e.*, SEQ ID NO:70 with an L18Q substitution).

[0130] In some embodiments, the Loop-8 modified variant is M69:

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVA
LRTVAIKGVH SVRYLCMGADGKMQLLQYSEEDCAFE~~EE~~IRPDGYNVYRSEKHRLPVS
LSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDS16MDPFG
LVTGLEAVRSPSF EK (SEQ ID NO:69), comprising a substitution in the FGF19 Loop-8 region (underlined). In certain embodiments, the Loop-8 modified M69 variant comprises a substitution in the FGF19 Loop-8 region (RPD; underlined) corresponding to (i) an R to L substitution, (ii) a P to E substitution, or (iii) an R to L substitution and a P to E substitution. In certain embodiments, the Loop-8 modified M69 variant further comprises or further comprises a

substitution in the FGF19 core region. In some embodiments, the Loop-8 modified M69 variant comprises a L17Q substitution (*i.e.*, SEQ ID NO:69 with an L17Q substitution).

[0131] Other counterpart modifications in other variants provided herein are also contemplated. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises four amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises five amino acid substitutions to the EIRPD (amino acids 2-6 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In other embodiments, the amino acid sequence of the peptide comprises three amino acid substitutions to the IRP (amino acids 3-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid sequence of the peptide comprises one amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In some embodiments, the amino acid sequence of the peptide comprises two amino acid substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19. In certain embodiments, the amino acid substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution. In other embodiments, the substitution to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is a Pro (P) to Glu (E) substitution. In some embodiments, the substitutions to the RP (amino acids 4-5 of SEQ ID NO:190) amino acid sequence in the Loop-8 region of FGF19 is an Arg (R) to Leu (L) substitution and a Pro (P) to Glu (E) substitution. In specific embodiments, the foregoing substitution(s) in the Loop-8 region of FGF19 is in the corresponding FGF19 sequence thereof in a variant peptide provided herein. That is,

said substitutions within a corresponding FGF19 sequence (*e.g.*, EIRPD, IRP or RP) of a peptide variant provided herein is also contemplated.

[0132] In further embodiments, a peptide sequence includes or consists of a FGF19 variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19. In additional embodiments, a peptide sequence includes or consists of a FGF21 sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF21. In yet additional embodiments, a peptide sequence includes or consists of a portion of a FGF19 sequence fused to a portion of a FGF21 sequence. In still additional embodiments, a peptide sequence includes or consists of a portion of a FGF19 sequence fused to a portion of a FGF21 sequence, where the FGF19 and/or FGF21 sequence portion(s) have one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19 and/or FGF21. Examples of such sequences are disclosed in PCT Pub. No. WO 2013/006486 and US Pub. No. 2013/0023474, as well as PCT Publ. No. WO 2014/085365, published June 5, 2014. Tables 1-11 and the Sequence Listing also sets forth representative sequences that may be used in the methods provided herein.

[0133] In some embodiments, the treatment peptides provided herein include variants and fusions of FGF19 and/or FGF21 peptide sequences. In one embodiment, the treatment peptides include one or more variant or fusion FGF19 and/or FGF21 peptide. In other embodiments, the methods provided herein include contacting or administering to a subject one or more nucleic acid molecules encoding a variant or fusion FGF19 and/or FGF21 peptide sequence (for example, an expression control element in operable linkage with the nucleic acid encoding the peptide sequence, optionally including a vector), in an amount effective for treating a bile acid-related or associated disorder.

[0134] A representative reference or wild type FGF19 sequence is set forth as:

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKH
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDP
FGLVTGLEAVRSPSEK (SEQ ID NO:99).

[0135] A representative reference or wild type FGF21 sequence is set forth as:

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALK
PGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLP

GNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYA S (SEQ ID NO:100). FGF21 allelic variants include, *e.g.*, M70, M71 and M72.

[0136] The terms “peptide,” “protein,” and “polypeptide” sequence are used interchangeably herein to refer to two or more amino acids, or “residues,” including chemical modifications and derivatives of amino acids, covalently linked by an amide bond or equivalent. The amino acids forming all or a part of a peptide may be from among the known 21 naturally occurring amino acids, which are referred to by both their single letter abbreviation or common three-letter abbreviation. In the peptide sequences provided herein, conventional amino acid residues have their conventional meaning. Thus, “Leu” is leucine, “Ile” is isoleucine, “Nle” is norleucine, and so on.

[0137] In various particular aspects, a peptide or chimeric sequence provided herein has at the N-terminal region first amino acid position an “M” residue, an “R” residue, a “S” residue, a “H” residue, a “P” residue, a “L” residue or an “D” residue. In various alternative particular aspects, a peptide or chimeric sequence peptide sequence does not have a “M” residue or an “R” residue at the first amino acid position of the N-terminal region.

[0138] Also provided herein are subsequences, variants and modified forms of the exemplified peptide sequences (including the FGF19 and FGF21 variants and subsequences listed in the Sequence Listing, or Tables 1-11), so long as the foregoing retains at least a detectable or measureable activity or function. Also, certain exemplified variant peptides, for example, those having all or a portion of FGF21 sequence at the amino-terminus, have an “R” residue positioned at the N-terminus, which can be omitted. Similarly, certain exemplified variant peptides, include an “M” residue positioned at the N-terminus, which can be appended to or further substituted for an omitted residue, such as an “R” residue. More particularly, in various embodiments peptide sequences at the N-terminus include any of: RDSS (SEQ ID NO:115), DSS, MDSS (SEQ ID NO:116) or MRDSS (SEQ ID NO:117). Furthermore, when a “M” residue is adjacent to a “S” residue, the “M” residue may be cleaved such that the “M” residue is deleted from the peptide sequence, whereas when the “M” residue is adjacent to a “D” residue, the “M” residue may not be cleaved. Thus, by way of example, in various embodiments peptide sequences include those with the following residues at the N-terminus: MDSSPL (SEQ ID NO:119), MSDSSPL (SEQ ID NO:120) (cleaved to SDSSPL (SEQ ID NO:112)) and MSSPL (SEQ ID NO:113) (cleaved to SSPL (SEQ ID NO:114)).

[0139] Exemplified herein are peptide sequences, distinct from reference FGF19 and FGF21 polypeptides set forth herein, that modulate bile acid homeostasis, hyperglycemic conditions, insulin resistance, hyperinsulinemia, glucose intolerance, metabolic syndrome, or related disorders, *in vivo* (e.g., Tables 1-11 and the Sequence Listing). Non-limiting particular examples are a peptide sequence with amino-terminal amino acids 1-16 of FGF21 fused to carboxy-terminal amino acids 21-194 of FGF19; a peptide sequence with amino-terminal amino acids 1-147 of FGF19 fused to carboxy-terminal amino acids 147-181 of FGF21; a peptide sequence with amino-terminal amino acids 1-20 of FGF19 fused to carboxy-terminal amino acids 17-181 of FGF21; a peptide sequence with amino-terminal amino acids 1-146 of FGF21 fused to carboxy-terminal amino acids 148-194 of FGF19; and a peptide sequence with amino-terminal amino acids 1-20 of FGF19 fused to internal amino acids 17-146 of FGF21 fused to carboxy-terminal amino acids 148-194 of FGF19.

[0140] Additional particular peptides sequences have a WGDPI (SEQ ID NO:170) sequence motif corresponding to the WGDPI sequence of amino acids 16-20 of FGF19 (SEQ ID NO:99), lack a WGDPI (SEQ ID NO:170) sequence motif corresponding to the WGDPI sequence of amino acids 16-20 of FGF19 (SEQ ID NO:99), or have a substituted (*i.e.*, mutated) WGDPI (SEQ ID NO:170) sequence motif corresponding to FGF19 WGDPI sequence of amino acids 16-20 of FGF19 (SEQ ID NO:99).

[0141] Particular peptide sequences provided herein also include sequences distinct from FGF19 and FGF21 (e.g., as set forth herein), and FGF 19 variant sequences having any GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAIP (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for FGF19 WGDPI (SEQ ID NO:170) sequence at amino acids 16-20. Accordingly, the wild-type FGF19 and FGF21 (e.g., as set forth herein as SEQ ID NOS:99 and 100, respectively) may be excluded sequences, and FGF19 having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAIP (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDPI (SEQ ID NO:183) or

FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19 may also be excluded. This exclusion, however, does not apply to where a sequence has, for example, 3 FGF21 residues fused to FGF19 having, for example, any of GQV, GQV, GDI, or GPI, or 2 FGF21 residues fused to any of WGPI (SEQ ID NO:171), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), or WGDPI (SEQ ID NO:183).

[0142] Particular non-limiting examples of peptide sequences include or consist of all or a part of a sequence variant specified herein as M1-M98 (SEQ ID NOs:1-52, 192, and 54-98, respectively), M101 to M160, or M200 to M207. More particular non-limiting examples of peptide sequences include or consist of all or a part of a sequence set forth as:

HPIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLLEIKAVA
LRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVS
LSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVT
GLEAVRSPSF EK (M5-R) (SEQ ID NO:160) (FGF21 sequences can also include an "R"
residue at the amino terminus);

DSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLLEIKAVLRTV
AIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSA
KQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (SEQ ID NO:138 and 161);

RPLAFSDASPHVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLLEI
KAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKH
RLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDP
FGLVTGLEAVRSPSF EK (M1) (SEQ ID NO:1 or 139);

RPLAFSDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLLEI
KAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKH
RLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDP
FGLVTGLEAVRSPSF EK (M2) (SEQ ID NO:2 or 140);

DSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLLEIKAVL
RTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVS

SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVT
GLEAVRSPSF EK (SEQ ID NO:141);

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVA
LRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVS
LSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVT
GLEAVRSPSF EK (M69) (SEQ ID NO:69);

RDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLS
AKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGL
EAVRSPSF EK (M52) (SEQ ID NO:52);

HPIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVA
LRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVS
LSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVT
GLEAVRSPSF EK (M5-R) (SEQ ID NO:160);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPESLLQLKALK
PGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHSLPLHLP
GNKSPHRDPAPRGP ARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYA
S (M71) (SEQ ID NO:71);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPESLLQLKALK
PGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLP
GNKSPHRDPAPRGP ARFLPLPGLPPAPPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYA
S (M72) (SEQ ID NO:72);

HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPESLLQLKALK
PGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLP
GNKSPHRDPAPRGP ARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVVQDELQGVGG
EGCHMHPENCKTLLTDIDRTHTEKPVWDGITGE (M73) (SEQ ID NO:73);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEILEDGYNVYRSEKHR

LPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPF
GLVTGLEAVRSPSFEK (M3) (SEQ ID NO:3);

RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSS
AKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGL
EAVRSPSFEK (M48) (SEQ ID NO:48, 6 or 148);

RPLAFSDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLP
VSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGL
VTGLEAVRSPSFEK (M49) (SEQ ID NO:49, 7 or 149);

RHIPDSSPLLQFGDQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPV
SLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLV
TGLEAVRSPSFEK (M50) (SEQ ID NO:50);

RHIPDSSPLLQFGGNVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPV
SLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLV
TGLEAVRSPSFEK (M51) (SEQ ID NO:51, 36 or 155);

MDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSS
AKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGL
EAVRSPSFEK (M53) (SEQ ID NO:192);

MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPV
SLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLV
TGLEAVRSPSFEK (M70) (SEQ ID NO:70);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILPDGYNVYRSEKHR

LPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPF
GLVTGLEAVRSPSFEK (M139) (SEQ ID NO:193);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIREDGYNVYRSEKH
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDP
FGLVTGLEAVRSPSFEK (M140) (SEQ ID NO:194);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILCDGYNVYRSEKH
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDP
FGLVTGLEAVRSPSFEK (M141) (SEQ ID NO:195); or

RPLAFSDAGPHVHYGWGDPIRQRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLE
IKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKH
RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDP
FGLVTGLEAVRSPSFEK (M160) (SEQ ID NO:196);

or a subsequence or fragment thereof any of the foregoing peptide sequences. In certain embodiments of any of the foregoing peptide sequences, the R terminal residue is deleted.

[0143] Additional particular non-limiting examples of peptide sequences, having at the N-terminus, a peptide sequence including or consisting of all or a part of any of:

HPIPDSSPLLQFGGQVRLRHL YTSG (M5-R) (amino acids 1-25 of SEQ ID NO:160);
DSSPLLQFGGQVRLRHL YTSG (M6) (M6-R) (amino acids 2-22 of SEQ ID NO:6);
RPLAFSDSSPLLQFGGQVRLRHL YTSG (M7) (amino acids 1-27 of SEQ ID NO:7);
HPIPDSSPLLQWGDPIRLRHL YTSG (M8-R) (amino acids 2-26 of SEQ ID NO:8);
HPIPDSSPLLQFGWGDPIRLRHL YTSG (M9-R) (amino acids 2-28 of SEQ ID NO:9);
HPIPDSSPHVHYGWGDPIRLRHL YTSG (M10-R) (amino acids 2-28 of SEQ ID NO:10);
RPLAFSDAGPLLQWGDPIRLRHL YTSG (M11) (amino acids 1-27 of SEQ ID NO:11);
RPLAFSDAGPLLQFGWGDPIRLRHL YTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
RPLAFSDAGPLLQFGGQVRLRHL YTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
HPIPDSSPHVHYGGQVRLRHL YTSG (M14-R) (amino acids 2-26 of SEQ ID NO:14);
RPLAFSDAGPHVHYGGQVRLRHL YTSG (M15) (amino acids 1-27 of SEQ ID NO:15);
RPLAFSDAGPHVHWGDPIRLRHL YTSG (M16) (amino acids 1-27 of SEQ ID NO:16);

RPLAFSDAGPHVGGWGDPIRLRHL YTSG (M17) (amino acids 1-27 of SEQ ID NO:17);
RPLAFSDAGPHYGGWGDPIRLRHL YTSG (M18) (amino acids 1-27 of SEQ ID NO:18);
RPLAFSDAGPVYGGWGDPIRLRHL YTSG (M19) (amino acids 1-27 of SEQ ID NO:19);
RPLAFSDAGPVHGGWGDPIRLRHL YTSG (M20) (amino acids 1-27 of SEQ ID NO:20);
RPLAFSDAGPVHYGGWGDPIRLRHL YTSG (M21) (amino acids 1-27 of SEQ ID NO:21);
RPLAFSDAGPHVHGGWGDPIRLRHL YTSG (M22) (amino acids 1-27 of SEQ ID NO:22);
RPLAFSDAGPHHGGWGDPIRLRHL YTSG (M23) (amino acids 1-27 of SEQ ID NO:23);
RPLAFSDAGPHHYGGWGDPIRLRHL YTSG (M24) (amino acids 1-27 of SEQ ID NO:24);
RPLAFSDAGPHVYGGWGDPIRLRHL YTSG (M25) (amino acids 1-27 of SEQ ID NO:25);
RPLAFSDSSPLVHWGDPIRLRHL YTSG (M26) (amino acids 1-27 of SEQ ID NO:26);
RPLAFSDSSPHVHWGDPIRLRHL YTSG (M27) (amino acids 1-27 of SEQ ID NO:27);
RPLAFSDAGPHVWGDPIRLRHL YTSG (M28) (amino acids 1-26 of SEQ ID NO:28);
RPLAFSDAGPHVHYGGWGDPIRLRHL YTSG (M29) (amino acids 1-28 of SEQ ID NO:29);
RPLAFSDAGPHVHYAWGDPIRLRHL YTSG (M30) (amino acids 1-29 of SEQ ID NO:30);
RHIPDSSPLLQFGAQVRLRHL YTSG (M31) (amino acids 1-26 of SEQ ID NO:31);
RHIPDSSPLLQFGDQVRLRHL YTSG (M32) (amino acids 1-26 of SEQ ID NO:32);
RHIPDSSPLLQFGPQVRLRHL YTSG (M33) (amino acids 1-26 of SEQ ID NO:33);
RHIPDSSPLLQFGGAVRLRHL YTSG (M34) (amino acids 1-26 of SEQ ID NO:34);
RHIPDSSPLLQFGGEVRLRHL YTSG (M35) (amino acids 1-26 of SEQ ID NO:35);
RHIPDSSPLLQFGGNVRLRHL YTSG (M36) (amino acids 1-26 of SEQ ID NO:36);
RHIPDSSPLLQFGGQARLRHL YTSG (M37) (amino acids 1-26 of SEQ ID NO:37);
RHIPDSSPLLQFGGQIRLRHL YTSG (M38) (amino acids 1-26 of SEQ ID NO:38);
RHIPDSSPLLQFGGQTRLRHL YTSG (M39) (amino acids 1-26 of SEQ ID NO:39);
RHIPDSSPLLQFGWGQPVRRLRHL YTSG (M40) (amino acids 1-28 of SEQ ID NO:40);
DAGPHVHYGGWGDPIRLRHL YTSG (M74-R) (amino acids 2-24 of SEQ ID NO:74);
VHYGGWGDPIRLRHL YTSG (M75-R) (amino acids 2-19 of SEQ ID NO:75);
RLRHL YTSG (M77-R) (amino acids 2-10 of SEQ ID NO:77);
RHIPDSSPLLQFGWGDPIRLRHL YTSG (M9) (amino acids 1-28 of SEQ ID NO:9);
RHIPDSSPLLQWGDPIRLRHL YTSG (M8) (amino acids 1-26 of SEQ ID NO:8);
RPLAFSDAGPLLQFGWGDPIRLRHL YTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
RHIPDSSPHVHYGGWGDPIRLRHL YTSG (M10) (amino acids 1-28 of SEQ ID NO:10);

RPLAFSDAGPLLQFGGQVRLRHL YTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 RHIPDSSPHVHYGGQVRLRHL YTSG (M14) (amino acids 1-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGDIRLRHL YTSG (M43) amino acids 1-27 of SEQ ID NO:43); or
 RDSSPLLQFGGQVRLRHL YTSG (M6) (amino acids 1-22 of SEQ ID NO:6);
 and for any of the foregoing peptide sequences the amino terminal R residue may be deleted.

[0144] In certain embodiments, the peptide comprises or consists of any of:

HPIPDSSPLLQFGGQVRLRHL YTSG (M5-R) (amino acids 1-25 of SEQ ID NO:160);
 DSSPLLQFGGQVRLRHL YTSG (M6-R) (amino acids 2-22 of SEQ ID NO:6);
 RPLAFSDSSPLLQFGGQVRLRHL YTSG (M7) (amino acids 1-27 of SEQ ID NO:7);
 HPIPDSSPLLQWGDPIRLRHL YTSG (M8-R) (amino acids 2-26 of SEQ ID NO:8);
 HPIPDSSPLLQFGWGDPIRLRHL YTSG (M9-R) (amino acids 2-28 of SEQ ID NO:9);
 HPIPDSSPHVHYGWGDPIRLRHL YTSG (M10-R) (amino acids 2-28 of SEQ ID NO:10);
 RPLAFSDAGPLLQWGDPIRLRHL YTSG (M11) (amino acids 1-27 of SEQ ID NO:11);
 RPLAFSDAGPLLQFGWGDPIRLRHL YTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
 RPLAFSDAGPLLQFGGQVRLRHL YTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 HPIPDSSPHVHYGGQVRLRHL YTSG (M14-R) (amino acids 2-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGQVRLRHL YTSG (M15) (amino acids 1-27 of SEQ ID NO:15);
 RPLAFSDAGPHVHWGDPIRLRHL YTSG (M16) (amino acids 1-27 of SEQ ID NO:16);
 RPLAFSDAGPHVHWGDPIRLRHL YTSG (M17) (amino acids 1-27 of SEQ ID NO:17);
 RPLAFSDAGPHYGWGDPIRLRHL YTSG (M18) (amino acids 1-27 of SEQ ID NO:18);
 RPLAFSDAGPVYGWGDPIRLRHL YTSG (M19) (amino acids 1-27 of SEQ ID NO:19);
 RPLAFSDAGPVHGWGDPIRLRHL YTSG (M20) (amino acids 1-27 of SEQ ID NO:20);
 RPLAFSDAGPVHYWGDPIRLRHL YTSG (M21) (amino acids 1-27 of SEQ ID NO:21);
 RPLAFSDAGPHVHWGDPIRLRHL YTSG (M22) (amino acids 1-27 of SEQ ID NO:22);
 RPLAFSDAGPHHWGDPIRLRHL YTSG (M23) (amino acids 1-27 of SEQ ID NO:23);
 RPLAFSDAGPHHYWGDPIRLRHL YTSG (M24) (amino acids 1-27 of SEQ ID NO:24);
 RPLAFSDAGPHVYWGDPIRLRHL YTSG (M25) (amino acids 1-27 of SEQ ID NO:25);
 RPLAFSDSSPLVHWGDPIRLRHL YTSG (M26) (amino acids 1-27 of SEQ ID NO:26);
 RPLAFSDSSPHVHWGDPIRLRHL YTSG (M27) (amino acids 1-27 of SEQ ID NO:27);
 RPLAFSDAGPHVWGDPIRLRHL YTSG (M28) (amino acids 1-26 of SEQ ID NO:28);
 RPLAFSDAGPHVHYWGDPIRLRHL YTSG (M29) (amino acids 1-28 of SEQ ID NO:29);
 RPLAFSDAGPHVHYAWGDPIRLRHL YTSG (M30) (amino acids 1-29 of SEQ ID NO:30);

RHPIPDSSPLLQFGAQVRLRHLTYTSG (M31) (amino acids 1-26 of SEQ ID NO:31);
 RHPIPDSSPLLQFGDQVRLRHLTYTSG (M32) (amino acids 1-26 of SEQ ID NO:32);
 RHPIPDSSPLLQFGPQVRLRHLTYTSG (M33) (amino acids 1-26 of SEQ ID NO:33);
 RHPIPDSSPLLQFGGAVRLRHLTYTSG (M34) (amino acids 1-26 of SEQ ID NO:34);
 RHPIPDSSPLLQFGGEVRLRHLTYTSG (M35) (amino acids 1-26 of SEQ ID NO:35);
 RHPIPDSSPLLQFGGNVRLRHLTYTSG (M36) (amino acids 1-26 of SEQ ID NO:36);
 RHPIPDSSPLLQFGGQARLRHLTYTSG (M37) (amino acids 1-26 of SEQ ID NO:37);
 RHPIPDSSPLLQFGGQIRLRHLTYTSG (M38) (amino acids 1-26 of SEQ ID NO:38);
 RHPIPDSSPLLQFGGQTRLRHLTYTSG (M39) (amino acids 1-26 of SEQ ID NO:39);
 RHPIPDSSPLLQFGWGQPVRLRHLTYTSG (M40) (amino acids 1-28 of SEQ ID NO:40);
 DAGPHVHYGWGDPIRLRHLTYTSG (M74-R) (amino acids 2-24 of SEQ ID NO:74);
 VHYGWGDPIRLRHLTYTSG (M75-R) (amino acids 2-19 of SEQ ID NO:75);
 RLRHLTYTSG (M77-R) (amino acids 2-10 of SEQ ID NO:77);
 RHPIPDSSPLLQFGWGDPPIRLRHLTYTSG (M9) (amino acids 1-28 of SEQ ID NO:9);
 RHPIPDSSPLLQWGDPIRLRHLTYTSG (M8) (amino acids 1-26 of SEQ ID NO:8);
 RPLAFSDAGPLLQFGWGDPPIRLRHLTYTSG (M12) (amino acids 1-29 of SEQ ID NO:12);
 RHPIPDSSPHVHYGWGDPIRLRHLTYTSG (M10) (amino acids 1-28 of SEQ ID NO:10);
 RPLAFSDAGPLLQFGGQVRLRHLTYTSG (M13) (amino acids 1-27 of SEQ ID NO:13);
 RHPIPDSSPHVHYGGQVRLRHLTYTSG (M14) (amino acids 1-26 of SEQ ID NO:14);
 RPLAFSDAGPHVHYGGDIRLRHLTYTSG (M43) (amino acids 1-27 of SEQ ID NO:43); or
 RDSSPLLQFGGQVRLRHLTYTSG (M6) (amino acids 1-22 of SEQ ID NO:6). In some
 embodiments, the peptide comprise one of the foregoing sequences. In another embodiment, the
 peptide consists of one of the foregoing sequences. In some embodiments, the peptide comprises a
 C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a
 first amino acid position and a last amino acid position,
 wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 (FGF19),
 WGDPIRLRHLTYTSG (SEQ ID NO:169), wherein the W residue corresponds to the first amino acid
 position of the C-terminal region.

[0145] In a specific embodiment, a peptide sequence comprises or consists of:

MRDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLR
 TVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
 QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRS
 PSFEK (M70) (SEQ ID NO:70), or a subsequence or fragment thereof.

[0146] In another embodiment, a peptide sequence comprises or consists of:

RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M69) (SEQ ID NO:69), or a subsequence or fragment thereof.

[0147] In other embodiments, the peptide comprises or consists of:

RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIILEDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M200) (SEQ ID NO:197); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0148] In some embodiments, the peptide comprises or consists of:

[0149] RPLAFSDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAH
SLLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIILEDGYNVYRSEK
HRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPF
GLVTGLEAVRSPSFEK (M201) (SEQ ID NO:198); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0150] In certain embodiments, the peptide comprises or consists of:

[0151] RPLAFSDASPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSA
HSLLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIILEDGYNVYRSE
KHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDP
FGLVTGLEAVRSPSFEK (M202) (SEQ ID NO:199); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0152] In other embodiments, the peptide comprises or consists of:

[0153] RDSSPLLQWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLE
AVRSPSFEK (M203) (SEQ ID NO:200); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0154] In some embodiments, the peptide comprises or consists of:

[0155] RHPIPDSSPLLQFGDQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLE
IKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIILEDGYNVYRSEKHRLP
VSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVT

GLEAVRSPSF EK (M204) (SEQ ID NO:201); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0156] In certain embodiments, the peptide comprises or consists of:

[0157] RDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL EIK A VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (M205) (SEQ ID NO:202); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0158] In some embodiments, the peptide comprises or consists of:

[0159] RHPIPDSSPLLQFGGQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL EIK A VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (M206) (SEQ ID NO:203); or a subsequence or fragment thereof. In one embodiment, the N-terminal R residue is deleted.

[0160] In other embodiments, the peptide comprises or consists of:

[0161] MRDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLL EIK A VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (M207) (SEQ ID NO:204); or a subsequence or fragment thereof.

[0162] In some embodiments, the peptide is a variant peptide designated M139. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:193. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:193. In some embodiments, the peptide is a variant peptide designated M140. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:194. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:194. In some embodiments, the peptide is a variant peptide designated M141. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:195. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:195. In some embodiments, the peptide is a variant peptide designated M160. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:196. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:196. In some embodiments, the peptide is a variant peptide designated M200. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:197. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:197. In some

embodiments, the peptide is a variant peptide designated M201. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide is a variant peptide designated M202. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:199. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:199. In certain embodiments, the peptide is a variant peptide designated M203. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:200. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:200. In some embodiments, the peptide is a variant peptide designated M204. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:201. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:201. In another embodiment, the peptide is a variant peptide designated M205. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:202. In other embodiments, the peptide is a variant peptide designated M206. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:203. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:203. In yet other embodiments, the peptide is a variant peptide designated M207. In some embodiments, the peptide comprises an amino acid sequence set forth in SEQ ID NO:204. In other embodiments, the peptide consists of an amino acid sequence set forth in SEQ ID NO:204.

[0163] Peptide sequences provided herein additionally include those with reduced or absent induction or formation of HCC compared to FGF19, or a FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19. Peptide sequences provided herein also include those with greater glucose lowering activity compared to FGF19, or a FGF 19 variant sequence having any of GQV, GDI, WGPI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDPI (SEQ ID NO:179),

WGDP A (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19. Peptide sequences provided herein moreover include those with less lipid (*e.g.*, triglyceride, cholesterol, non-HDL or HDL) increasing activity compared to FGF19, or a FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDP A (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19.

[0164] Typically, the number of amino acids or residues in a peptide sequence provided herein will total less than about 250 (*e.g.*, amino acids or mimetics thereof). In various particular embodiments, the number of residues comprise from about 20 up to about 200 residues (*e.g.*, amino acids or mimetics thereof). In additional embodiments, the number of residues comprise from about 50 up to about 200 residues (*e.g.*, amino acids or mimetics thereof). In further embodiments, the number of residues comprise from about 100 up to about 195 residues (*e.g.*, amino acids or mimetics thereof) in length.

[0165] Amino acids or residues can be linked by amide or by non-natural and non-amide chemical bonds including, for example, those formed with glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, or N, N'-dicyclohexylcarbodiimide (DCC). Non-amide bonds include, for example, ketomethylene, aminomethylene, olefin, ether, thioether and the like (see, *e.g.*, Spatola in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357 (1983), "Peptide and Backbone Modifications," Marcel Decker, NY). Thus, when a peptide provided herein includes a portion of a FGF19 sequence and a portion of a FGF21 sequence, the two portions need not be joined to each other by an amide bond, but can be joined by any other chemical moiety or conjugated together via a linker moiety.

[0166] In some embodiments, the treatment peptides provided herein also include subsequences, variants and modified forms of the exemplified peptide sequences (including the FGF19 and FGF21 variants and subsequences listed in Tables 1-11 and Sequence Listing), so long as the foregoing retains at least a detectable or measureable activity or function. For example, certain exemplified variant peptides have FGF19 C-terminal sequence,

PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVLRRTVAIKGVHVSRYLCMGADGKM
QGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPML
PMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFEEK (SEQ ID NO:188) at
the C-terminal portion, *e.g.*, following the “TSG” amino acid residues of the variant.

[0167] Also, certain exemplified variant peptides, for example, those having all or a portion of FGF21 sequence at the amino-terminus, have an “R” residue positioned at the N-terminus, which can be omitted. Similarly, certain exemplified variant peptides, include an “M” residue positioned at the N-terminus, which can be appended to or further substituted for an omitted residue, such as an “R” residue. More particularly, in various embodiments peptide sequences at the N-terminus include any of: RDSS (SEQ ID NO:115), DSS, MDSS (SEQ ID NO:116) or MRDSS (SEQ ID NO:117). Furthermore, in cells when a “M” residue is adjacent to a “S” residue, the “M” residue may be cleaved such that the “M” residue is deleted from the peptide sequence, whereas when the “M” residue is adjacent to a “D” residue, the “M” residue may not be cleaved. Thus, by way of example, in various embodiments peptide sequences include those with the following residues at the N-terminus: MDSSPL (SEQ ID NO:119), MSDSSPL (SEQ ID NO:120) (cleaved to SDSSPL (SEQ ID NO:112)) and MSSPL (SEQ ID NO:113) (cleaved to SSPL (SEQ ID NO:114)).

[0168] Accordingly, in some embodiments, the “peptide,” “polypeptide,” and “protein” sequences provided herein include subsequences, variants and modified forms of the FGF19 and FGF21 variants and subsequences listed in Tables 1-11 and Sequence Listing, and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and Sequence Listing, so long as the subsequence, variant or modified form (*e.g.*, fusion or chimera) retains at least a detectable activity or function, *e.g.*, glucose lowering activity and/or modulation of bile acid homeostasis.

[0169] As used herein, the term “modify” and grammatical variations thereof, means that the composition deviates relative to a reference composition, such as a peptide sequence. Such modified peptide sequences, nucleic acids and other compositions may have greater or less activity or function, or have a distinct function or activity compared with a reference unmodified peptide sequence, nucleic acid, or other composition, or may have a property desirable in a protein formulated for therapy (*e.g.* serum half-life), to elicit antibody for use in a detection assay, and/or for protein purification. For example, a peptide sequence provided herein can be

modified to increase serum half-life, to increase *in vitro* and/or *in vivo* stability of the protein, *etc.*

[0170] Particular examples of such subsequences, variants and modified forms of the peptide sequences exemplified herein (*e.g.*, a peptide sequence listed in the Sequence Listing or Tables 1-11) include substitutions, deletions and/or insertions/additions of one or more amino acids, to or from the amino-terminus, the carboxy-terminus or internally. One example is a substitution of an amino acid residue for another amino acid residue within the peptide sequence. Another is a deletion of one or more amino acid residues from the peptide sequence, or an insertion or addition of one or more amino acid residues into the peptide sequence.

[0171] The number of residues substituted, deleted or inserted/added are one or more amino acids (*e.g.*, 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250, or more) of a peptide sequence. Thus, a FGF19 or FGF21 sequence can have few or many amino acids substituted, deleted or inserted/added (*e.g.*, 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250, or more). In addition, a FGF19 amino acid sequence can include or consist of an amino acid sequence of about 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250, or more amino acids from FGF21; or a FGF21 amino acid or sequence can include or consist of an amino acid sequence of about 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250, or more amino acids from FGF19.

[0172] Specific examples of substitutions include substituting a D residue for an L-residue. Accordingly, although residues are listed in the L-isomer configuration, D-amino acids at any particular or all positions of the peptide sequences provided herein are included, unless a D-isomer leads to a sequence that has no detectable or measurable function.

[0173] Additional specific examples are non-conservative and conservative substitutions. A “conservative substitution” is a replacement of one amino acid by a biologically, chemically or structurally similar residue. Biologically similar means that the substitution is compatible with a biological activity, *e.g.*, activity that improves PBC and/or the manifestations thereof.

Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or having similar size, or the structure of a first, second or additional peptide sequence is maintained. Chemical similarity means that the residues have the same charge or are both hydrophilic and hydrophobic. Particular examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine, for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, *etc.* Routine assays can be used to determine whether a subsequence, variant or modified form has activity, *e.g.*, activity that improves PBC and/or the manifestations thereof.

[0174] Particular examples of subsequences, variants and modified forms of the peptide sequences exemplified herein have 50%-60%, 60%-70%, 70%-75%, 75%-80%, 80%-85%, 85%-90%, 90%-95%, or 96%, 97%, 98%, or 99% identity to a reference peptide sequence. The term “identity” and “homology” and grammatical variations thereof mean that two or more referenced entities are the same. Thus, where two amino acid sequences are identical, they have the identical amino acid sequence. “Areas, regions or domains of identity” mean that a portion of two or more referenced entities are the same. Thus, where two amino acid sequences are identical or homologous over one or more sequence regions, they share identity in those regions.

[0175] The extent of identity between two sequences can be ascertained using a computer program and mathematical algorithm known in the art. Such algorithms that calculate percent sequence identity (homology) generally account for sequence gaps and mismatches over the comparison region. For example, a BLAST (*e.g.*, BLAST 2.0) search algorithm (see, *e.g.*, Altschul *et al.*, J. Mol. Biol. 215:403 (1990), publicly available through NCBI) has exemplary search parameters as follows: Mismatch -2; gap open 5; gap extension 2. For peptide sequence comparisons, a BLASTP algorithm is typically used in combination with a scoring matrix, such as PAM100, PAM 250, BLOSUM 62 or BLOSUM 50. FASTA (*e.g.*, FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantitate the extent of identity (Pearson *et al.*, Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol Biol. 132:185 (2000); and Smith *et al.*, J. Mol. Biol. 147:195 (1981)). Programs for quantitating protein structural similarity using Delaunay-based topological mapping have also been developed (Bostick *et al.*, Biochem Biophys Res Commun. 304:320 (2003)).

[0176] In the peptide sequences, including subsequences, variants and modified forms of the peptide sequences exemplified herein, an “amino acid” or “residue” includes conventional alpha-amino acids as well as beta-amino acids; alpha, alpha disubstituted amino acids; and N-substituted amino acids, wherein at least one side chain is an amino acid side chain moiety as defined herein. An “amino acid” further includes N-alkyl alpha-amino acids, wherein the N-terminus amino group has a C₁ to C₆ linear or branched alkyl substituent. The term “amino acid” therefore includes stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids (*e.g.*, by glycosylation, phosphorylation, ester or amide cleavage, *etc.*), enzymatically modified or synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, amino acids with a side chain moiety modified, derivatized from naturally occurring moieties, or synthetic, or not naturally occurring, *etc.* Modified and unusual amino acids are included in the peptide sequences provided herein (see, for example, in Synthetic Peptides: A User's Guide; Hruby *et al.*, Biochem. J. 268:249 (1990); and Toniolo C., Int. J. Peptide Protein Res. 35:287 (1990)).

[0177] In addition, protecting and modifying groups of amino acids are included. The term “amino acid side chain moiety” as used herein includes any side chain of any amino acid, as the term “amino acid” is defined herein. This therefore includes the side chain moiety in naturally occurring amino acids. It further includes side chain moieties in modified naturally occurring amino acids as set forth herein and known to one of skill in the art, such as side chain moieties in stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically modified or synthesized amino acids, derivatized amino acids, constructs or structures designed to mimic amino acids, *etc.* For example, the side chain moiety of any amino acid disclosed herein or known to one of skill in the art is included within the definition.

[0178] A “derivative of an amino acid side chain moiety” is included within the definition of an amino acid side chain moiety. Non-limiting examples of derivatized amino acid side chain moieties include, for example: (a) adding one or more saturated or unsaturated carbon atoms to an existing alkyl, aryl, or aralkyl chain; (b) substituting a carbon in the side chain with another atom, such as oxygen or nitrogen; (c) adding a terminal group to a carbon atom of the side chain, including methyl (--CH₃), methoxy (--OCH₃), nitro (--NO₂), hydroxyl (--OH), or cyano (--C=N);

(d) for side chain moieties including a hydroxy, thiol or amino groups, adding a suitable hydroxy, thiol or amino protecting group; or (e) for side chain moieties including a ring structure, adding one or more ring substituents, including hydroxyl, halogen, alkyl, or aryl groups attached directly or through, *e.g.*, an ether linkage. For amino groups, suitable protecting groups are known to the skilled artisan. Provided such derivatization provides a desired activity in the final peptide sequence (*e.g.*, activity that improves PBC and/or the manifestations thereof).

[0179] An “amino acid side chain moiety” includes all such derivatization, and particular non-limiting examples include: gamma-amino butyric acid, 12-amino dodecanoic acid, alpha-aminoisobutyric acid, 6-amino hexanoic acid, 4-(aminomethyl)-cyclohexane carboxylic acid, 8-amino octanoic acid, biphenylalanine, Boc--t-butoxycarbonyl, benzyl, benzoyl, citrulline, diaminobutyric acid, pyrrollysine, diaminopropionic acid, 3,3-diphenylalanine, orthonine, citrulline, 1,3-dihydro-2H-isoindolecarboxylic acid, ethyl, Fmoc—fluorenylmethoxycarbonyl, heptanoyl ($\text{CH}_3\text{--}(\text{CH}_2)_5\text{--C(=O)--}$), hexanoyl ($\text{CH}_3\text{--}(\text{CH}_2)_4\text{--C(=O)--}$), homoarginine, homocysteine, homolysine, homophenylalanine, homoserine, methyl, methionine sulfoxide, methionine sulfone, norvaline (NVA), phenylglycine, propyl, isopropyl, sarcosine (SAR), tert-butylalanine, and benzyloxycarbonyl.

[0180] A single amino acid, including stereoisomers and modifications of naturally occurring protein amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically-synthesized amino acids, non-naturally occurring amino acids including derivatized amino acids, an alpha, alpha disubstituted amino acid derived from any of the foregoing (*i.e.*, an alpha, alpha disubstituted amino acid, wherein at least one side chain is the same as that of the residue from which it is derived), a beta-amino acid derived from any of the foregoing (*i.e.*, a beta-amino acid which, other than for the presence of a beta-carbon, is the same as the residue from which it is derived) *etc.*, including all of the foregoing can be referred to herein as a “residue.” Suitable substituents, in addition to the side chain moiety of the alpha-amino acid, include C₁ to C₆ linear or branched alkyl. Aib is an example of an alpha, alpha disubstituted amino acid. While alpha, alpha disubstituted amino acids can be referred to using conventional L- and D-isomeric references, it is to be understood that such references are for convenience, and that where the substituents at the alpha-position are different, such amino acid can interchangeably be referred to as an alpha, alpha disubstituted amino acid derived from the L- or D-isomer, as appropriate, of a residue with the designated amino acid side chain moiety.

Thus (S)-2-Amino-2-methyl-hexanoic acid can be referred to as either an alpha, alpha disubstituted amino acid derived from L-Nle (norleucine) or as an alpha, alpha disubstituted amino acid derived from D-Ala. Similarly, Aib can be referred to as an alpha, alpha disubstituted amino acid derived from Ala. Whenever an alpha, alpha disubstituted amino acid is provided, it is to be understood as including all (R) and (S) configurations thereof.

[0181] An “N-substituted amino acid” includes any amino acid wherein an amino acid side chain moiety is covalently bonded to the backbone amino group, optionally where there are no substituents other than H in the alpha-carbon position. Sarcosine is an example of an N-substituted amino acid. By way of example, sarcosine can be referred to as an N-substituted amino acid derivative of Ala, in that the amino acid side chain moiety of sarcosine and Ala is the same, *i.e.*, methyl.

[0182] In certain embodiments, covalent modifications of the peptide sequences, including subsequences, variants and modified forms of the peptide sequences exemplified herein are provided. An exemplary type of covalent modification includes reacting targeted amino acid residues with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the peptide. Derivatization with bifunctional agents is useful, for instance, for cross-linking peptide to a water-insoluble support matrix or surface for use in the method for purifying anti-peptide antibodies, and vice-versa. Commonly used cross linking agents include, *e.g.*, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

[0183] Other modifications include deamidation of glutamyl and asparagyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, amidation of any C-terminal carboxyl group, *etc.*

[0184] Exemplified peptide sequences, and subsequences, variants and modified forms of the peptide sequences exemplified herein can also include alterations of the backbone for stability,

derivatives, and peptidomimetics. The term “peptidomimetic” includes a molecule that is a mimic of a residue (referred to as a “mimetic”), including but not limited to piperazine core molecules, keto-piperazine core molecules and diazepine core molecules. Unless otherwise specified, an amino acid mimetic of a peptide sequence provided herein includes both a carboxyl group and amino group, and a group corresponding to an amino acid side chain, or in the case of a mimetic of Glycine, no side chain other than hydrogen.

[0185] By way of example, these would include compounds that mimic the sterics, surface charge distribution, polarity, *etc.* of a naturally occurring amino acid, but need not be an amino acid, which would impart stability in the biological system. For example, Proline may be substituted by other lactams or lactones of suitable size and substitution; Leucine may be substituted by an alkyl ketone, N-substituted amide, as well as variations in amino acid side chain length using alkyl, alkenyl or other substituents, others may be apparent to the skilled artisan. The essential element of making such substitutions is to provide a molecule of roughly the same size and charge and configuration as the residue used to design the molecule.

Refinement of these modifications will be made by analyzing the compounds in a functional (*e.g.*, glucose lowering) or other assay, and comparing the structure-activity relationship. Such methods are within the scope of the skilled artisan working in medicinal chemistry and drug development.

[0186] The term “bind,” or “binding,” when used in reference to a peptide sequence, means that the peptide sequence interacts at the molecular level. Specific and selective binding can be distinguished from non-specific binding using assays known in the art (*e.g.*, competition binding, immunoprecipitation, ELISA, flow cytometry, Western blotting).

[0187] Peptides and peptidomimetics can be produced and isolated using methods known in the art. Peptides can be synthesized, in whole or in part, using chemical methods (see, *e.g.*, Caruthers (1980). *Nucleic Acids Res. Symp. Ser.* 215; Horn (1980); and Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA). Peptide synthesis can be performed using various solid-phase techniques (see, *e.g.*, Roberge *Science* 269:202 (1995); Merrifield, *Methods Enzymol.* 289:3 (1997)) and automated synthesis may be achieved, *e.g.*, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the manufacturer’s instructions. Peptides and peptide mimetics can also be synthesized using combinatorial methodologies. Synthetic

residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies known in the art (see, *e.g.*, Organic Syntheses Collective Volumes, Gilman, *et al.* (Eds) John Wiley & Sons, Inc., NY). Modified peptides can be produced by chemical modification methods (see, for example, Belousov, *Nucleic Acids Res.* 25:3440 (1997); Frenkel, *Free Radic. Biol. Med.* 19:373 (1995); and Blommers, *Biochemistry* 33:7886 (1994)). Peptide sequence variations, derivatives, substitutions and modifications can also be made using methods such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR-based mutagenesis. Site-directed mutagenesis (Carter *et al.*, *Nucl. Acids Res.*, 13:4331 (1986); Zoller *et al.*, *Nucl. Acids Res.* 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, *Gene* 34:315 (1985)), restriction selection mutagenesis (Wells *et al.*, *Philos. Trans. R. Soc. London SerA* 317:415 (1986)) and other techniques can be performed on cloned DNA to produce peptide sequences, variants, fusions and chimeras provided herein, and variations, derivatives, substitutions and modifications thereof.

[0188] A “synthesized” or “manufactured” peptide sequence is a peptide made by any method involving manipulation by the hand of man. Such methods include, but are not limited to, the aforementioned, such as chemical synthesis, recombinant DNA technology, biochemical or enzymatic fragmentation of larger molecules, and combinations of the foregoing.

[0189] Peptide sequences provided herein including subsequences, sequence variants and modified forms of the exemplified peptide sequences (*e.g.*, sequences listed in the Sequence Listing or Tables 1-11), can also be modified to form a chimeric molecule. In certain embodiments, provided herein are peptide sequences that include a heterologous domain. Such domains can be added to the amino-terminus or at the carboxyl-terminus of the peptide sequence. Heterologous domains can also be positioned within the peptide sequence, and/or alternatively flanked by FGF19 and/or FGF21 derived amino acid sequences.

[0190] The term “peptide” also includes dimers or multimers (oligomers) of peptides. In certain embodiments, dimers or multimers (oligomers) of the exemplified peptide sequences are provided herein, as well as subsequences, variants and modified forms of the exemplified peptide sequences, including sequences listed in the Sequence Listing or Tables 1-11.

[0191] In certain embodiments, a peptide sequence provided herein comprises an amino acid sequence set forth in Table 1. In other embodiments, a peptide sequence provided herein consists of an amino acid sequence set forth in Table 1.

Table 1

SEQ ID NO.	Amino Acid Sequence
1.	RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
2.	RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
3.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
4.	RPLAFSDAGPHVHYAWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
5.	RHPIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
6.	RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDG YNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
7.	RPLAFSDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEE

	IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
8.	RHPIPDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
9.	RHPIPDSSPLLQFGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
10.	RHPIPDSSPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE E EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
11.	RPLAFSDAGPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
12.	RPLAFSDAGPLLQFGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
13.	RPLAFSDAGPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
14.	RHPIPDSSPHVHYGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEI RPGDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPE DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
15.	RPLAFSDAGPHVHYGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ

	SAHSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
16.	RPLAFSDAGPHVHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
17.	RPLAFSDAGPHVHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
18.	RPLAFSDAGPHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
19.	RPLAFSDAGPVYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
20.	RPLAFSDAGPVHGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
21.	RPLAFSDAGPVHYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLL EIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE IRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
22.	RPLAFSDAGPHVHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK

23.	RPLAFSDAGPHHGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
24.	RPLAFSDAGPHHYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
25.	RPLAFSDAGPHVYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
26.	RPLAFSDSSPLVHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
27.	RPLAFSDSSPHVHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
28.	RPLAFSDAGPHVWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED RPGGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
29.	RPLAFSDAGPHVHYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEED EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
30.	RPLAFSDAGPHVHYAWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE

	EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
31.	RHPIPDSSPLLQFGAQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
32.	RHPIPDSSPLLQFGDQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
33.	RHPIPDSSPLLQFGPQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
34.	RHPIPDSSPLLQFGGAVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
35.	RHPIPDSSPLLQFGGEVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
36.	RHPIPDSSPLLQFGGNVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
37.	RHPIPDSSPLLQFGGQARLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
38.	RHPIPDSSPLLQFGGQIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP

	DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
39.	RHIPDSSPLLQFGGQTRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
40.	RHIPDSSPLLQFGWGQPVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE E EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
41.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPEPPGI LAPQPPDVGSSDPLSMVGPSQGRSPSYAS
42.	HPIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPEPPGILAPQP PDVGSSDPLSMVGPSQGRSPSYAS
43.	RPLAFSDAGPHVHYGGDIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
44.	RPLAFSDAGPHVHYGWGDPIRQRYLYTDDAQQTEAHLEIREDGTVGGAAD QSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFREL LLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPP GILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
45.	HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPES LLQLKALKALKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLEDG YNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPMVPEEPE DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
46.	RPLAFSDAGPHVHYGWGDPIRQRYLYTDDAQQTEAHLEIREDGTVGGAAD

	QSPESLLQLKALKPGVIQILGVKTSRFLCQRPDGYSLHFDPEACSFREL LLEDGYNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPP GILAPQPPDVGSSDPLSMVGPSQGRSPSYASPMVPEEPEDLRGHLESDMFSS PLETDSMDPFGLVTGLEAVRSPSF EK
47.	HPIPDSSPLLQWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
48.	RDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDG YNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
49.	RPLAFSDSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
50.	RHPIPDSSPLLQFGDQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEILE DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
51.	RHPIPDSSPLLQFGGNVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
52.	RDSSPLLQWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEIRPDG YNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
53.	MDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIKAVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL

	RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
54.	RPLAFSDAGPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
55.	RPLAFSDAGPHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
56.	RPLAFSDAGPVYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
57.	RPLAFSDAGPVHGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
58.	RPLAFSDAGPVHYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
59.	RPLAFSDAGPHHWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
60.	RPLAFSDAGPHHYWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
61.	RPLAFSDAGPHVGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE

	IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
62.	RPLAFSDAGPHVYWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
63.	RPLAFSDAGPHVHWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
64.	RPLAFSDSSPLVHWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
65.	RPLAFSDSSPHVHWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
66.	RPLAFSDAGPHLQWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
67.	RPLAFSDAGPHVWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEI RPGDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPE DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
68.	RPLAFSDAGPHVHYWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE E EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
69.	RDSSPLVHYGWGDP IRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS

	LLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
70.	MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP RPGDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
71.	HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPES LLQLKALKPGVIQILGVKTSRFLCQRPD GALYGSLHFDPEACSFRELLLEDG YNVYQSEAHSLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAP QPPDVGSSDPLSMVGPSQGRSPSYAS
72.	HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPES LLQLKALKPGVIQILGVKTSRFLCQRPD GALYGSLHFDPEACSFRELLLEDG YNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPAPPEPPGILAP QPPDVGSSDPLSMVGPSQGRSPSYAS
73.	HPIPDSSPLLQFGGQVRQRYLYTDDAQQT EAHLEIREDGTVGGAADQSPES LLQLKALKPGVIQILGVKTSRFLCQRPD GALYGSLHFDPEACSFRELLLEDG YNVYQSEAHGLPLHLPGNKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAP QPPDVGSSDPLSMVVQDELQGVGGEGCHMHPENCKTLLTDIDRTHTEKPV WDGITGE
74.	RDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
75.	RVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYN VYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHL ESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
76.	RGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKH RLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSP

	LETDSMDPFGLVTGLEAVRSPSF EK
77.	RRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAI KGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRL PVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLE TDSMDPFGLVTGLEAVRSPSF EK
78.	RAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
79.	RGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDG YNVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
80.	RPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLE IK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGY NVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH LESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
81.	RHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI K AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGY NVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH LESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
82.	RPLAFSAAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
83.	RPLAFSDAAPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLS SAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
84.	RPLAFSDAGAHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCAR GQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAF

	EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVP EEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
85.	RPLAFSDAGPHVHYGAGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
86.	RPLAFSDAGPHVHYGWGAPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
87.	RPLAFSDAGPHVHYGWGDAICARGQSAHSLLEIKAVALRTVAIKGVH SVR YLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
88.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPAGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLAHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
89.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPAGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
90.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
91.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGFLPLAHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
92.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG

	QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGFLPLSAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
93.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQAQLYKNRGFLPLAHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
94.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLAAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
95.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKNRGFLPLSAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
96.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLAHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
97.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLSAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
98.	RPLAFSDAGPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKNRGFLPLAAFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK
138.	DSSPLLQFGGQVRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI KAVALRTVAIKGVH SVRYLCMGADGKMQG LLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK

139.	RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
140.	RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
141.	DSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
142.	RHPIPDSSPLLQFGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
143.	RHPIPDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
144.	RPLAFSDAGPLLQFGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARG QSAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
145.	RHPIPDSSPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
146.	RPLAFSDAGPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFEE EIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE PEEP

	EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
147.	RHPIPDSSPHVHYGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEI RPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPE DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
148.	RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSL LEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDG YNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
149.	RPLAFSDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEE IRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
150.	RHPIPDSSPLLQFGAQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
151.	RHPIPDSSPLLQFGDQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
152.	RHPIPDSSPLLQFGPQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
153.	RHPIPDSSPLLQFGGAVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
154.	RHPIPDSSPLLQFGGEVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP

	DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
155.	RHPIPDSSPLLQFGGNVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
156.	RHPIPDSSPLLQFGGQARLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
157.	RHPIPDSSPLLQFGGQIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
158.	RHPIPDSSPLLQFGGQTRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
159.	RHPIPDSSPLLQFGWGQPVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQ SAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE E EIRPDGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEE PEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
160.	HPIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRP DGYNVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
161.	DSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI KAVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGY NVYRSEKHRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGH LESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
162.	HPIPDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS

	LLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
163.	HPIPDSSPLLQFGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSA HSLLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP DLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
164.	HPIPDSSPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQS AHSLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEP EDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
165.	HPIPDSSPHVHYGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAH SLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
166.	DAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHS LLEIKAVALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRP DGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDL RGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
167.	VHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLEIKA VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNV YRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLE SDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
168.	RLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLEIKAVALRTVAIK GVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLP VSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLET DSMDPFGLVTGLEAVRSPSF EK
188.	PHGLSSCFLRIRADGVVDCARGQSAHSLEIKAVALRTVAIKGVHSVRYLC MGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSAKQRQ LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLV TGLEAVRSPSF EK

192.	MDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
193.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEILPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
194.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEIREDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
195.	RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEILCDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
196.	RPLAFSDAGPHVHYGWGDPIRQRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAF EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
197.	RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
198.	RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
199.	RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE

	EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
200.	RDSSPLLQWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
201.	RHIPDSSPLLQFGDQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
202.	RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
203.	RHIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK
204.	MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK AVALRTVAIKGVH SVRYLCMGADGKM QGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRG HLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK

[0192] In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:1. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:2. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:3. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:4. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:5. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:6. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:7. In another embodiment, the peptide sequence comprises an amino acid sequence

[illegible]

[illegible]

[illegible]

amino acid sequence set forth in SEQ ID NO:88. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:89. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:90. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:91. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:92. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:93. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:94. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:95. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:96. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:97. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:98. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:138. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:139. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:140. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:141. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:142. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:143. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:144. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:145. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:146. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:147. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:148. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:149. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:150. In one embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:151. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:152. In other embodiments, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:153. In one

[illegible]

sequence set forth in SEQ ID NO:203. In another embodiment, the peptide sequence comprises an amino acid sequence set forth in SEQ ID NO:204. In certain embodiments of the various peptide sequences provided herein, the R residue at the N-terminus is deleted.

[0193] In yet other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:1. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:2. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:3. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:4. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:5. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:6. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:7. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:8. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:9. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:10. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:11. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:12. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:13. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:14. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:15. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:16. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:17. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:18. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:19. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:20. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:21. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:22. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:23. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:24. In one

[illegible]

[illegible]

peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:78. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:79. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:80. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:81. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:82. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:83. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:84. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:85. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:86. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:87. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:88. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:89. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:90. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:91. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:92. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:93. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:94. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:95. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:96. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:97. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:98. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:138. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:139. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:140. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:141. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:142. In another embodiment, the peptide sequence consists of an amino acid sequence set

[illegible]

sequence consists of an amino acid sequence set forth in SEQ ID NO:193. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:194. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:195. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:196. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:197. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:198. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:199. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:200. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:201. In other embodiments, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:202. In one embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:203. In another embodiment, the peptide sequence consists of an amino acid sequence set forth in SEQ ID NO:204. In certain embodiments of the various peptide sequences provided herein, the R residue at the N-terminus is deleted.

4.3 Particular Modifications to Enhance Peptide Function

[0194] It is frequently beneficial, and sometimes imperative, to improve one or more physical properties of the treatment modalities disclosed herein and/or the manner in which they are administered. Improvements of physical properties include, for example, modulating immunogenicity; methods of increasing solubility, bioavailability, serum half-life, and/or therapeutic half-life; and/or modulating biological activity. Certain modifications may also be useful to, for example, raise of antibodies for use in detection assays (*e.g.*, epitope tags) and to provide for ease of protein purification. Such improvements must generally be imparted without adversely impacting the bioactivity of the treatment modality and/or increasing its immunogenicity.

[0195] Pegylation of is one particular modification contemplated herein, while other modifications include, but are not limited to, glycosylation (N- and O-linked); polysialylation; albumin fusion molecules comprising serum albumin (*e.g.*, human serum albumin (HSA), cyno serum albumin, or bovine serum albumin (BSA)); albumin binding through, for example a conjugated fatty acid chain (acylation); and Fc-fusion proteins.

4.3.1 Pegylation

[0196] The clinical effectiveness of protein therapeutics is often limited by short plasma half-life and susceptibility to protease degradation. Studies of various therapeutic proteins (*e.g.*, filgrastim) have shown that such difficulties may be overcome by, for example, conjugating or linking the protein to any of a variety of nonproteinaceous polymers, *e.g.*, polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes. This is frequently effected by a linking moiety covalently bound to both the protein and the nonproteinaceous polymer, *e.g.*, a PEG. Such PEG-conjugated biomolecules have been shown to possess clinically useful properties, including better physical and thermal stability, protection against susceptibility to enzymatic degradation, increased solubility, longer *in vivo* circulating half-life and decreased clearance, reduced immunogenicity and antigenicity, and reduced toxicity. In addition to the beneficial effects of pegylation on pharmacokinetic parameters, pegylation itself may enhance activity.

[0197] PEGs suitable for conjugation to a polypeptide sequence are generally soluble in water at room temperature, and have the general formula $R(O-CH_2-CH_2)_nO-R$, where R is hydrogen or a protective group such as an alkyl or an alkanol group, and where n is an integer from 1 to 1000. When R is a protective group, it generally has from 1 to 8 carbons. The PEG conjugated to the polypeptide sequence can be linear or branched. Branched PEG derivatives, “star-PEGs” and multi-armed PEGs are contemplated by the present disclosure. A molecular weight of the PEG used in embodiments provided herein is not restricted to any particular range, and examples are set forth elsewhere herein; by way of example, certain embodiments have molecular weights between 500 Da and 20kDa, while other embodiments have molecular weights between 4kDa and 10kDa.

[0198] In other embodiments, provided herein are compositions of conjugates wherein the PEGs have different n values, and thus the various different PEGs are present in specific ratios. For example, some compositions comprise a mixture of conjugates where n=1, 2, 3 and 4. In some compositions, the percentage of conjugates where n=1 is 18-25%, the percentage of conjugates where n=2 is 50-66%, the percentage of conjugates where n=3 is 12-16%, and the percentage of conjugates where n=4 is up to 5%. Such compositions can be produced by reaction conditions and purification methods known in the art. Cation exchange chromatography may be used to separate conjugates, and a fraction is then identified which contains the conjugate

having, for example, the desired number of PEGs attached, purified free from unmodified protein sequences and from conjugates having other numbers of PEGs attached.

[0199] Pegylation most frequently occurs at the alpha amino group at the N-terminus of the polypeptide, the epsilon amino group on the side chain of lysine residues, and the imidazole group on the side chain of histidine residues. Since most recombinant polypeptides possess a single alpha and a number of epsilon amino and imidazole groups, numerous positional isomers can be generated depending on the linker chemistry.

[0200] General pegylation strategies known in the art can be applied herein. PEG may be bound to a polypeptide provided herein via a terminal reactive group (a “spacer” or “linker”) which mediates a bond between the free amino or carboxyl groups of one or more of the polypeptide sequences and polyethylene glycol. The PEG having the spacer which may be bound to the free amino group includes N-hydroxysuccinylimide polyethylene glycol which may be prepared by activating succinic acid ester of polyethylene glycol with N-hydroxysuccinylimide. Another activated polyethylene glycol which may be bound to a free amino group is 2,4-bis(O-methoxypolyethyleneglycol)-6-chloro-s-triazine, which may be prepared by reacting polyethylene glycol monomethyl ether with cyanuric chloride. The activated polyethylene glycol which is bound to the free carboxyl group includes polyoxyethylenediamine.

[0201] Conjugation of one or more of the polypeptide sequences provided herein to PEG having a spacer may be carried out by various conventional methods. For example, the conjugation reaction can be carried out in solution at a pH of from 5 to 10, at temperature from 4°C to room temperature, for 30 minutes to 20 hours, utilizing a molar ratio of reagent to protein of from 4:1 to 30:1. Reaction conditions may be selected to direct the reaction towards producing predominantly a desired degree of substitution. In general, low temperature, low pH (*e.g.*, pH=5), and short reaction time tend to decrease the number of PEGs attached, whereas high temperature, neutral to high pH (*e.g.*, pH≥7), and longer reaction time tend to increase the number of PEGs attached. Various means known in the art may be used to terminate the reaction. In some embodiments, the reaction is terminated by acidifying the reaction mixture and freezing at, *e.g.*, -20°C. Pegylation of various molecules is discussed in, for example, U.S. Pat. Nos. 5,252,714; 5,643,575; 5,919,455; 5,932,462; and 5,985,263.

[0202] In some embodiments, also provided herein are uses of PEG mimetics. Recombinant PEG mimetics have been developed that retain the attributes of PEG (*e.g.*, enhanced serum half-life) while conferring several additional advantageous properties. By way of example, simple polypeptide chains (comprising, for example, Ala, Glu, Gly, Pro, Ser and Thr) capable of forming an extended conformation similar to PEG can be produced recombinantly already fused to the peptide or protein drug of interest (*e.g.*, XTEN technology; Amunix; Mountain View, CA). This obviates the need for an additional conjugation step during the manufacturing process. Moreover, established molecular biology techniques enable control of the side chain composition of the polypeptide chains, allowing optimization of immunogenicity and manufacturing properties.

4.3.2 Glycosylation

[0203] As used herein, “glycosylation” is meant to broadly refer to the enzymatic process by which glycans are attached to proteins, lipids or other organic molecules. The use of the term “glycosylation” herein is generally intended to mean adding or deleting one or more carbohydrate moieties (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that may or may not be present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins involving a change in the nature and proportions of the various carbohydrate moieties present.

[0204] Glycosylation can dramatically affect the physical properties (*e.g.*, solubility) of polypeptides and can also be important in protein stability, secretion, and subcellular localization. Glycosylated polypeptides may also exhibit enhanced stability or may improve one or more pharmacokinetic properties, such as half-life. In addition, solubility improvements can, for example, enable the generation of formulations more suitable for pharmaceutical administration than formulations comprising the non-glycosylated polypeptide.

[0205] Addition of glycosylation sites can be accomplished by altering the amino acid sequence. The alteration to the polypeptide may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues (for O-linked glycosylation sites) or asparagine residues (for N-linked glycosylation sites). The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type may be different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (hereafter referred to as sialic acid).

Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycoprotein. A particular embodiment comprises the generation and use of N-glycosylation variants.

[0206] The polypeptide sequences provided herein may optionally be altered through changes at the nucleic acid level, particularly by mutating the nucleic acid encoding the polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

[0207] Various cell lines can be used to produce proteins that are glycosylated. One non-limiting example is Dihydrofolate reductase (DHFR) - deficient Chinese Hamster Ovary (CHO) cells, which are a commonly used host cell for the production of recombinant glycoproteins. These cells do not express the enzyme beta-galactoside alpha-2,6-sialyltransferase and therefore do not add sialic acid in the alpha-2,6 linkage to N-linked oligosaccharides of glycoproteins produced in these cells.

4.3.3 Polysialylation

[0208] In certain embodiments, also provided herein is the use of polysialylation, the conjugation of polypeptides to the naturally occurring, biodegradable α -(2→8) linked polysialic acid ("PSA") in order to improve the polypeptides' stability and in vivo pharmacokinetics.

[0209] Albumin Fusion: Additional suitable components and molecules for conjugation include albumins such as human serum albumin (HSA), cyno serum albumin, and bovine serum albumin (BSA).

[0210] In some embodiments, albumin is conjugated to a drug molecule (*e.g.*, a polypeptide described herein) at the carboxyl terminus, the amino terminus, both the carboxyl and amino termini, and internally (see, *e.g.*, US Pat Nos. 5,876,969 and 7,056,701).

[0211] In the HSA–drug molecule conjugates embodiments provided herein, various forms of albumin may be used, such as albumin secretion pre-sequences and variants thereof, fragments and variants thereof, and HSA variants. Such forms generally possess one or more desired albumin activities. In additional embodiments, fusion proteins are provided herein comprising a polypeptide drug molecule fused directly or indirectly to albumin, an albumin fragment, an albumin variant, *etc.*, wherein the fusion protein has a higher plasma stability than the unfused drug molecule and/or the fusion protein retains the therapeutic activity of the

unfused drug molecule. In some embodiments, the indirect fusion is effected by a linker, such as a peptide linker or modified version thereof.

[0212] As alluded to above, fusion of albumin to one or more polypeptides provided herein can, for example, be achieved by genetic manipulation, such that the nucleic acid coding for HSA, or a fragment thereof, is joined to the nucleic acid coding for the one or more polypeptide sequences.

4.3.4 Alternative Albumin Binding Strategies

[0213] Several albumin – binding strategies have been developed as alternatives to direct fusion and may be used with the agents described herein. By way of example, in certain embodiments, provided herein is albumin binding through a conjugated fatty acid chain (acylation) and fusion proteins which comprise an albumin binding domain (ABD) polypeptide sequence and the sequence of one or more of the polypeptides described herein.

[0214] Fusion of albumin to a peptide sequence can, for example, be achieved by genetic manipulation, such that the DNA coding for HSA (human serum albumin), or a fragment thereof, is joined to the DNA coding for a peptide sequence. Thereafter, a suitable host can be transformed or transfected with the fused nucleotide sequence in the form of, for example, a suitable plasmid, so as to express a fusion polypeptide. The expression may be effected *in vitro* from, for example, prokaryotic or eukaryotic cells, or *in vivo* from, for example, a transgenic organism. In some embodiments, the expression of the fusion protein is performed in mammalian cell lines, for example, CHO cell lines.

[0215] Further means for genetically fusing target proteins or peptides to albumin include a technology known as Albufuse® (Novozymes Biopharma A/S; Denmark), and the conjugated therapeutic peptide sequences frequently become much more effective with better uptake in the body. The technology has been utilized commercially to produce Albuferon® (Human Genome Sciences), a combination of albumin and interferon α -2B used to treat hepatitis C infection.

[0216] Another embodiment entails the use of one or more human domain antibodies (dAb). dAbs are the smallest functional binding units of human antibodies (IgGs) and have favorable stability and solubility characteristics. The technology entails a dAb(s) conjugated to HSA (thereby forming a “AlbudAb”; see, *e.g.*, EP1517921B, WO2005/118642 and WO2006/051288) and a molecule of interest (*e.g.*, a peptide sequence provided herein). AlbuDabs are often smaller and easier to manufacture in microbial expression systems, such as bacteria or yeast, than

current technologies used for extending the serum half-life of peptides. As HSA has a half-life of about three weeks, the resulting conjugated molecule improves the half-life. Use of the dAb technology may also enhance the efficacy of the molecule of interest.

4.3.5 Conjugation with Other Molecules

[0217] Additional suitable components and molecules for conjugation include, for example, thyroglobulin; tetanus toxoid; Diphtheria toxoid; polyamino acids such as poly(D-lysine:D-glutamic acid); VP6 polypeptides of rotaviruses; influenza virus hemagglutinin, influenza virus nucleoprotein; Keyhole Limpet Hemocyanin (KLH); and hepatitis B virus core protein and surface antigen; or any combination of the foregoing.

[0218] Thus, in certain embodiments, conjugation of one or more additional components or molecules at the N- and/or C-terminus of a polypeptide sequence, such as another polypeptide (*e.g.*, a polypeptide having an amino acid sequence heterologous to the subject polypeptide), or a carrier molecule is also contemplated. Thus, an exemplary polypeptide sequence can be provided as a conjugate with another component or molecule.

[0219] A polypeptide may also be conjugated to large, slowly metabolized macromolecules such as proteins; polysaccharides, such as sepharose, agarose, cellulose, or cellulose beads; polymeric amino acids such as polyglutamic acid, or polylysine; amino acid copolymers; inactivated virus particles; inactivated bacterial toxins such as toxoid from diphtheria, tetanus, cholera, or leukotoxin molecules; inactivated bacteria; and dendritic cells. Such conjugated forms, if desired, can be used to produce antibodies against a polypeptide provided herein.

4.3.6 Fc-fusion Molecules

[0220] In certain embodiments, the amino- or carboxyl- terminus of a polypeptide sequence provided herein is fused with an immunoglobulin Fc region to form a fusion conjugate (or fusion molecule). In a specific embodiment, the immunoglobulin Fc region is a human Fc region. Fusion conjugates have been shown to increase the systemic half-life of biopharmaceuticals, and thus the biopharmaceutical product may require less frequent administration. In certain embodiments, the half-life is increased as compared to the same polypeptide that is not fused to an immunoglobulin Fc region.

[0221] Fc binds to the neonatal Fc receptor (FcRn) in endothelial cells that line the blood vessels, and, upon binding, the Fc fusion molecule is protected from degradation and re-released into the circulation, keeping the molecule in circulation longer. This Fc binding is believed to be

the mechanism by which endogenous IgG retains its long plasma half-life. More recent Fc-fusion technology links a single copy of a biopharmaceutical to the Fc region of an antibody to optimize the pharmacokinetic and pharmacodynamic properties of the biopharmaceutical as compared to traditional Fc-fusion conjugates.

[0222] Well-known and validated Fc-fusion drugs consist of two copies of a biopharmaceutical linked to the Fc region of an antibody to improve pharmacokinetics, solubility, and production efficiency. More recent Fc-fusion technology links a single copy of a biopharmaceutical to the Fc region of an antibody to optimize the pharmacokinetic and pharmacodynamic properties of the biopharmaceutical as compared to traditional Fc-fusion conjugates.

[0223] In some embodiments, provided herein is a fusion of M70 to a human antibody Fc fragment. In some embodiments, provided herein is a fusion of M69 to a human antibody Fc fragment. Such fusions can be useful in the treatment of bile acid related disorders and other metabolic disorders provided herein. In some embodiments, the Fc-fusion of M70 has a longer half-life. In specific embodiments, the longer half-life of the Fc-fusion of M70 is as compared to M70 that is not an Fc-fusion. In some embodiments, the Fc-fusion of M69 has a longer half-life. In specific embodiments, the longer half life of the Fc-fusion of M69 is as compared to M69 that is not an Fc-fusion. Such a long half-life makes these fusions suitable for once weekly, or less frequent dosing.

[0224] In some embodiments, the Fc-fusion comprises a linker. Exemplary flexible linkers include glycine polymers (G_n), glycine-serine polymers, glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. In certain embodiments, the linker is $(G)_4S$. In some embodiments, the linker is $((G)_4S)_n$, where n is an integer of at least one. In some embodiments, the linker is $((G)_4S)_2$. Glycine and glycine-serine polymers are relatively unstructured, and therefore may serve as a neutral tether between components. In some embodiments, the glycine-serine polymer is $(GS)_n$, where n is an integer of at least one. In some embodiments, the glycine-serine polymer is $GSGGS_n$ (SEQ ID NO:129), where n is an integer of at least one. In some embodiments, the glycine-serine polymer is $GSGS_n$ (SEQ ID NO:130), where n is an integer of at least one. In certain embodiments, the linker comprises an additional G residue at the N' terminus of SEQ ID NO:130. In one embodiment, the linker is $GSGG$ (SEQ ID NO:131). In one embodiment, the linker is $GSGGG$ (SEQ ID NO:132). In one embodiment, the linker is

GSGSG (SEQ ID NO:133). In one embodiment, the linker is GSGGG (SEQ ID NO:134). In one embodiment, the linker is GGGSG (SEQ ID NO:189). In one embodiment, the linker is GSSSG (SEQ ID NO:135).

4.3.7 Purification

[0225] Additional suitable components and molecules for conjugation include those suitable for isolation or purification. Particular non-limiting examples include binding molecules, such as biotin (biotin-avidin specific binding pair), an antibody, a receptor, a ligand, a lectin, or molecules that comprise a solid support, including, for example, plastic or polystyrene beads, plates or beads, magnetic beads, test strips, and membranes.

[0226] Purification methods such as cation exchange chromatography may be used to separate conjugates by charge difference, which effectively separates conjugates into their various molecular weights. For example, the cation exchange column can be loaded and then washed with ~20 mM sodium acetate, pH ~4, and then eluted with a linear (0 M to 0.5 M) NaCl gradient buffered at a pH from 3 to 5.5, such as at pH ~4.5. The content of the fractions obtained by cation exchange chromatography may be identified by molecular weight using conventional methods, for example, mass spectroscopy, SDS-PAGE, or other known methods for separating molecular entities by molecular weight. A fraction is then identified which contains the conjugate having the desired number of PEGs attached, purified free from unmodified protein sequences and from conjugates having other numbers of PEGs attached.

4.3.8 Other Modifications

[0227] In certain embodiments, also provided herein is the use of other modifications, currently known or developed in the future, to improve one or more properties. Examples include hesylation, various aspects of which are described in, for example, U.S. Patent Appln. Nos. 2007/0134197 and 2006/0258607, and fusion molecules comprising SUMO as a fusion tag (LifeSensors, Inc.; Malvern, PA).

[0228] In still other embodiments, a peptide sequence provided herein is linked to a chemical agent (*e.g.*, an immunotoxin or chemotherapeutic agent), including, but are not limited to, a cytotoxic agent, including taxol, cytochalasin B, gramicidin D, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, and analogs or homologs thereof. Other chemical agents include, for example, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6- thioguanine, cytarabine, 5-fluorouracil decarbazine);

alkylating agents (*e.g.*, mechlorethamine, carmustine and lomustine, cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cisplatin); antibiotics (*e.g.*, bleomycin); and anti-mitotic agents (*e.g.*, vincristine and vinblastine). Cytotoxins can be conjugated to a peptide provided herein using linker technology known in the art and described herein.

[0229] Further suitable components and molecules for conjugation include those suitable for detection in an assay. Particular non-limiting examples include detectable labels, such as a radioisotope (*e.g.*, ^{125}I , ^{35}S , ^{32}P , ^{33}P), an enzyme which generates a detectable product (*e.g.*, luciferase, β -galactosidase, horse radish peroxidase and alkaline phosphatase), a fluorescent protein, a chromogenic protein, dye (*e.g.*, fluorescein isothiocyanate); fluorescence emitting metals (*e.g.*, ^{152}Eu); chemiluminescent compounds (*e.g.*, luminol and acridinium salts); bioluminescent compounds (*e.g.*, luciferin); and fluorescent proteins. Indirect labels include labeled or detectable antibodies that bind to a peptide sequence, where the antibody may be detected.

[0230] In certain embodiments, a peptide sequence provided herein is conjugated to a radioactive isotope to generate a cytotoxic radiopharmaceutical (radioimmunoconjugates) useful as a diagnostic or therapeutic agent. Examples of such radioactive isotopes include, but are not limited to, iodine 131 , indium 111 , yttrium 90 and lutetium 177 . Methods for preparing radioimmunoconjugates are known to the skilled artisan. Examples of radioimmunoconjugates that are commercially available include ibritumomab, tiuxetan, and tositumomab.

4.3.9 Linkers

[0231] Linkers and their use have been described above. Any of the foregoing components and molecules used to modify the polypeptide sequences provided herein may optionally be conjugated via a linker. Suitable linkers include “flexible linkers” which are generally of sufficient length to permit some movement between the modified polypeptide sequences and the linked components and molecules. The linker molecules are generally about 6-50 atoms long. The linker molecules may also be, for example, aryl acetylene, ethylene glycol oligomers containing 2-10 monomer units, diamines, diacids, amino acids, or combinations thereof. Suitable linkers can be readily selected and can be of any suitable length, such as 1 amino acid (*e.g.*, Gly), 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30, 30-50 or more than 50 amino acids.

[0232] Exemplary flexible linkers include glycine polymers (G_n), glycine-serine polymers (for example, $(GS)_n$, $GSGGS_n$ (SEQ ID NO:129) and $GGGS_n$ (SEQ ID NO:130), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers. Glycine and glycine-serine polymers are relatively unstructured, and therefore may serve as a neutral tether between components. Exemplary flexible linkers include, but are not limited to $GGSG$ (SEQ ID NO:131), $GGSGG$ (SEQ ID NO:132), $GSGSG$ (SEQ ID NO:133), $GSGGG$ (SEQ ID NO:134), $GGGSG$ (SEQ ID NO:189), and $GSSSG$ (SEQ ID NO:135). In certain embodiments, the linker is $(G)_4S$. In some embodiments, the linker is $((G)_4S)_n$, where n is an integer of at least one. In some embodiments, the linker is $((G)_4S)_2$. In some embodiments, the glycine-serine polymer is $(GS)_n$, where n is an integer of at least one. In some embodiments, the glycine-serine polymer is $GSGGS_n$ (SEQ ID NO:129), where n is an integer of at least one. In some embodiments, the glycine-serine polymer is $GGGS_n$ (SEQ ID NO:130), where n is an integer of at least one. In certain embodiments, the linker comprises an additional G residue at the N' terminus of SEQ ID NO:130. In one embodiment, the linker is $GGSG$ (SEQ ID NO:131). In one embodiment, the linker is $GGSGG$ (SEQ ID NO:132). In one embodiment, the linker is $GSGSG$ (SEQ ID NO:133). In one embodiment, the linker is $GSGGG$ (SEQ ID NO:134). In one embodiment, the linker is $GGGSG$ (SEQ ID NO:189). In one embodiment, the linker is $GSSSG$ (SEQ ID NO:135).

[0233] Peptide sequences provided herein, including the FGF19 and FGF21 variants and subsequences and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and Sequence Listing, as well as subsequences, sequence variants and modified forms of the sequences listed in Tables 1-11 and Sequence Listing have one or more activities as set forth herein. One example of an activity is modulating bile acid homeostasis. Another example of an activity is reduced stimulation or formation of HCC, for example, as compared to FGF19. An additional example of an activity is lower or reduced lipid (*e.g.*, triglyceride, cholesterol, non-HDL) or HDL increasing activity, for example, as compared to FGF21. A further example of an activity is a lower or reduced lean muscle mass reducing activity, for example, as compared to FGF21. Yet another example of an activity is binding to FGFR4, or activating FGFR4, for example, peptide sequences that bind to FGFR4 with an affinity comparable to or greater than FGF19 binding affinity for FGFR4; and peptide sequences that activate FGFR4 to an extent or amount comparable to or greater than FGF19 activates FGFR4. Still further examples of activities include treating a bile acid-related or associated disorder. Activities such as, for example, modulation of bile acid homeostasis, glucose lowering activity, analysis of a bile acid-related or

associated disorder, HCC formation or tumorigenesis, lipid increasing activity, or lean mass reducing activity can be ascertained in an animal, such as a *db/db* mouse. Measurement of binding to FGFR4 or activation of FGFR4 can be ascertained by assays disclosed herein or known to the skilled artisan.

[0234] Various methodologies can be used in the screening and diagnosis of HCC and are well known to the skilled artisan. Indicators for HCC include detection of a tumor marker such as elevated alpha-fetoprotein (AFP) or des-gamma carboxyprothrombin (DCP) levels. A number of different scanning and imaging techniques are also helpful, including ultrasound, CT scans and MRI. In certain embodiments, evaluation of whether a peptide (*e.g.*, a candidate peptide) exhibits evidence of inducing HCC may be determined *in vivo* by, for example, quantifying HCC nodule formation in an animal model, such as *db/db* mice, administered a peptide, compared to HCC nodule formation by wild type FGF19. Macroscopically, liver cancer may be nodular, where the tumor nodules (which are round-to-oval, grey or green, well circumscribed but not encapsulated) appear as either one large mass or multiple smaller masses. Alternatively, HCC may be present as an infiltrative tumor which is diffuse and poorly circumscribed and frequently infiltrates the portal veins. Pathological assessment of hepatic tissue samples is generally performed after the results of one or more of the aforementioned techniques indicate the likely presence of HCC. Thus, methods provided herein may further include assessing a hepatic tissue sample from an *in vivo* animal model (*e.g.*, a *db/db* mouse) useful in HCC studies in order to determine whether a peptide sequence exhibits evidence of inducing HCC. By microscopic assessment, a pathologist can determine whether one of the four general architectural and cytological types (patterns) of HCC are present (*i.e.*, fibrolamellar, pseudoglandular (adenoid), pleomorphic (giant cell) and clear cell).

[0235] More particularly, peptide sequences provided herein, including the FGF19 and FGF21 variants and subsequences and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and Sequence Listing, as well as subsequences, variants and modified forms of the sequences listed in Tables 1-11 and Sequence Listing include those with the following activities: peptide sequences modulating bile acid homeostasis or treating a bile acid-related or associated disorder while having reduced HCC formation compared to FGF19, or a FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPV (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAPI

(SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; peptide sequences having greater bile acid modulating activity compared to FGF19, or FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAIP (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; peptide sequences having less lipid increasing activity (*e.g.*, less triglyceride, cholesterol, non-HDL) or more HDL increasing activity compared to FGF19, or a FGF 19 variant sequence having any of GQV, GDI, WGPI (SEQ ID NO:171), WGDPI (SEQ ID NO:172), WGDI (SEQ ID NO:173), GDPI (SEQ ID NO:174), GPI, WGQPI (SEQ ID NO:175), WGAIP (SEQ ID NO:176), AGDPI (SEQ ID NO:177), WADPI (SEQ ID NO:178), WGDAI (SEQ ID NO:179), WGDPA (SEQ ID NO:180), WDPI (SEQ ID NO:181), WGDI (SEQ ID NO:182), WGDP (SEQ ID NO:183) or FGDPI (SEQ ID NO:184) substituted for the WGDPI (SEQ ID NO:170) sequence at amino acids 16-20 of FGF19; and peptide sequences having less lean mass reducing activity as compared to FGF21.

[0236] More particularly, peptide sequences provided herein, including the FGF19 and FGF21 variants and subsequences and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and Sequence Listing, as well as subsequences, variants and modified forms of the sequences listed in Tables 1-11 and the Sequence Listing include those with the following activities: peptide sequences that modulate bile acid homeostasis; peptide sequences that treat a bile acid-related or associated disorder, peptide sequences that bind to FGFR4, or activate FGFR4, such as peptide sequences that bind to FGFR4 with an affinity comparable to or greater than FGF19 binding affinity for FGFR4; peptide sequences that activate FGFR4 to an extent or amount comparable to or greater than FGF19 activates FGFR4; peptide sequences that down-regulate or reduce aldo-keto reductase gene expression, for example, compared to FGF19; and peptide sequences that up-regulate or increase solute carrier family 1, member 2 (Slc1a2) gene expression as compared to FGF21.

[0237] As disclosed herein, variants include various N-terminal modifications and/or truncations of FGF19, including variants in which there has been a substitution of one or several N-terminal FGF19 amino acids with amino acids from FGF21. Such variants include variants having glucose lowering activity, as well as a favorable lipid profile and are not measurably or detectably tumorigenic.

4.4 Dosing and Administration

[0238] Peptide sequences provided herein including subsequences, sequence variants and modified forms of the exemplified peptide sequences (*e.g.*, sequences listed in the Sequence Listing or Tables 1-11), may be formulated in a unit dose or unit dosage form. In a particular embodiment, a peptide sequence is in an amount effective to treat a subject in need of treatment, *e.g.*, due to abnormal or aberrant bile acid homeostasis, such as metabolic syndrome; a lipid- or glucose-related disorder; cholesterol or triglyceride metabolism; type 2 diabetes; cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, PBC, PFIC, PSC, PIC, neonatal cholestasis, and drug induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile duct compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, BAD) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to NASH, cirrhosis and portal hypertension. Exemplary unit doses range from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 ng; from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 µg; and from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 mg.

[0239] Peptide sequences provided herein including subsequences, sequence variants and modified forms of the exemplified peptide sequences (*e.g.*, sequences listed in the Sequence Listing or Tables 1-11) can be administered to provide the intended effect as a single dose or multiple dosages, for example, in an effective or sufficient amount. Exemplary doses range from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 pg/kg; from about 50-500, 500-5000, 5000-25,000 or 25,000-50,000 ng/kg; and from about 25-250, 250-500, 500-1000, 1000-2500 or 2500-5000, 5000-25,000, 25,000-50,000 µg/kg. Single or

multiple doses can be administered, for example, multiple times per day, on consecutive days, alternating days, weekly or intermittently (*e.g.*, twice per week, once every 1, 2, 3, 4, 5, 6, 7 or 8 weeks, or once every 2, 3, 4, 5 or 6 months).

[0240] Peptide sequences provided herein including subsequences, variants and modified forms of the exemplified peptide sequences (*e.g.*, sequences listed in the Sequence Listing or Tables 1-11) can be administered and methods may be practiced via systemic, regional or local administration, by any route. For example, a peptide sequence can be administered parenterally (*e.g.*, subcutaneously, intravenously, intramuscularly, or intraperitoneally), orally (*e.g.*, ingestion, buccal, or sublingual), inhalation, intradermally, intracavity, intracranially, transdermally (topical), transmucosally or rectally. Peptide sequences provided herein including subsequences, variants and modified forms of the exemplified peptide sequences (*e.g.*, sequences listed in the Sequence Listing or Tables 1-11) and methods provided herein including pharmaceutical compositions can be administered via a (micro)encapsulated delivery system or packaged into an implant for administration.

[0241] A particular non-limiting example of parenteral (*e.g.*, subcutaneous) administration entails the use of Intarcia's subcutaneous delivery system (Intarcia Therapeutics, Inc.; Hayward, CA). The system comprises a miniature osmotic pump that delivers a consistent amount of a therapeutic agent over a desired period of time. In addition to maintaining drug levels within an appropriate therapeutic range, the system can be used with formulations that maintain the stability of proteinaceous therapeutic agents at human body temperature for extended periods of time.

[0242] Another non-limiting example of parenteral administration entails the use of DUROS®-type implantable osmotic pumps (from, *e.g.*, DURECT Corp.). The DUROS® system can be used for therapies requiring systemic or site-specific administration of a drug. To deliver drugs systemically, the DUROS® system is placed just under the skin, for example in the upper arm, in an outpatient procedure that is completed in just a few minutes using local anesthetic. To deliver a drug to a specific site, miniaturized catheter technology can be used. The catheter can be attached to the DUROS® system to direct the flow of a drug to the target organ, tissue or synthetic medical structure, such as a graft. Site-specific delivery enables a therapeutic concentration of a drug to be administered to the desired target without exposing the entire body to a similar concentration. The precision, size and performance of the DUROS® system will allow for continuous site-specific delivery to a variety of precise locations within the body.

[0243] Yet another non-limiting example of parenteral administration entails the use of an on-body delivery system (*e.g.*, the Neulasta® Delivery Kit by Amgen). This on-body delivery system includes an on-body injector, which is a small, lightweight, injection system applied on the same day as a doctor visit (such as the day of chemotherapy). It is designed to deliver a dose of the therapeutic agent the next day, or in the near future of the doctor visit, so that the patient does not need to return to the doctor's office to receive the injection.

[0244] Various methods of controlled release is also contemplated herein. Encapsulation of therapeutic molecules within polymer particles is a well-established method for achieving controlled release and can be used in methods provided herein. Also, by taking advantage of the adsorption of protein therapeutics to poly(lactic-co-glycolic acid) (PLGA) nanoparticles, controlled release can also be achieved without encapsulation. In particular, extended-release for protein therapeutics can be applied with and without encapsulation in PLGA nanoparticles embedded within a hydrogel. The release profile tunable by modifying nanoparticle concentration, nanoparticle size, or environmental pH. Pakulska *et al.*, *Science Advances* 2(5): e1600519 (2016)

4.5 Methods of Preventing, Treating and Managing Diseases and Disorders

[0245] In one embodiment, provided herein is a method of preventing a disease or disorder in a subject having, or at risk of having, a disease or disorder preventable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for preventing the disease or disorder. In another embodiment, provided herein is a method of treating a disease or disorder in a subject having, or at risk of having, a disease or disorder treatable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for treating the disease or disorder. In yet another embodiment, provided herein is a method of managing a disease or disorder in a subject having, or at risk of having, a disease or disorder manageable by a peptide sequence provided herein, comprising administering a pharmaceutical composition comprising a peptide provided herein to a subject in an amount effective for managing the disease or disorder. In one embodiment, the disease or disorder is a bile acid-related disease or associated disorder. In another embodiment, the disease or disorder is a metabolic disease or disorder. In other embodiments, the disease or disorder is a cancer or tumor.

[0246] Administration of various FGF19 and/ FGF21 variants and fusion peptide sequences to mice successfully modulated bile acid homeostasis and hyperglycemia (data not shown).

Furthermore, in contrast to FGF19, certain peptide sequences did not stimulate or induce HCC formation or tumorigenesis in mice (data not shown). Thus, administration of peptides provided herein, including subsequences, variants and modified forms of the exemplified peptide sequences (including the FGF19 and FGF21 variants and subsequences listed in Tables 1-11 and the Sequence Listing, and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and the Sequence Listing), into an animal, either by direct or indirect *in vivo* or by *ex vivo* methods (*e.g.*, administering the variant or fusion peptide, a nucleic acid encoding the variant or fusion peptide, or a transformed cell or gene therapy vector expressing the variant or fusion peptide), can be used to treat various disorders, such as bile-acid related or associated disorders, and metabolic disorders, such as disorders related to high sugar levels, hyperglycemic conditions, insulin resistance, hyperinsulinemia, glucose intolerance, metabolic syndrome, or related disorders, as set forth herein,

4.5.1 Methods of Preventing, Treating and Managing Bile Acid-Related or Associated Disorders

[0247] As used herein, the phrases “bile acid-related disorder,” “bile acid-related or associated disorder,” and the like, when used in reference to a condition of a subject, means a disruption of bile acid homeostasis, which may manifest itself as, for example, an acute, transient or chronic abnormal level of a bile acid or one or more bile acids. The condition can be caused by inhibition, reduction or a delay in bile acid synthesis, metabolism or absorption such that the subject exhibits a bile acid level not typically found in normal subjects.

[0248] Also provided herein are *in vitro*, *ex vivo* and *in vivo* (*e.g.*, on or in a subject) methods and uses. Such methods and uses can be practiced with any of the peptide sequences set forth herein. In various embodiments, the methods include administering a peptide sequence, such as a FGF19 or FGF21 variant, fusion or chimera disclosed herein (*e.g.*, in the Sequence Listing or Tables 1-11), or a subsequence, a variant or modified form of a FGF19 or FGF21 variant, fusion or chimera disclosed herein (*e.g.*, the Sequence Listing or Tables 1-11), to a subject in an amount effective for treating a bile acid-related or associated disorder.

[0249] In certain embodiments, the peptide is administered in combination with an additional therapeutic agent(s) and/or treatment modalities (*e.g.*, an agent useful in the treatment and/or prevention of PBC). The additional therapeutic agent(s) can be administered before, with, or following administration of the peptides described herein.

[0250] Also provided herein are methods of preventing (*e.g.*, in subjects predisposed to having a particular disorder(s)), delaying, slowing or inhibiting progression of, the onset of, or treating (*e.g.*, ameliorating) a bile acid-related or associated disorder relative to an appropriate matched subject of comparable age, gender, race, *etc.*). Thus, in various embodiments, a method provided herein for, for example, modulating bile acid homeostasis or treating a bile acid-related or associated disorder includes contacting or administering one or more peptides provided herein (*e.g.*, a variant or fusion of FGF19 and/or FGF21 as set forth in the Sequence Listing or Tables 1-11) in an amount effective to modulate bile acid homeostasis or treat a bile acid-related or associated disorder. In certain embodiments the method further comprises contacting or administering at least one additional therapeutic agent or treatment modality that is useful in the treatment or prevention of a bile acid-related or associated disorder (*e.g.*, PBC).

[0251] The term “subject” refers to an animal. Typically, the animal is a mammal that would benefit from treatment with a peptide sequence provided herein. Particular examples include primates (*e.g.*, humans), dogs, cats, horses, cows, pigs, and sheep.

[0252] Subjects include those having a disorder, *e.g.*, a bile acid-related or associated disorder, such as cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, PBC, PFIC, PSC, PIC, neonatal cholestasis, and drug induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile cut compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn’s disease and ulcerative colitis), short bowel syndrome, disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, BAD) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to NASH, cirrhosis and portal hypertension; or subjects that do not have a disorder but may be at risk of developing the disorder.

[0253] Non-limiting exemplary bile acid-related or associated disorders preventable, treatable or manageable according to the methods and uses provided herein include: cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, primary biliary cirrhosis (PBC), primary familial intrahepatic cholestasis (PFIC) (*e.g.*, progressive PFIC), primary sclerosing choangitis (PSC), pregnancy intrahepatic cholestasis (PIC), neonatal cholestasis, and drug-induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile cut

compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), short bowel syndrome, disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, bile acid diarrhea (BAD)) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to non-alcoholic steatohepatitis (NASH), cirrhosis and portal hypertension; *e.g.*, in mammals, such as humans. Additional bile acid-related or associated disorders include metabolic syndrome; a lipid or glucose disorder; cholesterol or triglyceride metabolism; type 2 diabetes. In one particular embodiment, the bile acid-related or associated disorder is bile acid malabsorption. In another particular embodiment, the bile acid-related or associated disorder is diarrhea. In a still further particular embodiment, the bile acid-related or associated disorder is cholestasis (*e.g.*, intrahepatic or extrahepatic cholestasis). In another further particular embodiment, the bile acid-related or associated disorder is primary biliary cirrhosis (PBC). In other particular embodiments, the bile acid-related or associated disorder is primary sclerosing cholangitis. In another embodiment, the bile acid-related or associated disorder is PFIC (*e.g.*, progressive PFIC). In another embodiment, the bile acid-related or associated disorder is NASH. In another embodiment, the bile acid-related or associated disorder is a hyperglycemic condition. In a specific embodiment, the bile acid-related or associated disorder is type 2 diabetes.

[0254] In some embodiments, the methods provided herein comprises administration of at least one additional agent effective in modulating bile acid homeostasis or treating a bile acid-related or associated disorder, wherein the additional agent is: a glucocorticoid; CDCA; UDCA; insulin, an insulin secretagogues, an insulin mimetic, a sulfonylurea and a meglitinide; a biguanide; an alpha-glucosidase inhibitors; a DPP-IV inhibitor, GLP-1, a GLP-1 agonists and a GLP-1 analog; a DPP-IV-resistant analogue; a PPAR gamma agonist, a dual-acting PPAR agonist, a pan-acting PPAR agonist; a PTP1B inhibitor; an SGLT inhibitor; an RXR agonist; a glycogen synthase kinase-3 inhibitor; an immune modulator; a beta-3 adrenergic receptor agonist; an 11beta-HSD1 inhibitor; amylin and an amylin analogue; a bile acid sequestrant; or an SGLT-2 inhibitor. In certain embodiments, the at least one additional agent effective in modulating PBC is UDCA, an FXR agonist, OCA, an ASBT inhibitor, an autoimmune agent, an anti-IL-12 agent, an anti-CD80 agent, an anti-CD20 agent, a CXCL10 neutralizing antibody, a

ligand for CXCR3, a fibrate, fish oil, colchicine, methotrexate, azathioprine, cyclosporine, or an anti-retroviral therapy. In particular embodiments, the at least one additional agent effective in modulating PBC is UDCA, OCA, an ASBT inhibitor, an anti-IL-12 agent, an anti-CD20 agent, or a fibrate.

[0255] Additional bile acid-related or associated disorders that may be treated or prevented with the peptide sequences provided herein include metabolic syndrome, a lipid or glucose disorder, cholesterol or triglyceride metabolism, diabetes (*e.g.*, type 2 diabetes), other hyperglycemic-related disorders, including kidney damage (*e.g.*, tubule damage or nephropathy), liver degeneration, eye damage (*e.g.*, diabetic retinopathy or cataracts), and diabetic foot disorders, and dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary artery disease, cerebrovascular disorders and the like.

[0256] Other conditions which may be associated with metabolic syndrome, such as obesity and elevated body mass (including the co-morbid conditions thereof such as, but not limited to, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS)), and also include thromboses, hypercoagulable and prothrombotic states (arterial and venous), hypertension (including portal hypertension (defined as a hepatic venous pressure gradient (HVPG) greater than 5 mm Hg), cardiovascular disease, stroke and heart failure; Disorders or conditions in which inflammatory reactions are involved, including atherosclerosis, chronic inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), asthma, lupus erythematosus, arthritis, or other inflammatory rheumatic disorders; Disorders of cell cycle or cell differentiation processes such as adipose cell tumors, lipomatous carcinomas including, for example, liposarcomas, solid tumors, and neoplasms; Neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, progressive multifocal leukoencephalopathy and Guillian-Barre syndrome; Skin and dermatological disorders and/or disorders of wound healing processes, including erythemato-squamous dermatoses; and Other Disorders such as syndrome X, osteoarthritis, and acute respiratory distress syndrome.

[0257] Treatment of a bile acid-related or associated disorder (*e.g.*, NASH) may have the benefit of alleviating or abolishing a disorder secondary thereto. By way of example, a subject

suffering from NASH may also have depression or anxiety due to NASH; thus, treating the subject's NASH may also indirectly treat the depression or anxiety. The use of the therapies disclosed herein to target such secondary disorders is also contemplated in certain embodiments.

[0258] In particular embodiments, the subject has or is at risk of having PBC. In other particular embodiments, the subject has or is at risk of having NASH.

[0259] Subjects at risk of developing a bile acid-related or associated disorder (such as the disorders described above) include, for example, those who may have a family history or genetic predisposition toward such disorder, as well those whose diet may contribute to development of such disorders.

[0260] As disclosed herein, treatment methods include contacting or administering a peptide as set forth herein (*e.g.*, a variant or fusion of FGF19 and/or FGF21 provided herein, for example, as set forth in the Sequence Listing or Tables 1-11) in an amount effective to achieve a desired outcome or result in a subject. A treatment that results in a desired outcome or result includes decreasing, reducing or preventing the severity or frequency of one or more symptoms of the condition in the subject, *e.g.*, an improvement in the subject's condition or a "beneficial effect" or "therapeutic effect." Therefore, treatment can decrease or reduce or prevent the severity or frequency of one or more symptoms of the disorder, stabilize or inhibit progression or worsening of the disorder, and in some instances, reverse the disorder, transiently (*e.g.*, for 1-6, 6-12, or 12-24 hours), for medium term (*e.g.*, 1-6, 6-12, 12-24 or 24-48 days) or long term (*e.g.*, for 1-6, 6-12, 12-24, 24-48 weeks, or greater than 24-48 weeks). Thus, in the case of a bile acid-related or associated disorder, treatment can lower or reduce one or more symptoms or effects of the bile acid-related or associated disorders described above.

[0261] In certain embodiments, the various methods provided herein further include contacting or administering one or more additional agents or therapeutic modalities useful in the treatment or prevention of a bile acid-related or associated disorder, such as those agents or therapeutic modalities described herein, in an amount effective to achieve a desired outcome or result in a subject.

[0262] An "effective amount" or a "sufficient amount" for use and/or for treating a subject refers to an amount that provides, in single or multiple doses, alone, or in combination with one or more other agents, treatments, protocols, or therapeutic regimens, a detectable response of any duration of time (transient, medium or long term), a desired outcome in or an objective or

subjective benefit to a subject of any measurable or detectable degree or for any duration of time (*e.g.*, for hours, days, months, years, in remission or cured). Such amounts typically are effective to ameliorate a disorder, or one, multiple or all adverse symptoms, consequences or complications of the disorder, to a measurable extent, although reducing or inhibiting a progression or worsening of the disorder, is considered a satisfactory outcome.

[0263] As used herein, the term “ameliorate” means an improvement in the subject’s disorder, a reduction in the severity of the disorder, or an inhibition of progression or worsening of the disorder (*e.g.*, stabilizing the disorder). In the case of a bile acid-related or associated disorder such as those described above, including cholestasis (*e.g.*, PBC), disorders impairing absorption of bile acids leading to diarrhea (*e.g.*, BAD) and bile acid synthesis abnormalities (*e.g.*, NASH), an improvement can be a lowering or a reduction in one or more symptoms or effects of the disorder.

[0264] A therapeutic benefit or improvement therefore need not be complete ablation of any one, most or all symptoms, complications, consequences or underlying causes associated with the disorder or disease. Thus, a satisfactory endpoint is achieved when there is a transient, medium or long term, incremental improvement in a subject’s condition, or a partial reduction in the occurrence, frequency, severity, progression, or duration, or inhibition or reversal, of one or more associated adverse symptoms or complications or consequences or underlying causes, worsening or progression (*e.g.*, stabilizing one or more symptoms or complications of the condition, disorder or disease), of the disorder or disease, over a duration of time (hours, days, weeks, months, *etc.*).

[0265] Thus, in the case of a disorder treatable by a peptide sequence provided herein, either alone or in combination with an additional agent, the amount of the peptide (and optionally the additional agent)sufficient to ameliorate a disorder will depend on the type, severity and extent, or duration of the disorder, the therapeutic effect or outcome desired, and can be readily ascertained by the skilled artisan. Appropriate amounts will also depend upon the individual subject (*e.g.*, the bioavailability within the subject, gender, age, *etc.*). For example, a transient, or partial, restoration of normal bile acid homeostasis in a subject can reduce the dosage amount or frequency of the peptides and agents described herein in order to treat the bile acid-related or associated disorders described previously even though complete freedom from treatment has not

resulted. An effective amount can be ascertained, for example, by measuring one or more relevant physiological effects.

[0266] Methods and uses provided herein for treating a subject are applicable for prophylaxis to prevent or reduce the likelihood of a disorder in a subject, such as a bile acid-related or associated disorder. Accordingly, methods and uses provided herein for treating a subject having, or at risk of developing, a bile acid-related or associated disorder can be practiced prior to, substantially contemporaneously with, or following administration or application of another agent useful for the treatment or prevention of a bile acid-related or associated disorder, and/or can be supplemented with other forms of therapy. Supplementary therapies include other glucose lowering treatments, such as insulin, an insulin sensitivity enhancer and other drug treatments, a change in diet (low sugar, fats, *etc.*), weight loss surgery- (reducing stomach volume by gastric bypass, gastrectomy), gastric banding, gastric balloon, gastric sleeve, *etc.* For example, a method or use provided herein for treating a hyperglycemic or insulin resistance disorder can be used in combination with drugs or other pharmaceutical compositions that lower glucose or increase insulin sensitivity in a subject.

[0267] In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for preventing a bile-acid related or associated disorder. In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for treating a bile-acid related or associated disorder. In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for managing a bile-acid related or associated disorder.

4.5.1.1 PBC and Therapy with Agents Effective in the Treatment or Prevention Thereof

[0268] Primary biliary cirrhosis (PBC), the most common cholestatic liver disease, is a progressive hepatic disease that primarily results from autoimmune destruction of the bile ducts that transport bile acids out of the liver. As the disease progresses, persistent toxic build-up of bile acids causes progressive liver damage marked by chronic inflammation and fibrosis. Because patients with PBC have an increased risk of HCC, therapy with the variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions

(chimeras) of FGF19 and/or FGF21 peptide sequences described herein is of particular import, as such sequences do not induce, or do not substantially increase, HCC formation or HCC tumorigenesis.

[0269] Although patients with PBC are often asymptomatic at the time of initial diagnosis, most present, or subsequently develop, one or more of the following: pruritus; fatigue; jaundice; xanthoma; disorders associated with an extrahepatic autoimmune disorder (*e.g.*, Sjögren's Syndrome and rheumatoid arthritis); and complications that result from cirrhosis or portal hypertension (*e.g.*, ascites, esophageal varices and hepatic encephalopathy).

[0270] While a definitive cause of PBC has not been identified, most research suggests that it is an autoimmune disorder. There appears to be a genetic predisposition, and genetic studies have indicated that part of the IL-12 signaling cascade, including IL-12A and I-12RB2 polymorphisms, is important in the etiology of the disease.

[0271] There is no definitive means of diagnosing PBC; rather, assessment of a number of factors is generally required. Moreover, diagnosis of PBC requires that other conditions with similar symptoms (*e.g.*, autoimmune hepatitis and primary sclerosing cholangitis) be ruled out; by way of example, abdominal ultrasound or CT scan is usually performed to rule out blockage of the bile ducts.

[0272] Diagnostic blood tests include deranged liver function tests (gamma-glutamyl transferase and alkaline phosphatase) and the presence of particular antibodies (antimitochondrial antibody (AMA) an antinuclear antibody (ANA)). Antinuclear antibodies are believed to be prognostic indicators of PBC. When other tests and procedures are indicative of PBC, a liver biopsy is frequently performed to confirm disease. Endoscopic retrograde cholangiopancreatography (ERCP), an endoscopic evaluation of the bile duct, may also be employed to confirm disease.

[0273] PBC is classified into four stages marking the progression of disease. Stage 1 (Portal Stage) is characterized by portal inflammation and mild bile duct damage; Stage 2 (Periportal Stage) is characterized by enlarged triads, periportal fibrosis or inflammation; Stage 3 (Septal Stage) is characterized by active and/or passive fibrous septa; and Stage 4 (Biliary Cirrhosis) is characterized by the presence of hepatic nodules. Liver biopsy is required to determine the stage of disease.

[0274] Serum bilirubin is an indicator of PBC progression and prognosis. Patients with a serum bilirubin level of 2–6 mg/dL have a mean survival time of 4.1 years, patients with a serum bilirubin level of 6–10 mg/dL have a mean survival time of 2.1 years, and patients with a serum bilirubin level above 10 mg/dL have a mean survival time of 1.4 years. Liver transplantation is an option in advanced cases of PBC, although the recurrence rate may be as high as 18% at 5 years, and up to 30% at 10 years.

[0275] Although disease progression may be slowed, pharmaceutical intervention with currently used therapies is neither curative nor effective in all patient populations. In order to improve the therapeutic outcome of pharmacological therapy, one aspect pertains to the use of one or more current therapies in combination with variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities associated with the treatment and/or prevention of PBC and associated diseases, disorders and conditions. The most commonly used and/or promising agents for combination therapy are set forth hereafter, although it is to be understood that these agents are illustrative, and not exclusionary.

[0276] PBC treatment most frequently involves the bile acid ursodeoxycholic acid (Urosdiol, UDCA). UDCA therapy is helpful in reducing the cholestasis and improving the liver function tests in PBC patients; however, it does not demonstrably improve symptoms and has a questionable impact on prognosis. UDCA has been shown to reduce mortality, adverse events and the need for transplantation in PBC. Although UDCA is considered the first-line therapy, approximately one-third of patients may be non-responsive and remain at risk of progressive liver disease and are candidates for alternative or additive therapy.

[0277] There are several alternative and adjuvant therapies, some of which are currently in clinical development, that can be used in combination with variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences provided herein having one or more activities associated with the treatment and/or prevention of PBC and associated diseases, disorders and conditions.

[0278] Farnesoid-X-receptor agonists represent a promising class of agents that may be used in combination therapy. One of the primary functions of agonists of FXR, a nuclear receptor expressed at high levels in the liver and intestine, is the suppression of cholesterol 7 α hydroxylase-1 (CYP7A1), the rate-limiting enzyme in the synthesis of bile acids from

cholesterol. Obeticholic acid (OCA; Intercept Pharmaceuticals, NY) is a bile acid analog and FXR agonist derived from the primary human bile acid chenodeoxycholic acid, or CDCA. OCA is currently being evaluated for patients having an inadequate therapeutic response to ursodiol or who are unable to tolerate ursodiol.

[0279] Inhibitors of the apical sodium-dependent bile acid transporter (ASBT) represent another class of agents that may be used in combination with the variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences described herein for the treatment and/or prevention of PBC and associated diseases. ASBT, a member of the sodium/bile-salt co-transport family coded by gene SLC10A2, is currently thought to be the primary mechanism for bile acid reabsorption in the intestine. Examples of ASBT inhibitors include LUM001 and SC-435, both of which are being developed by Lumena Pharmaceuticals (San Diego, CA).

[0280] Bile acid sequestrants also find use in the treatment of PBC. Cholestyramine and colestipol are the best known bile acid sequestrants. However, their use is sometimes limited because they are only available in powder form and are not tolerated by many patients, often because of the poor texture and taste of the resin powder. The bile acid sequestrant colesevelam is available in tablet form and is often better tolerated. All bile acid sequestrants are capable of binding other compounds, including the fat-soluble vitamins A, D, E and K, and deficiencies of these vitamins many necessitate supplementation. Importantly, the PBC patient population inherently has poor lipid-dependent absorption of vitamins A, D, E and K, and thus patients taking bile acid sequestrants are at particular risk for deficiency of those vitamins.

[0281] Agents associated with immune and inflammatory function are candidates for combination therapy with the variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities associated with the treatment and/or prevention of PBC and associated diseases, disorders and conditions.

[0282] The interleukin IL-12 is linked with autoimmunity. Data indicate that the IL-12 signaling pathway plays a key role in the effector mechanisms that lead to biliary destruction. Targeting the p40 subunit of IL-12 has also been shown to ameliorate experimental immune-mediated cholangiopathy. Thus, anti-IL-12 agents (*e.g.*, monoclonal Ab inhibitors) provide a promising treatment. Furthermore, because polymorphisms in CD80 have been identified as

conferring an increased susceptibility to PBC, blockade of co-stimulation between T cells and antigen-presenting cells through CD80 by use of an anti-CD80 agent could represent an important therapeutic approach for the treatment of PBC. In addition, improvement in IgM titre and an increase in intrahepatic regulatory T-cell number using the anti-CD20 antibody rituximab (RITUXAN) have shown promise.

[0283] The immune-mediated destruction of small-sized bile ducts in PBC is predominantly cell-mediated, characterized by Th1 cells, CD8⁺ T cells, NK cells and NKT cells which express CXCR3. Therefore, neutralizing antibodies to CXCL10, a ligand for CXCR3, may offer the possibility to interfere with one of the key inflammatory processes and contribute to immune-mediated biliary destruction in PBC. Similarly, blockade of co-stimulatory signals between T cells expressing CD28 and antigen-presenting cells expressing CD80 (*e.g.* cholangiocytes, antibody-secreting B cells) might represent an important approach for the treatment of autoimmune diseases.

[0284] The variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences described herein can be used alone or in combination with other agents for the treatment and/or prevention of those bile acid-related or associated disorders referenced herein that have an immune and/or inflammatory component, including, but not limited to, PBC and associated diseases, disorders and conditions. Examples of such other agents include, for example, non-steroidal anti-inflammatory drugs (NSAID); steroids; cytokine suppressive anti-inflammatory drug(s) (CSAIDs); antibodies to, or antagonists of, other human cytokines or growth factors (*e.g.*, IL-2, IL-6, or PDGF); TNF antagonists (*e.g.*, agents such as REMICADE, p75TNFR1gG (ENBREL) or p55TNFR1gG (LENERCEPT)); interferon- β 1a (AVONEX); interferon- β 1b (BETASERON); and immune checkpoint inhibitors, including PD1 (associated agents include the antibodies nivolumab and lambrolizumab), PDL1, BTLA, CTLA4 (associated agents include the fully humanized CTLA4 monoclonal antibody ipilimumab (YERVOY), TIM3, LAG3, and A2aR.

[0285] Fibrates have been shown to improve various aspects of PBC, including liver function tests, both as monotherapy and in combination with UDCA non-responders. In certain embodiments, a fibrate is a member selected from the group of bezafibrate (BEZALIP), ciprofibrate (MODALIM), gemfibrozil (LOPID), clofibrate, and fenofibrate (TRICOR). Fish oil has exhibited similar benefits.

[0286] In PBC patients demonstrating certain characteristics of hepatitis on biopsy, corticosteroids such as budesonide may improve liver histology and biochemistry, particularly when used in combination with UDCA. Colchicine has been shown to improve liver function tests (*e.g.*, AST and ALP) and represents another alternative treatment for PBC.

[0287] Though not an exhaustive list, other drugs that have shown promise include methotrexate as an immunomodulatory treatment, azathioprine, cyclosporine, and certain agents used in anti-retroviral therapy (*e.g.*, combivir).

[0288] Various treatments exist for the sequelae associated with PBC. For example, itching can be relieved by the bile acid sequestrant cholestyramine, or alternatively naltrexone and rifampicin. The fatigue associated with PBC may effectively be treated with modafinil (Provigil; Teva (formerly Cephalon)) without damaging the liver. As patients with PBC have increased risk of developing osteoporosis and esophageal varices compared to the general population (and others with liver disease), screening and treatment of these complications is an important part of the management of PBC. Variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities associated with the treatment and/or prevention of PBC and associated diseases, disorders and conditions, as provided herein, either alone or in combination with other agents, offer novel, promising alternatives to the management of such sequelae.

4.5.1.2 NASH and NAFLD and Therapy with Agents Effective in the Treatment or Prevention Thereof

[0289] Non-alcoholic steatohepatitis (NASH), considered part of a spectrum of non-alcoholic fatty liver diseases (NAFLD), causes inflammation and accumulation of fat and fibrous tissue in the liver. Although the exact cause of NASH is unknown, risk factors include central obesity, type-2 diabetes mellitus, insulin resistance (IR) and dyslipidemia; combinations of the foregoing are frequently described as the metabolic syndrome. In addition, certain drugs have been linked to NASH, including tamoxifen, amiodarone and steroids (*e.g.*, prednisone and hydrocortisone). Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the United States, and the estimated prevalence of NAFLD is 20-30% and for NASH it is estimated at 3.5-5%. (See, *e.g.*, Abrams, G.A., *et al.*, Hepatology, 2004. 40(2):475-83; Moreira, R.K., Arch Pathol Lab Med, 2007. 131(11):1728-34).

[0290] NASH frequently presents with no overt symptoms, complicating its diagnosis. Liver function tests generally begin the diagnostic process, with levels of AST (aspartate aminotransferase) and ALT (alanine aminotransferase) elevated in about 90% percent of individuals with NASH. Other blood tests are often used for ruling out other causes of liver disease, such as hepatitis. Imaging tests (*e.g.*, ultrasound, CT scan, or MRI) may reveal fat accumulation in the liver but frequently cannot differentiate NASH from other causes of liver disease that have a similar appearance. A liver biopsy is required to confirm NASH.

[0291] The prognosis for individuals suffering from NASH is difficult to predict, although features in the liver biopsy can be helpful. The most serious complication of NASH is cirrhosis, which occurs when the liver becomes severely scarred. It has been reported that between 8 and 26 percent of individuals with NASH develop cirrhosis, and it is predicted that NASH will be the leading indication for liver transplantation by 2020.

[0292] At the present time, treatment of NASH focuses primarily on pharmacological and non-pharmacological management of those medical conditions associated with it, including hyperlipidemia, diabetes and obesity. Although not curative, pharmacological intervention of NASH itself includes treatment with vitamin E, pioglitazone, metformin, statins, omega-3 fatty acids, and ursodeoxycholic acid (UDCA (ursodiol)). Other agents being evaluated, currently approved for different indications, include losartan and telisartan, exenatide, GLP-1 agonists, DPP IV inhibitors, and carbamazepine.

[0293] In view of the deficiencies of the aforementioned current therapies, therapy with agents having distinct mechanisms of action offers a promising new avenue for the treatment and prevention of NASH and NAFLD. Addressing such deficiencies is contemplated, for example, by using the variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences as taught herein. In certain embodiments, the peptides are used in combination with other therapeutic agents and/or treatment modalities. Also provided herein is the prophylactic and/or therapeutic use of these variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences, either alone or in combination with therapies developed in the future, for the treatment or prevention of NASH and NAFLD.

4.5.1.3 Therapy for the Treatment or Prevention of Other Bile Acid-Related Disorders and Associated Diseases, Disorders and Conditions

[0294] Also provided herein is the use of variants of FGF19 peptide sequences, fusions of FGF19 and/or FGF21 peptide sequences and variants of fusions (chimeras) of FGF19 and/or FGF21 peptide sequences having one or more activities associated with the treatment and/or prevention of other bile acid-related disorders and associated diseases, disorders and conditions besides PBC. In certain embodiments, the peptides are used in combination with other therapeutic agents and/or treatment modalities.

[0295] By way of example, patients with bile acid diarrhea secondary to Crohn's ileitis will be helped with glucocorticoid treatment. Microscopic colitis is also helped by steroids. In patients with a short-bowel syndrome (a bile acid deficiency occurs in the proximal intestine that leads to impaired micellar solubilization), cholylsarcosine (choly-N-methylglycine), a synthetic bile acid analogue, has been shown to increase lipid absorption.

[0296] Administration of the primary bile acid chenodeoxycholic Acid (CDCA) has been shown to decrease biliary cholesterol secretion and gradual dissolution of gallstones. Because CDCA is slightly hepatotoxic, it was gradually replaced by UDCA. Despite the efficacy and safety of UDCA administration for cholesterol gallstone dissolution, it is not frequently used today because of the success of laparoscopic cholecystectomy, which provides a rapid cure for symptomatic disease. Medical therapy, in contrast, requires months of therapy, does not always dissolve stones, and is followed by gradual recurrence in some patients.

[0297] Bile acid replacement is used in inborn errors of bile acid biosynthesis, usually with a mixture of CDCA or UDCA and cholic acid, to suppress the synthesis of cytotoxic bile acid precursors and restore the input of primary bile acids into the enterohepatic circulation.

[0298] In addition to the agents and therapeutic modalities set forth above, combination therapy with numerous additional agents (and classes thereof) is also contemplated, including, but not limited to, 1) insulin *e.g.*, bolus and basal analogs), insulin mimetics and agents that entail stimulation of insulin secretion, including sulfonylureas (*e.g.*, chlorpropamide, tolazamide, acetohexamide, tolbutamide, glyburide, glimepiride, glipizide) and meglitinides (*e.g.*, repaglinide (PRANDIN) and nateglinide (STARLIX)); 2) biguanides (*e.g.*, metformin (GLUCOPHAGE)) and other agents that act by promoting glucose utilization, reducing hepatic glucose production and/or diminishing intestinal glucose output; 3) alpha-glucosidase inhibitors (*e.g.*, acarbose and

migliitol) and other agents that slow down carbohydrate digestion and consequently absorption from the gut and reduce postprandial hyperglycemia; 4) thiazolidinediones (*e.g.*, rosiglitazone (AVANDIA), troglitazone (REZULIN), pioglitazone (ACTOS), glipizide, balaglitazone, rivoglitazone, netoglitazone, troglitazone, englitazone, ciglitazone, adaglitazone, darglitazone that enhance insulin action (*e.g.*, by insulin sensitization), thus promoting glucose utilization in peripheral tissues; 5) glucagon-like-peptides including DPP-IV inhibitors (*e.g.*, vildagliptin (GALVUS) and sitagliptin (JANUVIA)) and Glucagon-Like Peptide-1 (GLP-1) and GLP-1 agonists and analogs (*e.g.*, exenatide (BYETTA and ITCA 650 (an osmotic pump inserted subcutaneously that delivers an exenatide analog over a 12-month period; Intarcia, Boston, MA)); 6) and DPP-IV-resistant analogues (incretin mimetics), PPAR gamma agonists, dual-acting PPAR agonists, pan-acting PPAR agonists, PTP1B inhibitors, SGLT inhibitors, insulin secretagogues, RXR agonists, glycogen synthase kinase-3 inhibitors, immune modulators, beta-3 adrenergic receptor agonists, 11beta-HSD1 inhibitors, and amylin analogues.

[0299] Other exemplary agents that can be used, in certain embodiments, in combination with the peptides and methods provided herein include dipeptidyl peptidase-4 (DPP-4) inhibitors, bromocriptine formulations (*e.g.* and bile acid sequestrants (*e.g.*, colesevelam), and SGLT-2 inhibitors. Appetite suppression drugs are also well known and can be used in combination with the compositions and methods provided herein. Supplementary therapies can be administered prior to, contemporaneously with or following methods and uses provided herein.

[0300] In one aspect, provided herein is a method for preventing or treating a bile acid related disorder (BARD), or a symptom thereof, in a subject comprising administering to the subject an effective amount of a peptide, wherein the peptide has an amino acid sequence comprising or consisting of:

MRDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (M70) (SEQ ID NO: 70).

[0301] In one aspect, provided herein is a method for preventing or treating a bile acid related disorder (BARD), or a symptom thereof, in a subject comprising administering to the subject an effective amount of a peptide, wherein the peptide has an amino acid sequence comprising or consisting of:

RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT

VAIKGVHHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSP
SFEK (M69) (SEQ ID NO:69).

[0302] In another aspect, provided herein is a method for preventing or treating a BARD, or a symptom thereof, in a subject comprising administering to the subject an effective amount of a peptide, wherein the peptide comprises: a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122); and b) a C-terminal region comprising a portion of SEQ ID NO:99 (FGF19), the C-terminal region having a first amino acid position and a last amino acid position, wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 (FGF19), WGDPIRLRHLTYTSG (SEQ ID NO:169), wherein the W residue corresponds to the first amino acid position of the C-terminal region.

[0303] Other peptides provided herein are also contemplated in the methods provided herein.

[0304] In certain embodiments, the BARD, or symptom thereof, is improved as compared to baseline. In some embodiments, baseline is a pre-dose baseline.

[0305] In some embodiments, the BARD is non-alcoholic fatty liver disease (NAFLD). In one embodiment, provided herein is a method of preventing or treating NAFLD, or a symptom thereof, in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0306] In some embodiments, the method results in an improvement of the NAFLD activity score (NAS).

[0307] In some embodiments, the BARD is hepatic fibrosis. In one embodiment, provided herein is a method of preventing or treating hepatic fibrosis, or a symptom thereof, in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0308] In some embodiments, the BARD is nonalcoholic steatohepatitis (NASH). In one embodiment, provided herein is a method of preventing or treating NASH or a symptom thereof, in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In some embodiments, the subject has biopsy-confirmed NASH.

[0309] In some embodiments, the BARD is cholestatic liver disease. In one embodiment, provided herein is a method of preventing or treating cholestatic liver disease, or a symptom thereof, in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0310] In some embodiments, the cholestatic liver disease is primary sclerosing cholangitis (PSC). In some embodiments, the cholestatic liver disease is primary biliary cirrhosis (PBC). In some

embodiments, the cholestatic liver disease is intrahepatic cholestasis of pregnancy. In some embodiments, the cholestatic liver disease is alcoholic hepatitis. In some embodiments, the cholestatic liver disease is drug-induced cholestasis.

[0311] In some embodiments, the methods provided herein result in a decrease in liver steatosis. In one embodiment, provided herein is a method of preventing or treating liver steatosis in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0312] In some embodiments, the methods provided herein result in a decrease in liver inflammation. In one embodiment, provided herein is a method of preventing or treating liver inflammation in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In certain embodiments, the liver inflammation is lobular inflammation.

[0313] In some embodiments, the methods provided herein result in a decrease in hepatocyte ballooning. In one embodiment, provided herein is a method of decreasing hepatocyte ballooning in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0314] In some embodiments, the methods provided herein result in a reduction of CYP7a1 levels in the subject. In one embodiment, provided herein is a method of reducing CYP7a1 levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0315] In some embodiments, the methods provided herein result in a reduction of serum bile acid levels in the subject. In one embodiment, provided herein is a method of reducing serum bile acid levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0316] In some embodiments, the methods provided herein result in a reduction of triglycerides in the subject. In one embodiment, provided herein is a method of reducing triglycerides in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0317] In some embodiments, the methods provided herein result in a reduction in alkaline phosphatase (ALP) levels in the subject. In one embodiment, provided herein is a method of reducing ALP levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In some embodiments, the ALP levels are reduced at least 10% in the subject. In some embodiments, the ALP levels are reduced at least 15% in the subject.

[0318] In some embodiments, the methods provided herein result in a reduction in alkaline aminotransferase (ALT) levels in the subject. In one embodiment, provided herein is a method of reducing ALT in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In one embodiment, provided herein is a method of reducing ALT levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0319] In some embodiments, the methods provided herein result in a reduction in aspartate aminotransferase (AST) levels in the subject. In one embodiment, provided herein is a method of reducing AST levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0320] In some embodiments, the methods provided herein result in a reduction in gamma-glutamyltransferase (GGT) levels in the subject. In one embodiment, provided herein is a method of reducing GGT levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0321] In some embodiments, the methods provided herein result in an improvement in a biochemical marker of liver function. In one embodiment, provided herein is a method of improving a biochemical marker of liver function in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In some embodiments, the biochemical marker of liver function is an enzyme. In some embodiments, the enzyme is ALP. In some embodiments, the enzyme is ALT. In some embodiments, the enzyme is AST. In some embodiments, the enzyme is GGT.

[0322] In some embodiments, the methods provided herein result in a reduction in cholesterol levels in the subject. In one embodiment, provided herein is a method of reducing cholesterol levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0323] In some embodiments, the methods provided herein result in a reduction in glucose levels in the subject. In one embodiment, provided herein is a method of reducing glucose levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0324] In some embodiments, the methods provided herein result in an improvement in insulin resistance in the subject. In one embodiment, provided herein is a method of improving insulin resistance in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0325] In some embodiments, the methods provided herein result in an improvement in insulin sensitivity in the subject. In one embodiment, provided herein is a method of improving insulin sensitivity in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In some embodiments, the insulin sensitivity is as measured by HOMA-IR.

[0326] In some embodiments, the methods provided herein result in a reduction in body weight in the subject. In one embodiment, provided herein is a method of reducing body weight in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0327] In some embodiments, the methods provided herein result in a reduction in liver weight in the subject. In one embodiment, provided herein is a method of reducing liver weight in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0328] In some embodiments, the methods provided herein result in a decrease in bilirubin levels in the subject. In one embodiment, provided herein is a method of reducing bilirubin levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0329] In some embodiments, the methods provided herein result in a decrease in a serum biomarker of early fibrosis in the subject. In one embodiment, provided herein is a method of reducing the level of a serum biomarker of early fibrosis in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0330] In some embodiments, the methods provided herein result in the reduction of serum C4 levels in the subject. In one embodiment, provided herein is a method of reducing serum C4 levels in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In some embodiments, the serum C4 levels are decreased by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% in the subject. In some embodiments, the reduction in serum C4 levels is a mean reduction in C4 levels. In some embodiments, the mean reduction in serum C4 levels is at least 90%. In some embodiments, the serum C4 levels are decreased as compared to the serum C4 levels in the subject prior to administration of the peptide.

[0331] In some embodiments, the methods provided herein result in an improvement in liver function in the subject. In one embodiment, provided herein is a method of improving liver function in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein.

[0332] In some embodiments, the methods provided herein result in improving pruritus, or a symptom thereof, in the subject. In one embodiment, provided herein is a method of preventing or treating pruritus, or a symptom thereof, in a subject, comprising administering a peptide (*e.g.*, M70, or M69) provided herein. In one embodiment, the method is a method of preventing pruritus, or a symptom thereof, in a subject. In one embodiment, the method is a method of treating pruritus, or a symptom thereof, in a subject. In some embodiments, the pruritus symptom is itching. In some embodiments, the pruritus symptom is impaired sleep. In some embodiments, the pruritus symptom is depression.

[0333] In some embodiments, the peptide is administered at a dose of 0.3 mg. In some embodiments, the peptide is administered at a dose of 1 mg. In some embodiments, the peptide is administered at a dose of 2 mg. In some embodiments, the peptide is administered at a dose of 3 mg. In some embodiments, the peptide is administered at a dose of 5 mg. In some embodiments, the peptide is administered at a dose of 10 mg.

[0334] In some embodiments, the peptide is administered once a day. In some embodiments, the peptide is administered twice a day.

[0335] In some embodiments, the peptide is administered subcutaneously.

[0336] In some embodiments, the peptide is administered for 7 days or longer. In some embodiments, the peptide is administered for 14 days or longer. In some embodiments, the peptide is administered for 21 days or longer. In some embodiments, the peptide is administered for 28 days or longer. In some embodiments, the peptide is administered for 1 to 12 months. In some embodiments, the peptide is administered for 12 months. In some embodiments, the peptide is administered for more than 12 months.

[0337] In some embodiments, the peptide is administered in combination with ursodeoxycholic acid (UDCA).

[0338] In some embodiments, the subject is overweight. In some embodiments, the subject is obese. In some embodiments, the subject has diabetes. In some embodiments, the subject does not have diabetes. In some embodiments, the diabetes is type 2 diabetes.

4.5.2 Methods of Preventing, Treating and Managing Metabolic Disorders

[0339] Also provided herein are *in vitro*, *ex vivo* and *in vivo* (*e.g.*, on or in a subject) methods and uses. Such methods and uses can be practiced with any of the peptide sequences set forth herein. In various embodiments, the methods include administering a peptide sequence, such as a FGF19 or FGF21 variant, fusion or chimera disclosed herein (*e.g.*, in the Sequence Listing or Tables 1-11), or a subsequence, a variant or modified form of a FGF19 or FGF21 variant, fusion or chimera disclosed herein (*e.g.*, the Sequence Listing or Tables 1-11), to a subject in an amount effective for treating a metabolic or associated disorder.

[0340] In certain embodiments, the peptide is administered in combination with an additional therapeutic agent(s) and/or treatment modalities (*e.g.*, an agent useful in the treatment and/or prevention of PBC). The additional therapeutic agent(s) can be administered before, with, or following administration of the peptides described herein.

[0341] Also provided herein are methods of preventing (*e.g.*, in subjects predisposed to having a particular disorder(s)), delaying, slowing or inhibiting progression of, the onset of, or treating (*e.g.*, ameliorating) a metabolic or associated disorder relative to an appropriate matched subject of comparable age, gender, race, *etc.*). Thus, in various embodiments, a method provided herein for, for example, modulating bile acid homeostasis or treating a metabolic or associated disorder includes contacting or administering one or more peptides provided herein (*e.g.*, a variant or fusion of FGF19 and/or FGF21 as set forth in the Sequence Listing or Tables 1-11) in

an amount effective to modulate bile acid homeostasis or treat a metabolic or associated disorder. In certain embodiments the method further comprises contacting or administering at least one additional therapeutic agent or treatment modality that is useful in the treatment or prevention of a metabolic or associated disorder (*e.g.*, PBC).

[0342] The term “subject” refers to an animal. Typically, the animal is a mammal that would benefit from treatment with a peptide sequence provided herein. Particular examples include primates (*e.g.*, humans), dogs, cats, horses, cows, pigs, and sheep.

[0343] Subjects include those having a disorder, *e.g.*, a metabolic or associated disorder, or subjects that do not have a disorder but may be at risk of developing the disorder.

[0344] Non-limiting exemplary disorders or conditions preventable, treatable or manageable with the peptide formulations, methods and uses thereof provided herein, include metabolic diseases and disorders. Non limiting examples of diseases and disorders include: metabolic syndrome; a lipid- or glucose-related disorder; cholesterol or triglyceride metabolism; type 2 diabetes; cholestasis, including, for example diseases of intrahepatic cholestasis (*e.g.*, PBC, PFIC, PSC, PIC, neonatal cholestasis, and drug induced cholestasis (*e.g.*, estrogen)), and diseases of extrahepatic cholestasis (*e.g.*, bile cut compression from tumor, bile duct blockade by gall stones); bile acid malabsorption and other disorders involving the distal small intestine, including ileal resection, inflammatory bowel diseases (*e.g.*, Crohn’s disease and ulcerative colitis), disorders impairing absorption of bile acids not otherwise characterized (idiopathic)) leading to diarrhea (*e.g.*, BAD) and GI symptoms, and GI, liver, and/or biliary cancers (*e.g.*, colon cancer and hepatocellular cancer); and/or bile acid synthesis abnormalities, such as those contributing to NASH, cirrhosis and portal hypertension. For treatment, peptide sequences provided herein can be administered to subjects in need of modulation of bile acid homeostasis or having a bile-acid related or associated disorder. Peptide sequences provided herein may also be useful in other hyperglycemic-related disorders, including kidney damage (*e.g.*, tubule damage or nephropathy), liver degeneration, eye damage (*e.g.*, diabetic retinopathy or cataracts), and diabetic foot disorders; dyslipidemias and their sequelae such as, for example, atherosclerosis, coronary artery disease, cerebrovascular disorders and the like.

[0345] Other conditions which may be associated with metabolic syndrome, such as obesity and elevated body mass (including the co-morbid conditions thereof such as, but not limited to, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and polycystic

ovarian syndrome (PCOS)), and also include thromboses, hypercoagulable and prothrombotic states (arterial and venous), hypertension (including portal hypertension (defined as a hepatic venous pressure gradient (HVPG) greater than 5 mm Hg), cardiovascular disease, stroke and heart failure; Disorders or conditions in which inflammatory reactions are involved, including atherosclerosis, chronic inflammatory bowel diseases (*e.g.*, Crohn's disease and ulcerative colitis), asthma, lupus erythematosus, arthritis, or other inflammatory rheumatic disorders; Disorders of cell cycle or cell differentiation processes such as adipose cell tumors, lipomatous carcinomas including, for example, liposarcomas, solid tumors, and neoplasms; Neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, progressive multifocal leukoencephalopathy and Guillian-Barre syndrome; Skin and dermatological disorders and/or disorders of wound healing processes, including erythemato-squamous dermatoses; and other disorders such as syndrome X, osteoarthritis, and acute respiratory distress syndrome.

[0346] In one embodiment, a subject has a hyperglycemic condition (*e.g.*, diabetes, such as insulin-dependent (type I) diabetes, type II diabetes, or gestational diabetes), insulin resistance, hyperinsulinemia, glucose intolerance or metabolic syndrome, is obese and/or has an undesirable body mass.

[00100] In particular aspects of the methods and uses, a peptide sequence or chimeric peptide sequence provided herein is administered to a subject in an amount effective to improve glucose metabolism in the subject. In more particular aspects, a subject has a fasting plasma glucose level greater than 100 mg/dl or has a hemoglobin A1c (HbA1c) level above 6%, prior to administration.

[00101] In further embodiments, a use or method of treatment of a subject is intended to or results in reduced glucose levels, increased insulin sensitivity, reduced insulin resistance, reduced glucagon, an improvement in glucose tolerance, or glucose metabolism or homeostasis, improved pancreatic function, or reduced triglyceride, cholesterol, IDL, LDL or VLDL levels, or a decrease in blood pressure, a decrease in intimal thickening of the blood vessel, or a decrease in body mass or weight gain.

[0347] Treatment of a metabolic or associated disorder (*e.g.*, hyperglycemia) may have the benefit of alleviating or abolishing a disorder secondary thereto. By way of example, a subject suffering from hyperglycemia may also have depression or anxiety due to the hyperglycemia; thus, treating the subject's hyperglycemia may also indirectly treat the depression or anxiety. The use of the therapies disclosed herein to target such secondary disorders is also contemplated in certain embodiments.

[0348] In particular embodiments, the subject has or is at risk of having hyperglycemia. In other particular embodiments, the subject has or is at risk of having diabetes, such as Type 2 diabetes.

[0349] Subjects at risk of developing a metabolic or associated disorder (such as the disorders described above) include, for example, those who may have a family history or genetic predisposition toward such disorder, as well those whose diet may contribute to development of such disorders.

[0350] As disclosed herein, treatment methods include contacting or administering a peptide as set forth herein (*e.g.*, a variant or fusion of FGF19 and/or FGF21 as set forth in the Sequence Listing or Tables 1-11) in an amount effective to achieve a desired outcome or result in a subject. A treatment that results in a desired outcome or result includes decreasing, reducing or preventing the severity or frequency of one or more symptoms of the condition in the subject, *e.g.*, an improvement in the subject's condition or a "beneficial effect" or "therapeutic effect." Therefore, treatment can decrease or reduce or prevent the severity or frequency of one or more symptoms of the disorder, stabilize or inhibit progression or worsening of the disorder, and in some instances, reverse the disorder, transiently (*e.g.*, for 1-6, 6-12, or 12-24 hours), for medium term (*e.g.*, 1-6, 6-12, 12-24 or 24-48 days) or long term (*e.g.*, for 1-6, 6-12, 12-24, 24-48 weeks, or greater than 24-48 weeks). Thus, in the case of a metabolic or associated disorder, treatment can lower or reduce one or more symptoms or effects of the metabolic or associated disorders described above.

[0351] In certain embodiments, the various methods provided herein further include contacting or administering one or more additional agents or therapeutic modalities useful in the treatment or prevention of a metabolic or associated disorder, such as those agents or therapeutic modalities described herein, in an amount effective to achieve a desired outcome or result in a subject.

[0352] An “effective amount” or a “sufficient amount” for use and/or for treating a subject refers to an amount that provides, in single or multiple doses, alone, or in combination with one or more other agents, treatments, protocols, or therapeutic regimens, a detectable response of any duration of time (transient, medium or long term), a desired outcome in or an objective or subjective benefit to a subject of any measurable or detectable degree or for any duration of time (*e.g.*, for hours, days, months, years, in remission or cured). Such amounts typically are effective to ameliorate a disorder, or one, multiple or all adverse symptoms, consequences or complications of the disorder, to a measurable extent, although reducing or inhibiting a progression or worsening of the disorder, is considered a satisfactory outcome.

[0353] As used herein, the term “ameliorate” means an improvement in the subject’s disorder, a reduction in the severity of the disorder, or an inhibition of progression or worsening of the disorder (*e.g.*, stabilizing the disorder). In the case of a metabolic or associated disorder such as those described above, an improvement can be a lowering or a reduction in one or more symptoms or effects of the disorder.

[0354] A therapeutic benefit or improvement therefore need not be complete ablation of any one, most or all symptoms, complications, consequences or underlying causes associated with the disorder or disease. Thus, a satisfactory endpoint is achieved when there is a transient, medium or long term, incremental improvement in a subject’s condition, or a partial reduction in the occurrence, frequency, severity, progression, or duration, or inhibition or reversal, of one or more associated adverse symptoms or complications or consequences or underlying causes, worsening or progression (*e.g.*, stabilizing one or more symptoms or complications of the condition, disorder or disease), of the disorder or disease, over a duration of time (hours, days, weeks, months, *etc.*).

[0355] Thus, in the case of a disorder treatable by a peptide sequence provided herein, either alone or in combination with an additional agent, the amount of the peptide (and optionally the additional agent) sufficient to ameliorate a disorder will depend on the type, severity and extent, or duration of the disorder, the therapeutic effect or outcome desired, and can be readily ascertained by the skilled artisan. Appropriate amounts will also depend upon the individual subject (*e.g.*, the bioavailability within the subject, gender, age, *etc.*). For example, a transient, or partial, restoration of normal bile acid homeostasis in a subject can reduce the dosage amount or frequency of the peptides and agents described herein in order to treat the metabolic or

associated disorders described previously even though complete freedom from treatment has not resulted. An effective amount can be ascertained, for example, by measuring one or more relevant physiological effects.

[0356] Methods and uses provided herein for treating a subject are applicable for prophylaxis to prevent or reduce the likelihood of a disorder in a subject, such as a metabolic or associated disorder. Accordingly, methods and uses provided herein for treating a subject having, or at risk of developing, a metabolic or associated disorder can be practiced prior to, substantially contemporaneously with, or following administration or application of another agent useful for the treatment or prevention of a metabolic or associated disorder, and/or can be supplemented with other forms of therapy. Supplementary therapies include other glucose lowering treatments, such as insulin, an insulin sensitivity enhancer and other drug treatments, a change in diet (low sugar, fats, *etc.*), weight loss surgery- (reducing stomach volume by gastric bypass, gastrectomy), gastric banding, gastric balloon, gastric sleeve, *etc.* For example, a method or use provided herein for treating a hyperglycemic or insulin resistance disorder can be used in combination with drugs or other pharmaceutical compositions that lower glucose or increase insulin sensitivity in a subject.

[0357] In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for preventing a metabolic or associated disorder. In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for treating a metabolic or associated disorder. In one embodiment, a method or use includes contacting or administering to a subject one or more variant or fusion FGF19 and/or FGF21 peptide sequences in an amount effective for managing a metabolic or associated disorder.

4.6 Nucleic Acid Molecules

[0358] Also provided are nucleic acid molecules encoding peptide sequences provided herein, including subsequences, sequence variants and modified forms of the sequences listed in the Sequence Listing (and in PCT Pub. No. WO 2013/006486 and US Pub. No. 2013/0023474, as well as PCT Publ. No. WO 2014/085365) or Tables 1-11, and vectors that include nucleic acid encoding the peptides used in the methods described herein. Accordingly, “nucleic acids” include those that encode the exemplified peptide sequences disclosed herein, as well as those

encoding functional subsequences, sequence variants and modified forms of the exemplified peptide sequences, so long as the foregoing retain at least detectable or measureable activity or function useful in the treatment or prevention of a bile acid-related or associated disorder (*e.g.*, PBC).

[0359] Nucleic acid, which can also be referred to herein as a gene, polynucleotide, nucleotide sequence, primer, oligonucleotide or probe, refers to natural or modified purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides and α -anomeric forms thereof. The two or more purine- and pyrimidine-containing polymers are typically linked by a phosphoester bond or analog thereof. The terms can be used interchangeably to refer to all forms of nucleic acid, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The nucleic acids can be single strand, double, or triplex, linear or circular. Nucleic acids include genomic DNA and cDNA. RNA nucleic acid can be spliced or unspliced mRNA, rRNA, tRNA or antisense. Nucleic acids include naturally occurring, synthetic, as well as nucleotide analogs and derivatives.

[0360] As a result of the degeneracy of the genetic code, the nucleic acid molecules provided herein include sequences degenerate with respect to nucleic acid molecules encoding the peptide sequences useful in the methods provided herein. Thus, degenerate nucleic acid sequences encoding peptide sequences, including subsequences, variants and modified forms of the peptide sequences exemplified herein (*e.g.*, in the Sequence Listing or Tables 1-11), are provided. The term “complementary,” when used in reference to a nucleic acid sequence, means the referenced regions are 100% complementary, *i.e.*, exhibit 100% base pairing with no mismatches.

[0361] Nucleic acid can be produced using any of a variety of known standard cloning and chemical synthesis methods, and can be altered intentionally by site-directed mutagenesis or other recombinant techniques known to one skilled in the art. Purity of polynucleotides can be determined through, for example, sequencing, gel electrophoresis, and UV spectrometry.

[0362] Nucleic acids may be inserted into a nucleic acid construct in which expression of the nucleic acid is influenced or regulated by an “expression control element,” referred to herein as an “expression cassette.” The term “expression control element” refers to one or more nucleic acid sequence elements that regulate or influence expression of a nucleic acid sequence to which it is operatively linked. An expression control element can include, as appropriate, promoters,

enhancers, transcription terminators, gene silencers, a start codon (*e.g.*, ATG) in front of a protein-encoding gene, *etc.*

[0363] An expression control element operatively linked to a nucleic acid sequence controls transcription and, as appropriate, translation of the nucleic acid sequence. The term “operatively linked” refers to a juxtaposition wherein the referenced components are in a relationship permitting them to function in their intended manner. Typically, expression control elements are juxtaposed at the 5’ or the 3’ ends of the genes but can also be intronic.

[0364] Expression control elements include elements that activate transcription constitutively, that are inducible (*i.e.*, require an external signal or stimuli for activation), or derepressible (*i.e.*, require a signal to turn transcription off; when the signal is no longer present, transcription is activated or “derepressed”). Also included in the expression cassettes provided herein are control elements sufficient to render gene expression controllable for specific cell types or tissues (*i.e.*, tissue-specific control elements). Typically, such elements are located upstream or downstream (*i.e.*, 5’ or 3’) of the coding sequence. Promoters are generally positioned 5’ of the coding sequence. Promoters, produced by recombinant DNA or synthetic techniques, can be used to provide for transcription of the polynucleotides provided herein. A “promoter” typically means a minimal sequence element sufficient to direct transcription.

[0365] Nucleic acids may be inserted into a plasmid for transformation into a host cell and for subsequent expression and/or genetic manipulation. A plasmid is a nucleic acid that can be stably propagated in a host cell; plasmids may optionally contain expression control elements in order to drive expression of the nucleic acid. As used herein, a vector is synonymous with a plasmid. Plasmids and vectors generally contain at least an origin of replication for propagation in a cell and a promoter. Plasmids and vectors may also include an expression control element for expression in a host cell, and are therefore useful for expression and/or genetic manipulation of nucleic acids encoding peptide sequences, expressing peptide sequences in host cells and organisms, or producing peptide sequences, for example.

[0366] As used herein, the term “transgene” means a polynucleotide that has been introduced into a cell or organism by artifice. For example, in a cell having a transgene, the transgene has been introduced by genetic manipulation or “transformation” of the cell. A cell or progeny thereof into which the transgene has been introduced is referred to as a “transformed cell” or “transformant.” Typically, the transgene is included in progeny of the transformant or becomes a

part of the organism that develops from the cell. Transgenes may be inserted into the chromosomal DNA or maintained as a self-replicating plasmid, YAC, minichromosome, or the like.

[0367] Bacterial system promoters include T7 and inducible promoters such as pL of bacteriophage λ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and tetracycline-responsive promoters. Insect cell system promoters include constitutive or inducible promoters (*e.g.*, ecdysone). Mammalian cell constitutive promoters include SV40, RSV, bovine papilloma virus (BPV) and other virus promoters, or inducible promoters derived from the genome of mammalian cells (*e.g.*, metallothionein IIA promoter; heat shock promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the inducible mouse mammary tumor virus long terminal repeat). Alternatively, a retroviral genome can be genetically modified for introducing and directing expression of a peptide sequence in appropriate host cells.

[0368] As methods and uses provided herein include *in vivo* delivery, expression systems further include vectors designed for *in vivo* use. Particular non-limiting examples include adenoviral vectors (U.S. Patent Nos. 5,700,470 and 5,731,172), adeno-associated vectors (U.S. Patent No. 5,604,090), herpes simplex virus vectors (U.S. Patent No. 5,501,979), retroviral vectors (U.S. Patent Nos. 5,624,820, 5,693,508 and 5,674,703), BPV vectors (U.S. Patent No. 5,719,054), CMV vectors (U.S. Patent No. 5,561,063) and parvovirus, rotavirus, Norwalk virus and lentiviral vectors (see, *e.g.*, U.S. Patent No. 6,013,516). Vectors include those that deliver genes to cells of the intestinal tract, including the stem cells (Croyle *et al.*, Gene Ther. 5:645 (1998); S.J. Henning, Adv. Drug Deliv. Rev. 17:341 (1997), U.S. Patent Nos. 5,821,235 and 6,110,456). Many of these vectors have been approved for human studies.

[0369] Yeast vectors include constitutive and inducible promoters (see, *e.g.*, Ausubel *et al.*, In: Current Protocols in Molecular Biology, Vol. 2, Ch. 13, ed., Greene Publish. Assoc. & Wiley Interscience, 1988; Grant *et al.* Methods in Enzymology, 153:516 (1987), eds. Wu & Grossman; Bitter Methods in Enzymology, 152:673 (1987), eds. Berger & Kimmel, Acad. Press, N.Y.; and, Strathern *et al.*, The Molecular Biology of the Yeast Saccharomyces (1982) eds. Cold Spring Harbor Press, Vols. I and II). A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (R. Rothstein In: DNA Cloning, A Practical Approach, Vol. 11, Ch. 3, ed. D.M. Glover, IRL Press, Wash., D.C., 1986). Vectors that facilitate integration of foreign nucleic acid sequences into a yeast chromosome, via homologous

recombination for example, are known in the art. Yeast artificial chromosomes (YAC) are typically used when the inserted polynucleotides are too large for more conventional vectors (*e.g.*, greater than about 12 Kb).

[0370] Expression vectors also can contain a selectable marker conferring resistance to a selective pressure or identifiable marker (*e.g.*, beta-galactosidase), thereby allowing cells having the vector to be selected for, grown and expanded. Alternatively, a selectable marker can be on a second vector that is co-transfected into a host cell with a first vector containing a nucleic acid encoding a peptide sequence. Selection systems include, but are not limited to, herpes simplex virus thymidine kinase gene (Wigler *et al.*, Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase gene (Szybalska *et al.*, Proc. Natl. Acad. Sci. USA 48:2026 (1962)), and adenine phosphoribosyltransferase (Lowy *et al.*, Cell 22:817 (1980)) genes that can be employed in tk⁻, hgp^{rt}- or ap^{rt}- cells, respectively. Additionally, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (O'Hare *et al.*, Proc. Natl. Acad. Sci. USA 78:1527 (1981)); the gpt gene, which confers resistance to mycophenolic acid (Mulligan *et al.*, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neomycin gene, which confers resistance to aminoglycoside G-418 (Colberre-Garapin *et al.*, J. Mol. Biol. 150:1(1981)); puromycin; and hygromycin gene, which confers resistance to hygromycin (Santerre *et al.*, Gene 30:147 (1984)). Additional selectable genes include trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman *et al.*, Proc. Natl. Acad. Sci. USA 85:8047 (1988)); and ODC (ornithine decarboxylase), which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue (1987) In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory).

4.7 Cell Lines and Animal Models

[0371] In certain embodiments, also provided is a transformed cell(s) (*in vitro*, *ex vivo* and *in vivo*) and host cells that produce a variant or fusion of FGF19 and/or FGF21 as set forth herein, where expression of the variant or fusion of FGF19 and/or FGF21 is conferred by a nucleic acid encoding the variant or fusion of FGF19 and/or FGF21. As used herein, a "transformed" or "host" cell is a cell into which a nucleic acid is introduced that can be propagated and/or transcribed for expression of an encoded peptide sequence. The term also includes any progeny or subclones of the host cell. Transformed and host cells that express peptide sequences

provided herein typically include a nucleic acid that encodes the peptide sequence. In one embodiment, a transformed or host cell is a prokaryotic cell. In another embodiment, a transformed or host cell is a eukaryotic cell. In various aspects, the eukaryotic cell is a yeast or mammalian (*e.g.*, human, primate, *etc.*) cell.

[0372] Transformed and host cells include but are not limited to microorganisms such as bacteria and yeast; and plant, insect and mammalian cells. For example, bacteria transformed with recombinant bacteriophage nucleic acid, plasmid nucleic acid or cosmid nucleic acid expression vectors; yeast transformed with recombinant yeast expression vectors; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid); insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus); and animal cell systems infected with recombinant virus expression vectors (*e.g.*, retroviruses, adenovirus, vaccinia virus), or transformed animal cell systems engineered for transient or stable propagation or expression.

[0373] For gene therapy uses and methods, a transformed cell can be in a subject. A cell in a subject can be transformed with a nucleic acid that encodes a peptide sequence as set forth herein *in vivo*. Alternatively, a cell can be transformed *in vitro* with a transgene or polynucleotide, and then transplanted into a tissue of subject in order to effect treatment. Alternatively, a primary cell isolate or an established cell line can be transformed with a transgene or polynucleotide that encodes a variant of FGF19 and/or FGF21 or a fusion/chimeric sequence (or variant) thereof, such as a chimeric peptide sequence including all or a portion of FGF19, or including all or a portion of FGF21, and then optionally transplanted into a tissue of a subject.

[0374] Non-limiting target cells for expression of peptide sequences, particularly for expression *in vivo*, include pancreas cells (islet cells), muscle cells, mucosal cells and endocrine cells. Such endocrine cells can provide inducible production (secretion) of a variant of FGF19 and/or FGF21, or a fusion/chimeric sequence (or variant) thereof, such as a chimeric peptide sequence including all or a portion of FGF19, or including all or a portion of FGF21. Additional cells to transform include stem cells or other multipotent or pluripotent cells, for example, progenitor cells that differentiate into the various pancreas cells (islet cells), muscle cells, mucosal cells and endocrine cells. Targeting stem cells provides longer term expression of peptide sequences provided herein.

[0375] As used herein, the term “cultured,” when used in reference to a cell, means that the cell is grown *in vitro*. A particular example of such a cell is a cell isolated from a subject, and grown or adapted for growth in tissue culture. Another example is a cell genetically manipulated *in vitro*, and transplanted back into the same or a different subject.

[0376] The term “isolated,” when used in reference to a cell, means a cell that is separated from its naturally occurring *in vivo* environment. “Cultured” and “isolated” cells may be manipulated by the hand of man, such as genetically transformed. These terms include any progeny of the cells, including progeny cells that may not be identical to the parental cell due to mutations that occur during cell division. The terms do not include an entire human being.

[0377] Nucleic acids encoding peptide sequences provided herein can be introduced for stable expression into cells of a whole organism. Such organisms, including non-human transgenic animals, are useful for studying the effect of peptide expression in a whole animal and therapeutic benefit. For example, nucleic acids for production of a variant of FGF19 and/or FGF21 or a fusion/chimeric sequence (or variant) thereof, such as a chimeric peptide sequence including all or a portion of FGF19, or including all or a portion of FGF21 as set forth herein, can be introduced for stable expression in mice.

[0378] Mice strains that develop or are susceptible to developing a particular disease (*e.g.*, diabetes, degenerative disorders, cancer, *etc.*) are also useful for introducing therapeutic proteins as described herein in order to study the effect of therapeutic protein expression in the disease-susceptible mouse. Transgenic and genetic animal models that are susceptible to particular disease or physiological conditions, such as streptozotocin (STZ)-induced diabetic (STZ) mice, are appropriate targets for expressing variants of FGF19 and/or FGF21, fusions/chimeric sequences (or variant) thereof, such as a chimeric peptide sequence including all or a portion of FGF19, or including all or a portion of FGF21, as set forth herein. Thus, in certain embodiments, there are provided non-human transgenic animals that produce a variant of FGF19 and/or FGF21, or a fusion/chimeric sequence (or variant) thereof, such as a chimeric peptide sequence including all or a portion of FGF19, or including all or a portion of FGF21, the production of which is not naturally occurring in the animal which is conferred by a transgene present in somatic or germ cells of the animal.

[0379] The term “transgenic animal” refers to an animal whose somatic or germ line cells bear genetic information received, directly or indirectly, by deliberate genetic manipulation at the

subcellular level, such as by microinjection or infection with recombinant virus. The term “transgenic” further includes cells or tissues (*i.e.*, “transgenic cell,” “transgenic tissue”) obtained from a transgenic animal genetically manipulated as described herein. In the present context, a “transgenic animal” does not encompass animals produced by classical crossbreeding or *in vitro* fertilization, but rather denotes animals in which one or more cells receive a nucleic acid molecule. Transgenic animals provided herein can be either heterozygous or homozygous with respect to the transgene. Methods for producing transgenic animals, including mice, sheep, pigs and frogs, are well known in the art (see, *e.g.*, U.S. Patent Nos. 5,721,367, 5,695,977, 5,650,298, and 5,614,396) and, as such, are additionally included.

[0380] Peptide sequences, nucleic acids encoding peptide sequences, vectors and transformed host cells expressing peptide sequences include isolated and purified forms. The term “isolated,” when used as a modifier of a composition provided herein, means that the composition is separated, substantially, completely, or at least in part, from one or more components in an environment. Generally, compositions that exist in nature, when isolated, are substantially free of one or more materials with which they normally associate with in nature, for example, one or more protein, nucleic acid, lipid, carbohydrate or cell membrane. The term “isolated” does not exclude alternative physical forms of the composition, such as variants, modifications or derivatized forms, fusions and chimeras, multimers/oligomers, *etc.*, or forms expressed in host cells. The term “isolated” also does not exclude forms (*e.g.*, pharmaceutical compositions, combination compositions, *etc.*) in which there are combinations therein, any one of which is produced by the hand of man. An “isolated” composition can also be “purified” when free of some, a substantial number of, or most or all of one or more other materials, such as a contaminant or an undesired substance or material.

[0381] As used herein, the term “recombinant,” when used as a modifier of peptide sequences, nucleic acids encoding peptide sequences, *etc.*, means that the compositions have been manipulated (*i.e.*, engineered) in a fashion that generally does not occur in nature (*e.g.*, *in vitro*). A particular example of a recombinant peptide would be where a peptide sequence provided herein is expressed by a cell transfected with a nucleic acid encoding the peptide sequence. A particular example of a recombinant nucleic acid would be a nucleic acid (*e.g.*, genomic or cDNA) encoding a peptide sequence cloned into a plasmid, with or without 5', 3' or intron regions that the gene is normally contiguous within the genome of the organism. Another

example of a recombinant peptide or nucleic acid is a hybrid or fusion sequence, such as a chimeric peptide sequence comprising a portion of FGF19 and a portion of FGF21.

[0382] In accordance with the methods provided herein, there are provided compositions and mixtures of peptide sequences provided herein, including subsequences, variants and modified forms of the exemplified peptide sequences (including the FGF19 and FGF21 variants and subsequences listed in Tables 1-11 and the Sequence Listing, and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and the Sequence Listing). In one embodiment, a mixture includes one or more peptide sequences and a pharmaceutically acceptable carrier or excipient. In another embodiment, a mixture includes one or more peptide sequences and an adjunct drug or therapeutic agent, such as a bile acid homeostasis modulating or anti-diabetic, or glucose lowering, drug or therapeutic agent. Combinations, such as one or more peptide sequences in a pharmaceutically acceptable carrier or excipient, with one or more of a bile acid homeostasis modulating or a treatment for a bile acid-related or associated disorder, or anti-diabetic, or glucose lowering drug or therapeutic agent are also provided. Such combinations of a peptide sequence provided herein with another drug or agent, such as a bile acid homeostasis modulating or acid related disorder treating, or glucose lowering drug or therapeutic agent, for example are useful in accordance with the methods and uses provided herein, for example, for treatment of a subject.

[0383] Combinations also include incorporation of peptide sequences or nucleic acids provided herein into particles or a polymeric substances, such as polyesters, carbohydrates, polyamine acids, hydrogel, polyvinyl pyrrolidone, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers; entrapment in microcapsules prepared by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin-microcapsules, or poly (methylmethacrolate) microcapsules, respectively; incorporation in colloid drug delivery and dispersion systems such as macromolecule complexes, nano-capsules, non-encapsulated nanoparticles, microspheres, beads, and lipid-based systems (*e.g.*, N-fatty acyl groups such as N-lauroyl, N-oleoyl, fatty amines such as dodecyl amine, oleoyl amine, *etc.*, see US Patent No. 6,638,513), including oil-in-water emulsions, micelles, mixed micelles, and liposomes, for example. Methods of preparing liposomes are described in, for example, U.S. Patent Nos.

4,235,871, 4,501,728, and 4,837,028. Methods of encapsulated-free controlled release using nanoparticles are described, for example, in Pakulska *et al.*, *Science Advances* 2(5): e1600519 (2016). Methods for preparation of the above-mentioned formulations will be apparent to those skilled in the art.

[0384] The peptides provided herein including subsequences, variants and modified forms of the exemplified peptide sequences (including the FGF19 and FGF21 variants and subsequences listed in Tables 1-11 and the Sequence Listing, and the FGF19/FGF21 fusions and chimeras listed in Tables 1-11 and the Sequence Listing) as set forth herein can be used to modulate glucose metabolism and facilitate transport of glucose from the blood to key metabolic organs such as muscle, liver and fat. Such peptide sequences can be produced in amounts sufficient or effective to restore glucose tolerance and/or to improve or provide normal glucose homeostasis.

[0385] In case of conflict, the specification, including definitions, will control. As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a peptide sequence” or “a treatment,” includes a plurality of such sequences, treatments, and so forth. It is further noted that the claims can be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology such as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0386] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges can independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0387] As used herein, numerical values are often presented in a range format throughout this document. The use of a range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention unless the context clearly indicates otherwise. Accordingly, the use of a range expressly includes all possible subranges, all individual numerical values within that range, and all numerical values or numerical ranges including integers within such ranges and fractions of the values or the integers within ranges, unless the context clearly

indicates otherwise. This construction applies regardless of the breadth of the range and in all contexts throughout this patent document. Thus, for example, reference to a range of 90-100% includes 91-99%, 92-98%, 93-95%, 91-98%, 91-97%, 91-96%, 91-95%, 91-94%, 91-93%, and so forth. Reference to a range of 90-100% also includes 91%, 92%, 93%, 94%, 95%, 96%, 97%, *etc.*, as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, *etc.*, 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, *etc.*, and so forth. In addition, reference to a range of 1-3, 3-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250 includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, *etc.* In a further example, reference to a range of 25-250, 250-500, 500-1000, 1000-2500, 2500-5000, 5000-25,000, or 5000-50,000 includes any numerical value or range within or encompassing such values, *e.g.*, 25, 26, 27, 28, 29...250, 251, 252, 253, 254...500, 501, 502, 503, 504..., *etc.* The use of a series of ranges includes combinations of the upper and lower ranges to provide another range. This construction applies regardless of the breadth of the range and in all contexts throughout this patent document. Thus, for example, reference to a series of ranges such as 5-10, 10-20, 20-30, 30-40, 40-50, 50-75, 75-100, 100-150, includes ranges such as 5-20, 5-30, 5-40, 5-50, 5-75, 5-100, 5-150, and 10-30, 10-40, 10-50, 10-75, 10-100, 10-150, and 20-40, 20-50, 20-75, 20-100, 20-150, and so forth.

[0388] For the sake of conciseness, certain abbreviations are used herein. One example is the single letter abbreviation to represent amino acid residues. The amino acids and their corresponding three letter and single letter abbreviations are as follows:

alanine	Ala	(A)
arginine	Arg	(R)
asparagine	Asn	(N)
aspartic acid	Asp	(D)
cysteine	Cys	(C)
glutamic acid	Glu	(E)
glutamine	Gln	(Q)
glycine	Gly	(G)
histidine	His	(H)
isoleucine	Ile	(I)
leucine	Leu	(L)
lysine	Lys	(K)

methionine	Met	(M)
phenylalanine	Phe	(F)
proline	Pro	(P)
serine	Ser	(S)
threonine	Thr	(T)
tryptophan	Trp	(W)
tyrosine	Tyr	(Y)
valine	Val	(V)

[0389] The invention is generally disclosed herein using affirmative language to describe the numerous embodiments. The invention also specifically includes embodiments in which particular subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, procedures, assays or analysis. Thus, even though the invention is generally not expressed herein in terms of what the invention does not include, aspects that are not expressly included in the invention are nevertheless disclosed herein.

[0390] Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Upon reading the foregoing description, variations of the disclosed embodiments may become apparent to individuals working in the art, and it is expected that those skilled artisans may employ such variations as appropriate. Accordingly, it is intended that the invention be practiced otherwise than as specifically described herein, and that the invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[0391] All publications, patent applications, accession numbers, and other references cited in this specification are herein incorporated by reference in its entirety as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided can be different from the actual publication dates which can need to be independently confirmed.

[0392] A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the descriptions in the Experimental section are intended to illustrate but not limit the scope of invention described in the claims.

5. Experimental

5.1 Example 1

[0393] The following is a description of various methods and materials used in the studies herein.

[0394] **Animals.** *db/db* mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were kept in accordance with welfare guidelines under controlled light (12 hr light and 12 hr dark cycle, dark 6:30 pm-6:30 am), temperature ($22\pm 4^{\circ}\text{C}$) and humidity ($50\%\pm 20\%$) conditions. Mice had free access to water (autoclaved distilled water) and were fed *ad libitum* on a commercial diet (Harlan Laboratories, Indianapolis, IN, Irradiated 2018 Teklad Global 18% Protein Rodent Diet) containing 17 kcal% fat, 23 kcal% protein and 60 kcal% carbohydrate. All animal studies were approved by the NGM Institutional Animal Care and Use Committee.

[0395] **DNA and amino acid sequences.** cDNA of ORF encoding human FGF19 (*Homo sapiens* FGF19, GenBank Accession No. NM_005117.2) variants. Protein sequence encoded by the cDNA (GenBank Accession No. NP_005108.1).

[0396] **PCR.** FGF19 ORF was amplified with polymerase chain reaction (PCR) using recombinant DNA (cDNA) prepared from human small intestinal tissue. PCR reagents kits with Phusion® high-fidelity DNA polymerase were purchased from New England BioLabs (F-530L, Ipswich, MA). The following primers were used: forward PCR primer:

5' CCGACTAGTCACCatgaggagcgggtgtgtgg (SEQ ID NO:136)

and reverse PCR primer:

5' ATAAGAATGCGGCCGCTTACTTCTCAAAGCTGGGACTCCTC (SEQ ID NO:137).

Amplified DNA fragment was digested with restriction enzymes Spe I and Not I (the restriction sites were included in the 5' or 3' PCR primers, respectively) and was then ligated with AAV transgene vectors that had been digested with the same restriction enzymes. The vector used for expression contained a selectable marker and an expression cassette composed of a strong eukaryotic promoter 5' of a site for insertion of the cloned coding sequence, followed by a 3' untranslated region and bovine growth hormone polyadenylation tail. The expression construct is also flanked by internal terminal repeats at the 5' and 3' ends.

[0397] Cyp7a1 repression assay in primary human hepatocytes. Primary human hepatocytes were plated on collagen coated plates (Becton Dickinson Biosciences) in Williams E media (Invitrogen) supplemented with 100 nM dexamethasone (Sigma) and 0.25 mg/ml MatriGel™ (Becton Dickinson Biosciences). Cells were treated with FGF19 or variants at 37°C for 6 hours. Cyp7a1 expression was evaluated in triplicate by quantitative RT-PCR (TaqMan® ABI PRISM 7700, Applied Biosystems) and normalized to GAPDH expression.

[0398] Cyp7a1 *in vivo* repression assay. Nine-week-old male *db/db* mice (Jackson Laboratories) were injected intraperitoneally with recombinant proteins FGF19 or FGF21 at 0.1 mg/kg, 1 mg/kg, and 10 mg/kg. Animals were euthanized 5 hours post-injection. Liver was harvested and homogenized in TRIzol® reagent (Invitrogen). Total RNA was extracted and treated with DNase (Ambion) followed by quantitative RT-PCR analysis and normalized to GAPDH expression.

[0399] Production and purification of AAV. AAV293 cells (obtained from Agilent Technologies, Santa Clara, CA) were cultured in Dulbecco's Modification of Eagle's Medium (DMEM, Mediatech, Inc. Manassas, VA) supplemented with 10% fetal bovine serum and 1x antibiotic-antimycotic solution (Mediatech, Inc. Manassas, VA). The cells were plated at 50% density on day 1 in 150 mm cell culture plates and transfected on day 2, using calcium phosphate precipitation method with the following 3 plasmids (20 µg/plate of each): AAV transgene plasmid, pHelper™ plasmids (Agilent Technologies) and AAV2/9 plasmid (Gao *et al.*, *J. Virol.* 78:6381 (2004)). Forty-eight (48) hours after transfection, the cells were scraped off the plates, pelleted by centrifugation at 3000xg and resuspended in buffer containing 20 mM Tris pH 8.5, 100 mM NaCl and 1 mM MgCl₂. The suspension was frozen in an alcohol dry ice bath and was then thawed in 37°C water bath. The freeze and thaw cycles were repeated three times; Benzonase® (Sigma-aldrich, St. Louis, MO) was added to 50 units/ml; deoxycholate was added to a final concentration of 0.25%. After an incubation at 37°C for 30 min, cell debris was pelleted by centrifugation at 5000 x g for 20 min. Viral particles in the supernatant were purified using a discontinued iodixanal (Sigma-aldrich, St. Louis, MO) gradient as previously described (Zolotukhin S. *et al* (1999) *Gene Ther.* 6:973). The viral stock was concentrated using Vivaspin® 20 (MW cutoff 100,000 Dalton, Sartorius Stedim Biotech, Aubagne, France) and re-suspended in phosphate-buffered saline (PBS) with 10% glycerol and stored at -80°C. To determine the viral genome copy number, 2 µl of viral stock were incubated in 6 µl of solution containing 50 units/ml Benzonase®, 50 mM Tris-HCl pH 7.5, 10 mM MgCl₂ and 10 mM CaCl₂ at 37°C for 30 minutes.

[0400] Afterwards, 15 μ l of the solution containing 2 mg/ml of Proteinase K, 0.5% SDS and 25 mM EDTA were added and the mixture was incubated for additional 20 min at 55°C to release viral DNA. Viral DNA was cleaned with mini DNeasy® Kit (Qiagen, Valencia, CA) and eluted with 40 μ l of water. Viral genome copy (GC) was determined by using quantitative PCR.

[0401] Viral stock was diluted with PBS to desirable GC/ml. Viral working solution (200 μ l) was delivered into mice via tail vein injection.

[0402] **Hepatocellular carcinoma (HCC) assay.** Liver specimens were harvested from *db/db* mice 24 weeks after AAV injection. HCC scores were recorded as the number of HCC nodules on the surface of the entire liver from variants-injected mice divided by the number of HCC nodules from wild-type FGF19-injected mice.

[0403] **Serum FGF19/FGF21/variants exposure level assay.** Whole blood (about 50 μ l/mouse) from mouse tail snips was collected into plain capillary tubes (BD Clay Adams SurePrep™, Becton Dickinson and Co. Sparks, MD). Serum and blood cells were separated by spinning the tubes in an Autocrit™ Ultra 3 (Becton Dickinson and Co. Sparks, MD). FGF19, FGF21, and variant exposure levels in serum was determined using EIA kits (Biovendor) by following the manufacturer's instructions.

[0404] **FGFR4 binding and activity assays.** Solid phase ELISA (binding) and ERK phosphorylation assay can be performed using purified recombinant proteins. FGFR binding assay can be conducted using solid phase ELISA. Briefly, a 96-well plate can be coated with 2 μ g/ml anti-hFc antibody and can be incubated with 1 μ g/ml FGFR1-hFc or FGFR4-hFc. Binding to FGF19 variants in the presence of 1 μ g/ml soluble β -klotho and 20 μ g/ml heparin can be detected by biotinylated anti-FGF19 antibodies (0.2 μ g/mL), followed by streptavidin-HRP incubation (100 ng/mL). For FGFR4 activation assay, Hep3B cells can be stimulated with FGF19 variants for 10 minutes at 37°C, then can be immediately lysed and assayed for ERK phosphorylation using a commercially available kit from Cis-Bio.

5.2 Example 2

[0405] In order to confirm that FGF19 variants such as those set forth herein repress *cyp7a1* expression, inhibition of *cyp7a1* expression by wild-type FGF19 was determined following administration of various concentrations. The effects of FGF21 were assessed in a comparable manner.

[0406] Briefly, at time 0, *db/db* mice were dosed intraperitoneally with either recombinant FGF19 (0.1 mg/kg; 1 mg/kg; 10 mg/kg) or recombinant FGF21 (0.1 mg/kg; 1 mg/kg; 10 mg/kg).

Five hours after dosing, livers were harvested, RNA was extracted, and cyp7a1 expression was determined by real-time PCR (QPCR) using GADPH as a normalization control. In each group of mice, n = 3, and cyp7a1 expression values for the various FGF19 and FGF21 concentrations were compared to mice dosed with PBS vehicle control.

[0407] As set forth in FIG. 1, FGF19 dramatically decreased cyp7a1 expression in a concentration-dependent manner. Although administration of FGF21 caused a reduction of cyp7a1 expression, the effect was demonstrably less than that observed with FGF19.

[0408] The effect of variant M70 on cyp7a1 expression in human primary hepatocytes was compared to that of FGF19. As noted in FIG. 2, variant M70 repressed cyp7a1 expression in an amount comparable to that of FGF19.

5.3 Example 3

[0409] Using the assays described above, repression of cyp7a1 in primary human hepatocytes was determined for a number of FGF19 variants. As indicated in FIG. 3 - FIG. 5, several variants (*e.g.*, M1, M2, *etc.*) exhibited strong cyp7a1 repression.

[0410] To evaluate effects of some additional FGF19 variants on Cyp7a1 repression, the *in vitro* cell-based assay (primary human hepatocyte) and the *in vivo* assay (protein dosing in *db/db* mice) were utilized in which the variants were compared with saline-treated controls. FIG. 5 sets forth the results (IC₅₀ and Cyp7a1 (%)) in tabular form. While most FGF19 variants that were evaluated exhibited Cyp7a1-inhibiting activity, a few variants (*e.g.*, M90, M96, M98, M5 and M32) no longer repressed Cyp7a1.

[0411] FGF19 variants that retain Cyp7a1 repression activity can be further evaluated in the HCC assay (or other relevant assay or model) described above to identify variants that might be useful for modulating bile acid metabolism and/or for treating bile acid-related diseases (*e.g.*, bile acid diarrhea and primary biliary cirrhosis) without causing induction of HCC. The figures set forth data for variants that were evaluated in the HCC assay.

5.4 Example 4

[0412] The following is a data summary of 25 additional variant peptides analyzed for lipid elevating activity and tumorigenesis. The data clearly show a positive correlation between lipid elevation and tumorigenesis, as determined by HCC formation in *db/db* mice.

[0413] The Tables summarize different variant peptides. Such exemplified variant peptides have FGF19 C-terminal sequence:

PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVLRITVAIKGVHVSRYLCMGADGKMQGL

LQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE
EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK (SEQ ID NO:188) at the C-terminal portion, *e.g.*, following the “TSG” amino acid residues. Notably, variant peptides (7 total, including M5) that did not cause a statistically significant elevation of lipids did not induce HCC formation. In contrast, all variant peptides (17 total) that caused a statistically significant elevation of lipids also caused HCC formation in mice. This data indicates that there is a strong positive correlation between lipid elevating activity and HCC formation. Accordingly, lipid elevating activity can be used as an indicator and/or predictor of HCC formation in animals.

[0414] Table 2: Elevated Triglyceride and Cholesterol in *db/db* Mice Appears to Positively Correlate With HCC Formation (see SEQ ID NOs:99, 5 and 74 to 81).

	N-terminal Domain	SEQ ID NO.	Core	SEQ ID NO.	Lipid Elevation	HCC Formation
FGF19	RPLAFSDAGPHVHYGWDPI	99 (aa 1-20)	RLRHLYTSG	185	+	+
FGF21	HPIPDSSPLLQ--FGGQV	100 (aa 1-16)	RQRYLYTDD	186	-	-
M5	R-HPIPDSSPLLQ--FGGQV	5 (aa 1-17)	RLRHLYTSG	185	-	-
M74	R-----DAGPHVHYGWDPI	74 (aa 1-15)	RLRHLYTSG	185	+	+
M75	R-----VHYGWDPI	75 (aa 1-10)	RLRHLYTSG	185	-	-
M76	R-----GDPI	76 (aa 1-5)	RLRHLYTSG	185	-	-
M77	R-----	77 (aa 1)	RLRHLYTSG	185	-	-
M78	R-----AGPHVHYGWDPI	78 (aa 1-14)	RLRHLYTSG	185	+	+
M79	R-----GPHVHYGWDPI	79 (aa 1-13)	RLRHLYTSG	185	+	+
M80	R-----PHVHYGWDPI	80 (aa 1-12)	RLRHLYTSG	185	-	-
M81	R-----HVHYGWDPI	81 (aa 1-11)	RLRHLYTSG	185	-	-

[0415] Table 3: Elevated Triglyceride and Cholesterol in *db/db* Mice Appears to Positively Correlate with HCC Formation (see SEQ ID NOs:99, 100 and 82 to 98).

	N-terminal Domain	SEQ ID NO.	Core	SEQ ID NO.	Lipid Elevation	HCC Formation
FGF19	RPLAFSDAGPHVHYGWDPI	99 (aa 1-20)	RLRHLYTSG	185	+	+
FGF21	HPIPDSSPLLQ--FGGQV	100 (aa 1-16)	RQRYLYTDD	186	-	-
M82	RPLAFSAAGPHVHYGWDPI	82 (aa 1-20)	RLRHLYTSG	185	+	+
M83	RPLAFSDAAPHVHYGWDPI	83 (aa 1-20)	RLRHLYTSG	185	+/-	+/-
M84	RPLAFSDAGAHVHYGWDPI	84 (aa 1-20)	RLRHLYTSG	185	+/-	+/-
M85	RPLAFSDAGPHVHYGAGDPI	85 (aa 1-20)	RLRHLYTSG	185	-	-
M86	RPLAFSDAGPHVHYGWAPI	86 (aa 1-20)	RLRHLYTSG	185	+	+
M87	RPLAFSDAGPHVHYGWDAI	87 (aa 1-20)	RLRHLYTSG	185	+	+

[0416] Table 4: Elevated Triglyceride and Cholesterol in *db/db* Mice Appears to Positively Correlate with HCC Formation (see SEQ ID NOs:99, 100 and 88 to 98)

	N-terminal Domain	Core	SEQ ID NO	Lipid Elevation	HCC Formation
FGF19	RPLAFSDAGPHVHYGWDPI	RLRHLYTSG	99 (aa 1-29)	+	+
FGF21	HPIPDSSPLLQ--FGGQV	RQRYLYTDD	100 (aa 1-25)	-	-
H31A/S141A(M88)		FGF19		+	+
H31A/H142A(M89)		FGF19		+	+
K127A/R129A(M90)		FGF19		+	+
K127A/S141A(M91)		FGF19		+	+
K127A/H142A(M92)		FGF19		+	+
R129A/S141A(M93)		FGF19		+	+
S141A/H142A(M94)		FGF19		+	+
K127A/H142A(M95)		FGF19		+	+
K127A/R129A/S141A(M96)		FGF19		+	+
K127A/R129A/H142A(M97)		FGF19		+	+
K127A/R129A/S141A/H142A(M98)		FGF19		+	+

[0417] M88 (H31A/S141A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPAGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKN
RGFLPLAHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:88)

[0418] M89 (H31A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPAGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKN
RGFLPLSAFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:89)

[0419] M90 (K127A/R129A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN
RGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:90)

[0420] M91 (K127A/S141A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN
RGFLPLAHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:91)

[0421] M92 (K127A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKN
RGFLPLSAFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ
ID NO:92)

[0422] M93 (R129A/S141A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN
RGFLPLAHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:93)

[0423] M94 (S141A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKN
RGFLPLAAFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:94)

[0424] M95 (K127A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQRQLYKN
RGFLPLSAFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:95)

[0425] M96 (K127A/R129A/S141A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN
RGFLPLAHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ ID
NO:96)

[0426] M97 (K127A/R129A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN
RGFLPLSAFLPMLPMVPEEPEDLRGHLESDFSSPLETDSMDPFGLVTGLEAVRSPSFKEK (SEQ
ID NO:97)

[0427] M98 (K127A/R129A/S141A/H142A):

RPLAFSDAGPHVHYGWDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALLRT
VAIKGVHSDVRYLCMGADGKMQLLQYSEEDCAFEEDIRPDGYNVYRSEKHRLPVSLSSAAQAQLYKN

RGFLPLAAFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (SEQ ID NO:98).

5.5 Example 5

[0428] The following is a data summary of additional FGF19 variant peptides analyzed for glucose lowering activity and lipid elevating activity.

[0429] Table 5 illustrates the peptide “core sequences” of 35 additional FGF19 variants, denoted M5 to M40. Such exemplified variant peptides have FGF19 C-terminal sequence, PHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTVAIKGVH SVRYLCMGADGKMQGL LQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPE EPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (SEQ ID NO: 188) at the C-terminal portion, *e.g.*, following the “TSG” amino acid residues of the core sequence. The data clearly show that variants M6, M7, M8, mM38 and M39 have the desired characteristics of glucose lowering activity and not statistically significant lipid elevating activity in *db/db* mice.

Table 5: Additional Variants and Fine Mapping of the N-terminal Domain (see SEQ ID NOs:99, 100, and 5 to 40)

	N-terminal Domain	SEQ ID NO of N-term- Domain	Core	SEQ ID NO.	Glucose Lowering	Lipid Elevation
FGF19	RPLAFSDAGPHVHYGWDPI	99 (aa 1-20)	RLRHLYTSG	185	+	+
FGF21	-HPIPDSSPLLQ--FGGQV	100 (aa 1-16)	RQRYLYTDD	186	+	-
M5	RHPIPDSSPLLQ--FGGQV	5 (aa 1-17)	RLRHLYTSG	185	+	-
M6	R----DSSPLLQ--FGGQV	6 (aa 1-18)	RLRHLYTSG	185	+	-
M7	RPLAFSDSSPLLQ--FGGQV	7 (aa 1-18)	RLRHLYTSG	185	+	-
M8	R-HPIPDSSPLLQ--WGDPI	8 (aa 1-17)	RLRHLYTSG	185	+	-
M9	R-HPIPDSSPLLQFGWGDPI	9 (aa 1-19)	RLRHLYTSG	185	+	+
M10	R-HPIPDSSPHVHYGWDPI	10 (aa 1-19)	RLRHLYTSG	185	-	+
M11	RPLAFSDAGPLLQ--WGDPI	11 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M12	RPLAFSDAGPLLQFGWGDPI	12 (aa 1-20)	RLRHLYTSG	185	-	+
M13	RPLAFSDAGPLLQ--FGGQV	13 (aa 1-18)	RLRHLYTSG	185	-	-
M14	R-HPIPDSSPHVHYG--GQV	14 (aa 1-17)	RLRHLYTSG	185	-	-
M15	RPLAFSDAGPHVHYG--GQV	15 (aa 1-18)	RLRHLYTSG	185	+	+
M16	RPLAFSDAGPHVH--WGDPI	16 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M17	RPLAFSDAGPHV--GWGDPI	17 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M18	RPLAFSDAGPH--YGWGDPI	18 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M19	RPLAFSDAGP-V-YGWGDPI	19 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M20	RPLAFSDAGP-VH-GWGDPI	20 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M21	RPLAFSDAGP-VHY-WGDPI	21 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M22	RPLAFSDAGPHVH-GWGDPI	22 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M23	RPLAFSDAGPH-H-GWGDPI	23 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M24	RPLAFSDAGPH-HY-WGDPI	24 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M25	RPLAFSDAGPHV-Y-WGDPI	25 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M26	RPLAFSDSSPLVH--WGDPI	26 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M27	RPLAFSDSSPHVH--WGDPI	27 (aa 1-18)	RLRHLYTSG	185	N/D	N/D
M28	RPLAFSDAPHV----WGDPI	28 (aa 1-16)	RLRHLYTSG	185	N/D	N/D

M29	RPLAFSDAGPHVHY-WGDPI	29 (aa 1-19)	RLRHLYTSG	185	N/D	N/D
M30	RPLAFSDAGPHVHYAWGDPI	30 (aa 1-20)	RLRHLYTSG	185	N/D	N/D
M31	R-HPIPDSSPLLQ--FGAQV	31 (aa 1-17)	RLRHLYTSG	185	+/-	-
M32	R-HPIPDSSPLLQ-- FGIYQV	32 (aa 1-18)	RLRHLYTSG	185	-	-
M33	R-HPIPDSSPLLQ--FGGQV	33 (aa 1-17)	RLRHLYTSG	185	-	-
M34	R-HPIPDSSPLLQ--FGGAV	34 (aa 1-17)	RLRHLYTSG	185	+/-	-
M35	R-HPIPDSSPLLQ--FGGEV	35 (aa 1-17)	RLRHLYTSG	185	+/-	+/
M36	R-HPIPDSSPLLQ--FGGQV	36 (aa 1-17)	RLRHLYTSG	185	+/-	-
M37	R-HPIPDSSPLLQ--FGGUA	37 (aa 1-17)	RLRHLYTSG	185	-	-
M38	R-HPIPDSSPLLQ--FGGQT	38 (aa 1-17)	RLRHLYTSG	185	+	-
M39	R-HPIPDSSPLLQ--FGGQT	39 (aa 1-17)	RLRHLYTSG	185	+	-
M40	R-HPIPDSSPLLQFGWGQP	40 (aa 1-16)	RLRHLYTSG	185	-	+

Table 5a: (see SEQ ID NOs:99, 100, 5, 9, 8, 12, 10, 13, 15, 14, 43, 6 and 7)

	N-terminal Domain	Core	SEQ ID NO.	<u>Glucose</u> <u>Lowering</u>	<u>Lipid</u> <u>Elevation</u>	<u>HCC</u> <u>Formation</u>
FGF19	RPLAFSDAGPHVHYGWGDPI	RLRHLYTSG	99 (aa 1-29)	+	+	+
FGF21	HPIPDSSPLLQ--FGGQV	RQRYLYTDD	100 (aa 1-25)	+	-	-
M5	R-HPIPDSSPLLQ--FGGQV	RLRHLYTSG	5 (aa 1-26)	+	-	-
M9	R-HPIPDSSPLLQFGWGDPI	RLRHLYTSG	9 (aa 1-28)	+	+	+
M8	R-HPIPDSSPLLQ--WGDPI	RLRHLYTSG	8 (aa 1-26)	+	+	+
M12	RPLAFSDAGPLLQFGWGDPI	RLRHLYTSG	12 (aa 1-29)	-	+	+
M10	R-HPIPDSSPHVHYGWGDPI	RLRHLYTSG	10 (aa 1-28)	-	+	+
M13	RPLAFSDAGPLLQ--FGGQV	RLRHLYTSG	13 (aa 1-27)	-	+	+
M15	RPLAFSDAGPHVHYG--GQV	RLRHLYTSG	15 (aa 1-27)	-	-	+/-
M14	R-HPIPDSSPHVHYG--GQV	RLRHLYTSG	14 (aa 1-26)	-	-	+/-
M43	RPLAFSDAGPHVHYG-GD-I	RLRHLYTSG	43 (aa 1-27)	+	-	+/-
M6	R-----DSSPLLQ--FGGQV	RLRHLYTSG	6 (aa 1-22)	+	-	-
M7	RPLAFSDSSPLLQ--FGGQV	RLRHLYTSG	7 (aa 1-27)	-	-	-

Table 5b: (see SEQ ID NOs:99, 5 and 31 to 40)

	N-terminal Domain Core	SEQ ID NO.	<u>Glucose</u> <u>Lowering</u>	<u>Lipid</u> <u>Elevation</u>	<u>HCC</u> <u>Formation</u>
FGF19	RPLAFSDAGPHVHYGWDPI RLRHLYTSG	99 (aa 1-29)	+	+	+
FGF21	HPIPDSSPLLQ--FGGQV RQRYLYTDD	100 (aa 1-25)	+	-	-
M5	R-HPIPDSSPLLQ--FGGQV RLRHLYTSG	5 (aa 1-26)	+	-	-
M31	R-HPIPDSSPLLQ--FGAQV RLRHLYTSG	31 (aa 1-26)	+	-	+
M32	R-HPIPDSSPLLQ--FGDQV RLRHLYTSG	32 (aa 1-26)	+	-	-
M33	R-HPIPDSSPLLQ--FGPQV RLRHLYTSG	33 (aa 1-26)	-	-	+
M34	R-HPIPDSSPLLQ--FGGAV RLRHLYTSG	34 (aa 1-26)	-	-	+
M35	R-HPIPDSSPLLQ--FGGEV RLRHLYTSG	35 (aa 1-26)	-	-	+
M36	R-HPIPDSSPLLQ--FGGNV RLRHLYTSG	36 (aa 1-26)	+	-	+/-
M37	R-HPIPDSSPLLQ--FGGQA RLRHLYTSG	37 (aa 1-26)	-	-	+
M38	R-HPIPDSSPLLQ--FGGQI RLRHLYTSG	38 (aa 1-26)	-	-	+
M39	R-HPIPDSSPLLQ--FGGQT RLRHLYTSG	39 (aa 1-26)	-	-	+
M40	R-HPIPDSSPLLQFGWGQPV RLRHLYTSG	40 (aa 1-28)	-	+	+

Table 5c: (see SEQ ID NOs:99, 100, 5, 52, 54, to 68, 4, 69, 70 and 53)

	N-terminal Domain Core	SEQ ID NO.	<u>Glucose</u> <u>Lowering</u>	<u>Lipid</u> <u>Elevation</u>	<u>HCC</u> <u>Formation</u>
FGF19	RPLAFSDAGPHVHYGWDPI RLRHLYTSG	99 (aa 1-29)	+	+	+
FGF21	HPIPDSSPLLQ--FGGQV RQRYLYTDD	100 (aa 1-25)	+	-	-
M5	R-HPIPDSSPLLQ--FGGQV RLRHLYTSG	5 (aa 1-26)	+	-	-
M52	R-----DSSPLLQ--WGDPI RLRHLYTSG	52 (aa 1-22)	+	+	-
M54	RPLAFSDAGPLLQ--WGDPI RLRHLYTSG	54 (aa 1-27)	-	+	+
M55	RPLAFSDAGPH--YGWDPI RLRHLYTSG	55 (aa 1-27)	-	+	+
M56	RPLAFSDAGP-V-YGWDPI RLRHLYTSG	56 (aa 1-27)	-	+	+
M57	RPLAFSDAGP-VT-GWGDPI RLRHLYTSG	57 (aa 1-27)	-	+	+
M58	RPLAFSDAGP-VHY-WGDPI RLRHLYTSG	58 (aa 1-27)	-	+	+
M59	RPLAFSDAGPH-H-GWGDPI RLRHLYTSG	59 (aa 1-27)	-	+	+

M60	RPLAFSDAGPH-HY-WGDPI RLRHLYTSG	60 (aa 1-27)	-	+	+
M61	RPLAFSDAGPHV--GWGDPI RLRHLYTSG	61 (aa 1-27)	-	+	+
M62	RPLAFSDAGPHV-Y-WGDPI RLRHLYTSG	62 (aa 1-27)	-	+	+
M63	RPLAFSDAGPHVH--GWGDPI RLRHLYTSG	63 (aa 1-27)	+	+	+
M64	RPLAFSDSSPLVH--GWGDPI RLRHLYTSG	64 (aa 1-27)	+	+	+
M65	RPLAFSDSSPHVH--GWGDPI RLRHLYTSG	65 (aa 1-27)	-	+	+
M66	RPLAFSDAGPHLQ--GWGDPI RLRHLYTSG	66 (aa 1-27)	+	+	+
M67	RPLAFSDAGPHV---GWGDPI RLRHLYTSG	67 (aa 1-26)	-	-	+/-
M68	RPLAFSDAGPHVHY-WGDPI RLRHLYTSG	68 (aa 1-28)	-	+	-
M4	RPLAFSDAGPHVHYAWGDPI RLRHLYTSG	4 (aa 1-29)	+	+	+
M69	R-----DSSPLVHYGWGDPI RLRHLYTSG	69 (aa 1-24)	+	+	-
M70	MR-----DSSPLVHYGWGDPI RLRHLYTSG	70 (aa 1-25)	+	+	-
M53	M-----DSSPLLQ--GWGDPI RLRHLYTSG	192 (aa 1-22)	+	+	-

[0430] Table 6 illustrates the peptide sequences of additional variants.

Table 6: Additional Variants (SEQ ID NOs: 41, 42 and 44-46)

M41:

RPLAFSDAGPHVHYGWGDPIRLRLHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (SEQ
ID NO: 41)

M42:

HPIPDSSPLLQFGGQVRLRLHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVLRT
VAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS (SEQ ID
NO: 42)

M44:

RPLAFSDAGPHVHYGWGDPIRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKA
LKPGVIQILGVKTSRFLCQRPDGAALYGSLLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPG
NKSPHRDPAPRGPARFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS
(SEQ ID NO: 44)

M45:

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPAPRFLPLPGLPPALPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK (SEQ ID NO:45)

M46:

RPLAFSDAGPHVHYGWGDPIRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKA
LKPGVIQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPG
NKSPHRDPAPRGPAPRFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYASPMV
PEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF EK (SEQ ID NO:46)

[0431] Table 7 illustrates the peptide sequences of 3 FGF19 variants, denoted M1, M2 and M69. The data clearly show that these three variants have the desired characteristics of glucose lowering activity in *db/db* mice. These three variants appear to elevate lipids in *db/db* mice.

Table 7: Additional Variants (SEQ ID NOs:1, 2 and 69)

M1:

RPLAFSDASPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (SEQ ID NO:1 or 139)

M2:

RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLPVSL
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSF EK (SEQ ID NO:2 or 140)

M69:

[0432] RDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEI
KAVALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIRPDGYNVYRSEKHRLP
VSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVT
GLEAVRSPSF EK (SEQ ID NO:69) .

5.6 Example 6

[0433] The following is a data summary showing that FGF19 reduces body weight in diet-induced obese mice and in *ob/ob* mice, and liver tumor formation activity and body weight in *db/db* mice.

[0434] Mice were injected with FGF19 or FGF21 in AAV vector. Body weight was recorded 4 weeks after injection.

Table 8: FGF19 reduces body weight in diet-induced obese mice and in *ob/ob* mice (sequences correspond to aa 1-29 of SEQ ID NO:99 and aa 1-25 of SEQ ID NO:100, respectively)

	N-terminal Domain	Core	Body Weight- Lowering in DIO	Body Weight- Lowering in <i>Ob/ob</i>
FGF19	RPLAFSDAGPHVHYGWDPI	RLRHLYTSG	+	+
FGF21	HPIPDSSPLLQ--FGGQV	RQRYLYTDD	+	+

Table 9: Correlation of body weight and liver tumor formation of FGF19, FGF21 and selected variants in *db/db* mice (see, e.g., SEQ ID NOs:99, 100, 5, 6, 32, 52 and 69)

	N-terminal Domain	core	SEQ ID NO	Liver Tumor Nodule	Body Weight
FGF19	RPLAFSDAGPHVHYGWDPI	RLRHLYTSG	99 (aa 1-29)	+	Increased
FGF21	HPIPDSSPLLQ--FGGQV	RQRYLYTDD	100 (aa 1-25)	-	Decreased
M5	R-HPIPDSSPLLQ--FGGQV	RLRHLYTSG	5 (aa 1-26)	-	Increased
M6	R-----DSSPLLQ--FGGQV	RLRHLYTSG	6 (aa 1-22)	-	Decreased
M32	R-HPIPDSSPLLQ--FGDQV	RLRHLYTSG	32 (aa 1-26)	-	Decreased
M52	R-----DSSPLLQ--WGDPI	RLRHLYTSG	52 (aa 1-22)	-	Decreased
M69	R-----DSSPLVHYGWDPI	RLRHLYTSG	69 (aa 1-24)	-	Increased

5.7 Example 7

[0435] The following is a study showing that variant M5 and variant M69 peptides reduce blood glucose.

[0436] Mice (*ob/ob*) were injected (subcutaneously) with M5 (0.1 and 1 mg/kg, s.c.) or FGF19 (1 mg/kg, s.c.), or variant M69 (0.1 and 1 mg/kg, s.c.) or FGF19 (1 mg/kg, s.c.). Plasma glucose

levels were measured at 2, 4, 7, and 24 hours after injection. The results of variant M5 and variant M69 showed similar glucose lowering effects as wild type FGF19 (data not shown) .

5.8 Example 8

[0437] This example sets forth several variant polypeptides and particular characteristics thereof, including the variants' effect on glucose lowering, lipid profile parameters, and HCC formation.

[0438] In particular, Table 10 compares data generated for variants M5 (SEQ ID NO:5), M6 (SEQ ID NO:6) and M50 (SEQ ID NO:50) with data generated for corresponding variant polypeptides (denoted as M144, M145, and M146, respectively) having N-terminal Arg (R) deletions. Only certain sequence domains for each variant are listed: N-terminal domain, Core, and Sheet-8/Loop-8/Sheet-9 region.

Table 10

	N-terminal Domain ~~~~~	Core	Sheet-8/Loop-8/Sheet-9 region	Glucose Lowering	Body Weight Reduction	HDL Elevation	Tri-glyceride Elevation	HCC Formation
FGF19	RPLAFSDAGPHVHYGWGDP (aa 1-20 of SEQ ID NO:99)	RLRHLYTSG (aa 21-29 of SEQ ID NO:99)	//EEIRPDGYNVY// (aa 102-112 of SEQ ID NO:99)	+	-	+	+	+
FGF21	HPIPDSSPLLQ--FGGQV (aa 1-20 of SEQ ID NO:100)	RQRYLYTDD (aa 21-29 of SEQ ID NO:100)	//ELLEDDGYNVY// (aa 97-107 of SEQ ID NO:100)	+	+	-	-	-
M5	R-HPIPDSSPLLQ--FGGQV (aa 1-17 of SEQ ID NO:5)	RLRHLYTSG (aa 18-26 of SEQ ID NO:5)	//EEIRPDGYNVY// (aa 99-109 of SEQ ID NO:5)	+	-	-	-	-
M6	R-----DSSPLLQ--FGGQV (aa 1-14 of SEQ ID NO:6)	RLRHLYTSG (aa 15-23 of SEQ ID NO:6)	//EEIRPDGYNVY// (aa 95-105 of SEQ ID NO:6)	+	-	-	-	-
M50	R-HPIPDSSPLLQ--FGDQV (aa 1-17 of SEQ ID NO:50)	RLRHLYTSG (aa 18-26 of SEQ ID NO:50)	//EEIRPDGYNVY// (aa 99-109 of SEQ ID NO:50)	+	+	-	-	-
M144	--HPIPDSSPLLQ--FGGQV (aa 2-17 of SEQ ID NO:5)	RLRHLYTSG (aa 18-26 of SEQ ID NO:5)	//EEIRPDGYNVY// (aa 99-109 of SEQ ID NO:5)	+	-	-	-	-
M145	-----DSSPLLQ--FGGQV (aa 2-14 of SEQ ID NO:6)	RLRHLYTSG(a a 15-23 of SEQ ID NO:6)	//EEIRPDGYNVY// (aa 95-105 of SEQ ID NO:6)	+	-	-	-	-
M146	--HPIPDSSPLLQ--FGDQV (aa 2-17 of SEQ ID NO:50)	RLRHLYTSG(a a 18-26 of SEQ ID NO:50)	//EEIRPDGYNVY// (aa 99-109 of SEQ ID NO:50)	+	+	-	-	-

[0439] As the data in Table 10 indicate, the deletion of the N-terminal Arg (R) did not significantly impact glucose lowering, body weight reduction, HDL and triglyceride elevation, and HCC formation.

5.9 Example 9

[0440] This example sets forth several variant peptides having amino acid substitutions in the Loop 8 region of FGF19, along with the variants' effect on body weight, certain metabolic parameters, and HCC formation.

[0441] The data in Table 10 are associated with variant polypeptides denoted as M3, M139, M140, M141 and M160. The amino acid sequence for M3 is set forth elsewhere herein, and the amino acid sequences for M139, M140, M141 and M160 are as follows:

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M139) (SEQ ID NO:193);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEIREDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M140) (SEQ ID NO:194);

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILCDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M141) (SEQ ID NO:195); and

RPLAFSDAGPHVHYGWGDPIRQRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVH SVRYLCMGADGKMQGLLQYSEEDCAFE EEEILEDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK (M160) (SEQ ID NO:196).

[0442] Only the following sequence domains for each of the aforementioned variants are listed in Table 10: N-terminal domain, Core, and Sheet-8/Loop-8/Sheet-9 region. While the particular amino acid residues making up the Loop 8 region are not universally accepted in the literature, FGF19 residues 127-129 are defined herein as constituting the Loop-8 region.

Table 11

	<u>N-terminal Domain</u>	<u>Core</u>		Glucose Lowering	Body Weight Reduction	HDL Elevation	Tri-glyceride Elevation	HCC Formation
FGF19	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:99)	RLRHLYTSG (aa 21-29 of SEQ ID NO:99)	//EEIRPDGYNVY// (aa 102-112 of SEQ ID NO:99)	+	-	+	+	+
FGF21	HPIPDSSPLLQ--FGGQV (aa 1-20 of SEQ ID NO:100)	RQRYLYTDD (aa 21-29 of SEQ ID NO:100)	//ELLEDDGYNVY// (aa 97-107 of SEQ ID NO:100)	+	+	-	-	-
M3	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:3)	RLRHLYTSG (aa 21-29 of SEQ ID NO:3)	//EEILEDGYNVY//(aa 102-112 of SEQ ID NO:3)	+	+	+	+	+/-
M139	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:193)	RLRHLYTSG (aa 21-29 of SEQ ID NO:193)	//EEILPDGYNVY// (aa 102-112 of SEQ ID NO:193)	+	-	+	+	+
M140	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:194)	RLRHLYTSG (aa 21-29 of SEQ ID NO:194)	//EEIREDGYNVY//(aa 102-112 of SEQ ID NO:194)	+	+	+	+	+/-
M141	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:195)	RLRHLYTSG (aa 21-29 of SEQ ID NO:195)	//EEILCDGYNVY// (aa 102-112 of SEQ ID NO:195)	+	-	+	+	+
M160	RPLAFSDAGPHVHYGWGDPI (aa 1-20 of SEQ ID NO:196)	RQRHLYTSG (aa 21-29 of SEQ ID NO:196)	//EEILEDGYNVY// (aa 102-112 of SEQ ID NO:196)	+	+	+	+	-

[0443] Referring to Table 11, the P128E substitution appears necessary to significantly prevent HCC formation, but is insufficient by itself to prevent HCC formation. In particular, an improvement in preventing HCC formation is observed with the P128E substitution in M140. Conversely, by itself the R127L substitution does not prevent HCC formation (see M139). As indicated in comparison to M3, a combination of the R127L and P128E substitutions decreases HCC formation but does not eliminate HCC formation. Surprisingly, however, a combination of the R127L and P128E substitutions along with a substitution of Gln (Q) for Leu (L) in the FGF19 core region does significantly prevent HCC formation (see M160).

[0444] These data indicate that the FGF19 Loop 8 region plays a role in HCC formation. Amino acid residues outside of the Loop 8 region (e.g., substitutions in the core region) may enhance the prevention of HCC formation.

[0445] **M1 (SEQ ID NO:1)**

RPLAFSDASPHVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA

VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK

[0446] M2 (SEQ ID NO:2)

RPLAFSDSSPLVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV
ALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSL
SAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEA
VRSPSF EK

[0447] M3 (SEQ ID NO:3)

RPLAFSDAGPHVHYGWGDPIRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSF EK

[0448] M5 (SEQ ID NO:5)

RHIPDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK

[0449] M5-R (SEQ ID NO:160)

HPIP DSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRT
VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK

[0450] M48 (SEQ ID NO:48)

RDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV ALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSF
E K

[0451] M49 (SEQ ID NO:49)

RPLAFSDSSPLLQFGGQVRLRHL YTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAV AL
RTVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHRLPVSLSSA
KQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVR
SPSF EK

[0452] M50 (SEQ ID NO:50)

RHPIPDSSPLLQFGDQVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEILEDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK

[0453] M51 (SEQ ID NO:51)

RHPIPDSSPLLQFGGNVRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK

[0454] M52 (SEQ ID NO:52)

RDSSPLLQWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAI
KGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K

[0455] M53 (SEQ ID NO:192)

MDSSPLLQWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVA
IKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQ
LYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFE
K

[0456] M69 (SEQ ID NO:69)

RDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRT
VAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQ
RQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSP
SFEK

[0457] M70 (SEQ ID NO:70)

MRDSSPLVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALR
TVAIKGVHSVRYLCMGADGKMQGLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAK
QRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRS
PSFEK

[0458] M71 (SEQ ID NO:71)

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV

IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHSLPLHLPGNKSPH
RDPAPRGPAPRFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS

[0459] M72 (SEQ ID NO:72)

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPAPRFLPLPGLPPAPPEPPGILAPQPPDVGSSDPLSMVGPSQGRSPSYAS

[0460] M73 (SEQ ID NO:73)

HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDGTVGGAADQSPESLLQLKALKPGV
IQILGVKTSRFLCQRPDGALYGSLHFDPEACSFRELLLEDGYNVYQSEAHGLPLHLPGNKSPH
RDPAPRGPAPRFLPLPGLPPALPEPPGILAPQPPDVGSSDPLSMVVQDELQGVGGEGCHMHPE
NCKTLLTDIDRTHTEKPVWDGITGE

[0461] M75 (SEQ ID NO:75)

RVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKG
VHSVRYLCMGADGKMQLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQLY
KNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK

[0462] M76 (SEQ ID NO:76)

RGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKAVALRTVAIKGVHVR
YLCMGADGKMQLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSLSSAKQRQLYKNRGFL
PLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLEAVRSPSFEK

[0463] FGF19 (SEQ ID NO:99)

RPLAFSDAGPHVHYGWGDPIRLRHLTYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHSVRYLCMGADGKMQLLQYSEEDCAFEIEIRPDGYNVYRSEKHRLPVSL
SSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDMFSSPLETDSMDPFGLVTGLE
AVRSPSFEK.

5.10 Example 10

[0464] This example shows that administration of M70 in human patients results in suppression of 7 α -hydroxy-4-cholsten-3-one (C4), a marker of bile acid synthesis.

[0465] Study subjects: Healthy adults in the age range 18–65 years and with normal body weight (body mass index, BMI 20–35) were enrolled in the study. The study protocol was approved by the Human Research Ethics Committee in Australia, and written informed consent was obtained from each subject. For inclusion in the study each subject had to be in good health determined by no clinically significant findings from medical history, physical exam, 12 lead ECG, clinical

laboratory findings, and vital signs at screening. Subjects with history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, or psychiatric disorder were excluded from enrollment.

[0466] Study Design: The study was a randomized, double-blind, placebo-controlled design. Prescreening of subjects was performed 7–30 days prior to entry, and baseline evaluations were performed before treatment. Each subject was given subcutaneous injection of M70 at doses 3 mg/day in a single bolus dose daily for 7 days. Blood samples were collected into heparinized tubes through an indwelling catheter. Blood samples taken on Day 1 and Day 7 at 4.5 hrs or 24 hrs after administration of M70 or placebo were analyzed. Serum levels of 7 α -hydroxy-4-cholesten-3-one (C4) were used to monitor CYP7A1 enzymatic activity (bile acid synthesis). They were analyzed from individual serum samples after sample extraction followed by high-pressure liquid chromatography (HPLC) as described previously (Galman *et al.* (2003) J Lipid Res. 2003;44(4):859-66).

[0467] Results: The data provided in FIG. 6 show that on days 1 and 7, at both 4.5 hours and 24 hours post-dose, serum levels of C4 were significantly suppressed in the patients, as compared to patients receiving a placebo.

5.11 Example 11

[0468] This example shows activation of mouse FGFR4- β -klotho signaling by FGF19, M3, and M70 in a rat myoblast cell line

[0469] Methods: An ELK luciferase assay was performed in L6 cells transiently transfected with mouse FGFR4, β -klotho, and reporter constructs containing 5xUAS luciferase and GAL4-DNA-binding domain (DBD) fused to ELK1. In this system, luciferase activity is regulated by the endogenous phosphorylated extracellular signal-regulated kinase (ERK). Cells were incubated with ligands for 6 hours before lysed for luciferase activity measurements.

[0470] A cell-based receptor activation assay was used to evaluate the ability of mouse FGFR4 to mediate ligand-dependent signaling in the presence of β -klotho. To this end, a rat L6 myoblast cell line, which lacks endogenous expression of these proteins, was transfected with DNAs encoding FGFR4 and β -klotho from mouse, as well as plasmids containing an Elk1-dependent chimeric transcription factor-based reporter system.

[0471] Following transfection, concentration response of ligand-dependent luciferase expression was analyzed in whole-cell lysates in the presence of luciferin substrate.

[0472] Results: Co-expression of FGFR4 and β -klotho in L6 cells was found to potentiate activation of intracellular signaling pathways by both M3, M70 and FGF19 (EC_{50} = 20, 38 and 53 pM, respectively (see Table 12 and FIG. 7).

Table 12: Co-expression of Mouse FGFR4/ β -klotho complex in L6 Cells Potentiates Activation of Intracellular Signaling Pathways by FGF19, M3 and M70.

Ligand	FGFR4 / β klotho	
	EC_{50} (pM)	E_{max} (fold potentiation)
FGF19	52.5 ± 0.01	1.82 ± 0.09
M3	19.8 ± 0.04	1.68 ± 0.04
M70	38.3 ± 0.12	1.85 ± 0.14

EC_{50} = half-maximal effective concentration; E_{max} = maximum efficacy. Data are expressed as mean $\pm$ SD

[0473] These data suggest that the formation of a ternary complex between the FGFR4- β -klotho co-receptors and cognate ligands is important for potent activation of intracellular signaling.

5.12 Example 12

[0474] This example shows that M70 selectively activates signaling through the KLB/FGFR4 receptor complex in a manner that beneficially does not cause HCC in mice, as shown in two different models of oncogenic potential.

[0475] Study subjects: An FDA-accepted model of accelerated tumorigenesis, known as the *rasH2* transgenic model, as well as the *db/db* animal model.

[0476] Study design and results: M70 expressed at exposures roughly 1,000 times greater than normal levels of FGF19 in human blood did not cause HCC after exposure for one year. By contrast, human FGF19, utilized as a positive control in the mouse experiment, did cause HCC.

[0477] Co-administration of M70 and FGF19 via gene delivery in the *db/db* animal model obviated the expected FGF19-driven HCC, suggesting that M70 blocked the ability of FGF19 to occupy the relevant receptor and signal in such a way as to cause HCC.

5.13 Example 13

[0478] This example discusses the results of a Phase 1 randomized, double blind, placebo controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of M70 in healthy adult participants. An overview of the study is provided in Table 13.

Table 13: Phase 1 Study Design to Evaluate the Safety, Tolerability and Pharmacokinetics of M70 in Healthy Adult Participants.

Study Population	Primary Outcome Measure	Primary Outcome Results	Selected Secondary Outcomes
Healthy subjects	Safety and tolerability	- No safety or tolerability signals identified - No serious adverse events reported - Majority of adverse events were mild	- PK supports <i>qd</i> dosing - Statistically significant reduction in C4 at all doses tested (0.3, 1 and 3 mg) vs. pre-dose levels (MAD); $p < 0.001$ - Statistically significant reduction in triglycerides with doses > 1 mg (MAD); $p < 0.05$ - Statistically significant increase in total cholesterol (MAD); $p < 0.05$

[0479] As shown in FIG. 8, the Phase 1 trial with M70 demonstrated a favorable safety profile with signs of biological activity consistent with FGF19-like activity related to FGFR1c and FGFR4 signaling, supports its application in NASH and bile acid related disorders (BARDs).

[0480] Study Design: In this blinded, placebo-controlled, Phase 1 trial, overweight or obese but otherwise healthy adults were randomized to receive M70 or placebo as a daily subcutaneous injection in escalating doses.

[0481] Results: As shown in FIG. 8, a rapid and dose-proportional reduction of serum C4 concentrations indicated that M70 has a statistically significant effect on bile acid synthesis at the 0.3 mg, 1 mg and 3 mg doses. A mean reduction of approximately 94% in serum C4 concentrations was noted after the sixth dose at 3 mg when compared with pre-dose levels. This rapid reduction in C4 supports the potential biological activity of M70 as an inhibitor of bile acid synthesis through CYP7a1. Two outlier data points are not shown in FIG. 8, but were included in the statistic analysis (placebo, Day 7: 45.1 ng/ml; 0.3mg NGM282 at baseline: 62.1 ng/ml).

[0482] Laboratory analysis of blood samples collected from subjects receiving M70 in the Phase 1 MAD trial showed administration of the drug was associated with statistically significant reductions in triglycerides at doses of 1 mg and greater ($p < 0.05$) and a statistically significant decrease in total cholesterol ($p < 0.05$) (data not shown).

[0483] In both the SAD and MAD trials, M70 was well tolerated and exhibited linear pharmacokinetics with no immunogenicity. There were no serious adverse events. The most frequently observed adverse events were diarrhea, vomiting and injection site reactions. Also, there were no clinically significant laboratory abnormalities documented in M70 -treated subjects, as

determined by the Safety Data Monitoring Committee for the study, and there were no anti-drug antibodies, or ADAs, observed.

5.14 Example 14

[0484] This example discusses the results of preclinical testing, which supports the role of M70 for the treatment of NASH.

[0485] Normally the liver contains some fat. However, if more than 5-10% of the liver's weight is fat, it is referred to as a fatty liver, or steatosis. The spectrum of NAFLD ranges from simple steatosis to NASH, which can ultimately progress to end-stage liver disease.

[0486] Bile acid synthesis and serum bile acid levels are correlated with NAFLD and progression of disease to NASH, as evidenced by elevations of CYP7a1 and increased serum bile acid levels observed in NAFLD and NASH patients, respectively. Accordingly, by reducing triglycerides and blocking bile acid synthesis through the CYP7a1 pathway, M70 can disrupt the cascade that leads from NAFLD to NASH, and through fibrosis and cirrhosis to either transplant or death.

[0487] Study design: A mouse model of NASH, known as STAM™ was used to study the beneficial effect of M70 in treatment of NASH. This model is characterized by steatosis, lobular inflammation and hepatocyte ballooning consistent with NASH pathology in humans. Mice in which M70 was continuously expressed had statistically significant decreases in total body weight, liver weight and liver-to-body weight ratio reflective of a decrease in total liver fat content ($p < 0.001$ relative to control).

[0488] Results: M70 expression demonstrated statistically significant improvements in all components of the NAFLD Activity Score (NAS), resulting in a total NAS score of 1.5 compared to 5.33 for control, as shown in the chart below. The NAS is a histological feature scoring system that is widely used to grade the activity of fatty liver disease and the total score represents the sum of the scores for steatosis, lobular inflammation and ballooning. Generally, a score of 5 or greater is considered to be diagnostic of NASH. These results are summarized below.

Table 14: Treatment Effect on NAS by M70

Treatment Effect on NAS				
NAS Component	NAS Score	M70 (n=6)	Control (n=6)	M70 vs. Control
Steatosis	0	6	1	P=0.0117
	1	0	4	
	2	0	1	
	3	0	0	

Lobular Inflammation	0	3	0	P=0.0041
	1	2	0	
	2	1	4	
	3	0	2	
Hepatocyte Ballooning	0	1	0	P=0.0009
	1	5	0	
	2	0	6	
Total NAS (mean $\pm$ SD)		1.5 $\pm$ 1.0	5.33 $\pm$ 1.5	P=0.0005

[0489] Additional preclinical work in a mouse bile duct ligation model of liver fibrosis has demonstrated that expression of M70 effectively prevents mice from developing hepatic fibrosis, as indicated by histology as well as gene expression analysis of several markers of fibrosis and inflammation. These preclinical data, combined with the Phase 1 MAD study data, further supports the role for M70 providing benefits in patients with NASH.

5.15 Example 15

[0490] This example shows the role of M70 in the treatment of cholestatic liver disease and other BARs.

[0491] Cholestatic liver disease is a form of BARD defined as an impairment of bile flow from the liver and is often characterized by fatigue, pruritus and, in its more advanced form, jaundice. Elevated serum bile acids are a hallmark of many cholestatic liver diseases including PSC, PBC, intrahepatic cholestasis of pregnancy, alcoholic hepatitis and drug-induced cholestasis. Impairment of bile acid flow from the liver leads to cholestasis, hepatocellular injury and progressive liver disease that may ultimately result in liver failure.

[0492] Bile acids are believed to play a role in causing pruritus, and elevated serum levels of certain forms of bile acid have been correlated to higher rates of pruritus. Severe pruritus, which patients often describe as intense, constant, unrelievable itching under the skin at any place on the body, may present at all stages of cholestatic liver disease and is the most debilitating symptom afflicting cholestatic disease patients. Patients often resort to destructive scratching behaviors that can cause bleeding and scarring, and the condition can lead to a marked decrease in quality of life, impaired sleep, depression and, potentially, suicidal thoughts or actions. Caregivers also suffer from impaired sleep and anxiety as they struggle to help manage this debilitating symptom. In some patients, the emotional and physical effects of pruritus alone can justify liver transplantation.

[0493] The potent bile acid regulation effect of M70, and the fact that it is not a derivative of a bile acid, support its role as a treatment for certain cholestatic liver diseases such as PSC, PBC and other BARs. A large body of *in vivo* preclinical data testing the efficacy of M70 in a bile duct

ligation (BDL) model, an alpha-naphthylisothiocyanate (ANIT) model, and an *Mdr2* knockout model showed statistically significant reduction of serum bile acid ($p < 0.001$) and improvements in biochemical markers of liver damage. In addition, as described above in Example 13, the Phase 1 data demonstrated that M70 administration statistically significant reductions in serum C4 levels ($p < 0.001$), indicating biological activity consistent with FGF19 suppression of CYP7a1 in the liver and reduction in serum bile acid levels. In a Phase 2a trial in PBC, subjects demonstrated statistically significant reductions in ALP, GGT, ALT and AST ($p < 0.05$) without generally exacerbating pruritus. All these observations support the view that M70 offers a safe and effective, non-invasive pharmacological approach to reduce serum bile acid and decrease the damaging effects of high bile acid levels in the liver and the debilitating pruritus often associated with cholestatic liver diseases. Accordingly, these results support that M70 can be effective in treating liver cholestatic diseases, such as PSC and other orphan BARs.

5.16 Example 16

[0494] This example shows that M70 improved liver function in preclinical studies.

[0495] M70 potently represses *in vitro* CYP7a1 expression in primary human hepatocytes, or liver cells, and *in vivo* CYP7a1 expression in mice. In addition, an average reduction of 81% in serum C4 concentrations was observed in cynomolgus monkeys treated for six days with FGF19 (1 mg/kg subcutaneous daily injection) relative to control. Furthermore, preclinical studies using two *in vivo* models of cholestasis showed that inhibiting *de novo* bile acid synthesis through the CYP7a1 pathway with M70 showed statistically significant improvements in biochemical markers of liver function in mice.

[0496] Study Design and Results: The first model, bile duct ligation (BDL), uses a surgical method to transect the common bile duct and prevent bile flow out of the liver and induce a state of cholestasis. Mice that were subjected to BDL and received M70 showed a statistically significant reduction of serum bile acids ($p < 0.001$) and improvements in biochemical markers of liver damage, such as alkaline phosphatase (ALP), alkaline aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT), following BDL surgery.

[0497] The results shown in FIG. 9 compare the results from the control group (the mice were subjected to BDL, but did not receive any treatment), a group receiving M70, a group receiving INT-747 (Intercept Pharmaceuticals, Inc.; an FXR agonist ligand and novel bile acid analogue shown to be efficacious in treating humans with PBC in Phase 3 studies), and a group receiving bezafibrate (a

drug that is not approved for the treatment of PBC but is nevertheless sometimes prescribed off-label by some physicians).

[0498] Notably, as shown in FIG. 9, M70 reduced circulating bile acid levels and improved liver function in the BDL animal model.

[0499] Mice treated with ANIT, represent an animal model in which the cholestatic state is pharmacologically induced by chemical treatment that leads to damage of the cells that line the bile ducts.

[0500] As shown in FIG. 10, ANIT-treated mice showed a statistically significant elevation in serum bile acids ($p < 0.01$) and an impaired liver function, similar to profiles of human patients suffering from cholestatic disease. As with the BDL model, inhibiting *de novo* bile acid synthesis through the classical pathway with M70 resulted in statistically significant improvements in biochemical markers of liver function ($p < 0.001$) in the ANIT model.

[0501] The *Mdr2* knockout mouse model of chronic cholestasis and liver inflammation resembles many aspects of human PSC. In a study in which M70 was continuously expressed in *Mdr2* knockout mice for 24 weeks, reduced serum levels of total bile acid, normalized liver enzymes such as ALP, ALT and AST, and reduced liver weight was observed.

[0502] Overall, these data further confirmed that M70 is a non-tumorigenic FGF19 variant that can effectively treat PSC and PBC and other manifestations of BARs. Results from a range of nonclinical safety studies indicated that M70 is safe and well-tolerated and support the dosing range and duration of treatment in clinical trials. Thus, M70 can be a safe and effective pharmacological approach to reducing serum bile acids and decreasing the damaging effects of high bile acid levels in the liver and, potentially, the debilitating pruritus often associated with cholestatic liver diseases.

5.17 Example 17

[0503] This example describes a Phase 2, randomized, double blind, placebo controlled, parallel group, multiple center study to evaluate the safety, tolerability and pharmacodynamic activity of M70 in combination with ursodeoxycholic acid (UDCA) administered for 28 days in patients with PBC, and shows the role of M70 in treating human patients.

[0504] PBC is a chronic cholestatic liver disease in which the bile ducts become inflamed and are slowly destroyed by an apparent autoimmune reaction, driving bile acid build-up in the liver and, eventually, leading to irreversible scarring. Although a large proportion of patients are asymptomatic at diagnosis, common symptoms of pruritus and fatigue can develop as the disease progresses. The

one approved treatment in the United States, UDCA has been shown to slow disease progression in some patients, but only approximately one-third of patients with PBC fully respond to treatment.

[0505] Study design and results: A Phase 2a PBC trial was designed to investigate the effects of M70 in combination with UDCA after 28 days of treatment, compared to control. Eligible subjects were randomized to control or one of two treatment groups, including a high dose (3.0 mg) or a low dose (0.3 mg) of M70.

Table 15: Clinical Trial Design on PBC treatment by M70)

Study Population	Primary Outcome Measure	Primary Outcome Results	Selected Secondary Outcomes	Safety and Tolerability
PBC subjects on UDCA for at least 12 months with an incomplete response	Change in ALP (absolute international units per liter, or IU/L, %) from baseline at Day 28	- Statistically significant ALP reductions with both doses 0.3 mg: -49 IU/L (-15.8%) 3 mg: -69 IU/L (-19.2%)	- Liver enzymes: statistically significant reduction in ALT, AST and GGT at both dose levels vs. placebo ($p < 0.05$) - Serum C4: reduction observed with 3 mg dose - Cholesterol: no statistically significant change	- No statistically significant evidence of drug-induced pruritus - Majority of adverse events were mild or moderate - One serious adverse event reported (not drug related)

[0506] All subjects completed the 28-day treatment phase of the study and were eligible to participate in a 52-week extension trial, also referred to as the Phase 2b trial in PBC subjects. The Phase 2a trial achieved statistical significance in the primary endpoint (change in ALP from baseline, as noted below) at both doses. There were improvements in a number of secondary endpoints (change in the biochemical markers, ALT, AST, GGT, C4, fasting serum bile levels and pruritus and fatigue), including: (1) statistically significant percentage reduction in ALP from baseline to Day 28 with both M70 doses (0.3 mg = -15.8%, p -value = 0.009; 3.0 mg = -19.2%, p -value = 0.003); (2) marked reductions in other markers of liver injury, including ALT (0.3 mg = -17.5 IU/L; 3.0 mg = -26.7 IU/L), AST (0.3 mg = -10.9 IU/L; 3.0 mg = -15.3 IU/L) and GGT (0.3 mg = -28.2 IU/L; 3.0 mg = -50.9 IU/L); (3) no statistically significant change in pruritus in either M70 treatment arm; and (4) acceptable safety and tolerability profile with no drug-related safety signals. Most adverse events were mild, with a single serious adverse event that was deemed not related to treatment. The most frequent adverse events were mild headache and mild lower GI symptoms. The lower GI symptoms

were observed in 21% of the 0.3 mg and 43% of the 3 mg cohorts, compared to 13% of the control group. Mild injection site reactions were also observed more frequently with M70.

[0507] The Phase 2b trial was designed as a 52-week extension to enable subjects from the Phase 2a 28-day PBC study to get access to M70 for an extended period and thus allow collection of data on the longer term safety profile and disease impact of M70. An analysis of available data was performed for those subjects that transitioned from the Phase 2a study and reached 12 weeks of treatment. A reduction of ALP from baseline was observed in all groups at that time point, with the lowest dose (0.3 mg) cohort achieving a statistically significant reduction ($p=0.004$). In the Phase 2b PBC trial, M70 has thus far exhibited a safety and tolerability profile consistent with that seen in the Phase 2a PBC trial.

[0508] While UDCA is the only treatment approved for PBC in the United States, there are several treatments in development. INT-747, an FXR agonist ligand and novel bile acid analogue, is one such treatment. FXR is a nuclear receptor involved in regulating the expression of numerous genes, including the gene that produces the FGF19 hormone. Although INT-747's Phase 3 trial demonstrated a statistically significant effect on ALP reduction ($p<0.0001$), the drug nearly doubled the rate of pruritus in PBC subjects as compared to control (68% and 38% at the 10 mg and placebo doses, respectively), perhaps as a consequence of introducing a bile acid analog into the livers of subjects suffering from excessive bile acid accumulation.

5.18 Example 18

[0509] This example discussed the role of M70 for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic cholestatic liver disease, characterized by progressive inflammation, fibrosis and obstruction of the bile ducts leading to cholestasis and, in most cases, liver failure and an increased risk of liver cancer. Though cholestatic symptoms will eventually present, patients can remain asymptomatic and undiagnosed for several years. The median life expectancy after diagnosis with PSC is 12 to 18 years without liver transplantation and, even in the case of liver transplanted patients, PSC returns in 30% to 50% of patients within ten years. PSC is often associated with ulcerative colitis and also appears to have overlap with other forms of autoimmune disease, including autoimmune hepatitis and autoimmune pancreatitis. The patient population is estimated to be between 50,000 and 132,000 in the United States and Europe, with a 2:1 incidence in men versus women and a particularly high incidence in northern Europe. There are no approved therapeutics for the treatment of PSC, but liver transplantation is the most frequent treatment approach in end-stage PSC, making it the fifth leading indication for liver transplant in the United

States. Many PSC patients suffer from the same pruritus symptoms of PBC and for which there are currently no drug treatments available.

[0510] The bile acid synthesis-inhibiting properties of M70 can help slow the progression of PSC by reducing the pool of bile acid in the obstructed bile ducts and thereby lessening the impact on liver fibrosis.

[0511] Study design: The study of M70 in PSC subjects will explore the activity of the compound in approximately 60 subjects in a 12-week, randomized, placebo-controlled, double-blind, multi-center trial. The subjects will be confirmed PSC patients as assessed by elevated ALP and cholangiography or liver biopsy with no evidence of cirrhosis or advanced liver disease. The primary endpoint will be change in ALP from baseline at 12 weeks of treatment. The study is designed to investigate the effects of M70 on changes from baseline in other biochemical markers associated with PSC, such as ALT, GGT and bilirubin, serum bile acid, C4, pruritus and inflammatory bowel disease symptoms, following daily dosing over 12 weeks.

5.19 Example 19

[0512] This example describes a Phase 2 randomized, double blind, placebo controlled, parallel group, multiple center study to evaluate the safety, tolerability and activity of M70 administered for 28 days to participants with type 2 diabetes

[0513] Study Design: A four-week, randomized, double-blind, multi-center trial was conducted to evaluate M70 in subjects with type 2 diabetes. As a consequence of the contribution of obesity and insulin resistance to both conditions, there is a substantial overlap in the prevalence of type 2 diabetes and NASH patients.

[0514] The type 2 diabetes trial was also designed to measure several of the metabolic parameters that are believed to play a role in the disease progression of NAFLD and NASH, including indicators of insulin sensitivity, triglyceride levels and liver enzyme levels. Three doses of M70 were tested in subjects with type 2 diabetes inadequately controlled by metformin to assess changes from baseline in biochemical markers associated with type 2 diabetes, such as fasting plasma glucose and stimulated glucose/insulin.

[0515] The primary endpoint measured by this trial was the change in fasting plasma glucose after 28 days of treatment. Although this endpoint was not different in the M70 subjects as compared to the control arm, there were trends towards improvement in insulin sensitivity, as measured by HOMA-IR and a statistically significant weight loss observed in the 10 mg group, which lost an average of 2.6 kilograms over the 28 days of treatment ($p < 0.041$). Moreover, there was a statistically

significant reduction in triglycerides with the 2 mg ($p=0.009$) and 10 mg ($p=0.007$) doses and dose-dependent reductions in ALT, or alanine transaminase, and AST, or aspartate transaminase, consistent with improvements in liver health. The trial further established that M70 improves both metabolic and liver health in a patient population that closely resembles NASH patients.

Table 16: Clinical Trial Design on Type 2 Diabetes treatment by M70

Study Population	Primary Outcome Measure	Primary Outcome Results	Selected Secondary Outcomes	Safety and Tolerability
Type 2 diabetes subjects inadequately controlled by metformin	Change in fasting plasma glucose (FPG) from baseline at Day 28	No statistically significant reduction in FPG	- HOMA-IR: statistically significant reduction at 10 mg dose ($p=0.001$) - Body weight: statistically significant reduction at 10 mg dose ($p=0.019$) - Serum triglycerides: statistically significant reduction at 2 and 10 mg doses ($p=0.009$ and $p=0.007$, respectively) - Liver enzymes: reduction in ALT and AST - Cholesterol: statistically significant increase ($p<0.05$)	- No serious adverse events reported - Majority of adverse events were mild or moderate

[0516] Overall, M70 was well tolerated at each dose. There were no serious adverse events reported. These preclinical and clinical data suggest that M70 offers a potentially novel approach in the treatment of NASH by reducing body weight and triglyceride levels and improving insulin sensitivity to combat the metabolic drivers of the disease, while also reducing bile acid synthesis to combat the liver damage caused by pooling of toxic bile acid.

6. Sequence Listing

[0517] The present specification is being filed with a computer readable form (CRF) copy of the Sequence Listing. The CRF entitled 13370-038-228_SEQLIST.txt, which was created on November 6, 2016 and is 262,144 bytes in size, is identical to the paper copy of the Sequence Listing and is incorporated herein by reference in its entirety.

Claims

What is Claimed is:

1. A method for preventing or treating a bile acid related disorder (BARD), or a symptom thereof, in a subject comprising administering to the subject an effective amount of a peptide, wherein the peptide has an amino acid sequence comprising or consisting of:
MRDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIK
AVALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEK
HRLPVSLSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDS
MDPFGLVTGLEAVRSPSF EK (M70) (SEQ ID NO:70); or

RDSSPLVHYGWGDPIRLRHLYTSGPHGLSSCFLRIRADGVVDCARGQSAHSLLEIKA
VALRTVAIKGVHVSRYLCMGADGKMQGLLQYSEEDCAFEIIIIRPDGYNVYRSEKHR
LPVSLSSAKQRQLYKNRGFLPLSHFLPMLPMVPEEPEDLRGHLESDFSSPLETDSM
DPFGLVTGLEAVRSPSF EK (M69) (SEQ ID NO:69)

2. A method for preventing or treating a BARD, or a symptom thereof, in a subject comprising administering to the subject an effective amount of a peptide, wherein the peptide comprises:
 - a) an N-terminal region comprising at least seven amino acid residues, the N-terminal region having a first amino acid position and a last amino acid position, wherein the N-terminal region comprises DSSPL (SEQ ID NO:121) or DASPH (SEQ ID NO:122); and
 - b) a C-terminal region comprising a portion of SEQ ID NO:99 [FGF19], the C-terminal region having a first amino acid position and a last amino acid position,
wherein the C-terminal region comprises amino acid residues 16-29 of SEQ ID NO:99 [FGF19], WGDPIRLRHLYTSG (SEQ ID NO:169), wherein the W residue corresponds to the first amino acid position of the C-terminal region.

3. The method of claim 1 or 2, wherein the BARD, or symptom thereof, is improved as compared to baseline.

4. The method of claim 3, wherein baseline is a pre-dose baseline.

5. The method of any one of claims 1 to 4, wherein the BARD is non-alcoholic fatty liver disease (NAFLD).
6. The method of any one of claims 1 to 5, wherein the method results in an improvement of the NAFLD activity score (NAS).
7. The method of any one of claims 1 to 5, wherein the BARD is hepatic fibrosis.
8. The method of any one of claims 1 to 5, wherein the BARD is nonalcoholic steatohepatitis (NASH).
9. The method of claim 8, wherein the subject has biopsy-confirmed NASH.
10. The method of any one of claims 1 to 5, wherein the BARD is cholestatic liver disease.
11. The method of claim 10, wherein the cholestatic liver disease is primary sclerosing cholangitis (PSC).
12. The method of claim 10, wherein the cholestatic liver disease is primary biliary cirrhosis (PBC).
13. The method of claim 10, wherein the cholestatic liver disease is intrahepatic cholestasis of pregnancy.
14. The method of claim 10, wherein the cholestatic liver disease is alcoholic hepatitis.
15. The method of claim 10, wherein the cholestatic liver disease is drug-induced cholestasis.
16. The method of any one of claims 1 to 15, wherein the method results in a decrease in liver steatosis.
17. The method of any one of claims 1 to 16, wherein the method results in a decrease in liver inflammation.
18. The method of claim 17, wherein the liver inflammation is lobular inflammation.
19. The method of any one of claims 1 to 18, wherein the method results in a decrease in hepatocyte ballooning.

20. The method of any one of claims 1 to 19, wherein the method results in a reduction of CYP7a1 levels in the subject.
21. The method of any one of claims 1 to 20, wherein the method results in a reduction of serum bile acid levels in the subject.
22. The method of any one of claims 1 to 21, wherein the method results in a reduction of triglycerides in the subject.
23. The method of any one of claims 1 to 22, wherein the method results in a reduction in alkaline phosphatase (ALP) levels in the subject.
24. The method of claim 23, wherein the ALP levels are reduced at least 10% in the subject.
25. The method of claim 23, wherein the ALP levels are reduced at least 15% in the subject.
26. The method of any one of claims 1 to 25, wherein the method results in a reduction in alkaline aminotransferase (ALT) levels in the subject.
27. The method of any one of claims 1 to 26, wherein the method results in a reduction in aspartate aminotransferase (AST) levels in the subject.
28. The method of any one of claims 1 to 27, wherein the method results in a reduction in gamma-glutamyltransferase (GGT) levels in the subject.
29. The method of any one of claims 1 to 28, wherein the method results in an improvement in a biochemical marker of liver function.
30. The method of claim 29, wherein the biochemical marker of liver function is an enzyme.
31. The method of claim 30, wherein the enzyme is ALP.
32. The method of claim 30, wherein the enzyme is ALT.
33. The method of claim 30, wherein the enzyme is AST.
34. The method of claim 30, wherein the enzyme is GGT.

35. The method of any one of claims 1 to 34, wherein the method results in a reduction in cholesterol levels in the subject.
36. The method of any one of claims 1 to 35, wherein the method results in a reduction in glucose levels in the subject.
37. The method of any one of claims 1 to 36, wherein the method results in an improvement in insulin resistance in the subject.
38. The method of any one of claims 1 to 37, wherein the method results in an improvement in insulin sensitivity in the subject.
39. The method of claim 38, wherein insulin sensitivity is as measured by HOMA-IR.
40. The method of any one of claims 1 to 39, wherein the method results in a reduction in body weight in the subject.
41. The method of any one of claims 1 to 40, wherein the method results in a reduction in liver weight in the subject.
42. The method of any one of claims 1 to 41, wherein the method results in a decrease in bilirubin levels in the subject.
43. The method of any one of claims 1 to 42, wherein the method results in a decrease in a serum biomarker of early fibrosis in the subject.
44. The method of any one of claims 1 to 43, wherein the method results in the reduction of serum C4 levels in the subject.
45. The method of claim 44, wherein serum C4 levels are decreased by at least 50% in the subject.
46. The method of claim 44 or 45, wherein the reduction in serum C4 levels is a mean reduction in C4 levels.
47. The method of claim 46, wherein the mean reduction in serum C4 levels is at least 90%.

48. The method of any one of claims 44 to 47, wherein the serum C4 levels are decreased as compared to the serum C4 levels in the subject prior to administration of the peptide.
49. The method of any one of claims 1 to 48, wherein the method results in an improvement in liver function in the subject.
50. The method of any one of claims 1 to 49, wherein the method results in improving pruritus, or a symptom thereof, in the subject.
51. The method of claim 50, wherein the pruritus symptom is itching.
52. The method of claim 50, wherein the pruritus symptom is impaired sleep.
53. The method of claim 50, wherein the pruritus symptom is depression.
54. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 0.3 mg.
55. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 1 mg.
56. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 2 mg.
57. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 3 mg.
58. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 5 mg.
59. The method of any one of claims 1 to 53, wherein the peptide is administered at a dose of 10 mg.
60. The method of any one of claims 1 to 59, wherein the peptide is administered once a day.
61. The method of any one of claims 1 to 59, wherein the peptide is administered twice a day.

62. The method of any one of claims 1 to 61, wherein the peptide is administered subcutaneously.
63. The method of any one of claims 1 to 62, wherein the peptide is administered for 7 days or longer.
64. The method of any one of claims 1 to 62, wherein the peptide is administered for 14 days or longer.
65. The method of any one of claims 1 to 62, wherein the peptide is administered for 21 days or longer.
66. The method of any one of claims 1 to 62, wherein the peptide is administered for 28 days or longer.
67. The method of any one of claims 1 to 62, wherein the peptide is administered for 1 to 12 months.
68. The method of any one of claims 1 to 62, wherein the peptide is administered for 12 months.
69. The method of any one of claims 1 to 62, wherein the peptide is administered for more than 12 months.
70. The method of any one of claims 1 to 69, wherein the peptide is administered in combination with ursodeoxycholic acid (UDCA).
71. The method of any one of claims 1 to 70, wherein the subject is overweight.
72. The method of any one of claims 1 to 70, wherein the subject is obese.
73. The method of any one of claims 1 to 72, wherein the subject has diabetes.
74. The method of any one of claims 1 to 72, wherein the subject does not have diabetes.
75. The method of claim 73 or 74, wherein the diabetes is type 2 diabetes.
76. The method of any one of claims 1 to 75, wherein the peptide is fused with an immunoglobulin Fc region.

FIG.1




FIG.2A-2D




FIG.3A-3D





FIG. 4A-4D



5 / 11

FIG. 5

Variants	Cyp7a1 IC50 (pM)	Relative Cyp7a1 Expression	HCC Score
Saline-treated	n/a	100%	0.00
FGF19	2.3	4%	1.00
FGF21	n/a	35%	0.00
M1	1.1	10%	0.04
M2	0.9	2%	0.06
M5	n/a	100%	0.00
M32	n/a	100%	0.00
M69	8.6	0.5%	0.00
M70	4.8	0.2%	0.00
M75	34	12%	0.00
M76	n/a	17%	0.00
M85	3.6	16%	0.00
M90	859	100%	1.00
M96	n/a	100%	1.00
M98	n/a	100%	1.00

FIG. 6





FIG. 7



M70




FIG. 8




FIG. 9




FIG. 10

11 / 11




FIG. 11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/060944

Box No. I **Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

a. ☒ forming part of the international application as filed:

☒ in the form of an Annex C/ST.25 text file.

☐ on paper or in the form of an image file.

b. ☐ furnished together with the international application under PCT Rule 13*ter*. 1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.

c. ☐ furnished subsequent to the international filing date for the purposes of international search only:

☐ in the form of an Annex C/ST.25 text file (Rule 13*ter*. 1(a)).

☐ on paper or in the form of an image file (Rule 13*ter*. 1(b) and Administrative Instructions, Section 713).

2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

SEQ ID NOs: 69, 70, 99, 121, 122, and 169 were searched.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/060944

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-76
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/060944

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 38/18; A61P 3/00; C07K 14/50; C07K 19/00 (2016.01)

CPC - A61K 38/00; A61K 38/1825; C07K 14/50; C07K 2319/00 (2016.11)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC - A61K 38/18; A61P 3/00; C07K 14/50; C07K 19/00

CPC - A61K 38/00; A61K 38/1825; C07K 14/50; C07K 2319/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 435/375; 514/1.1; 514/9.1; 536/23.4 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, ProQuest, PubMed

Search terms used: bile acid related disorder FGF19 FGF21

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2014/0243266 A1 (NGM BIOPHARMACEUTICALS, INC) 28 August 2014 (28.08.2014) entire document	1-4
A	WO 2013/033452 A2 (AMGEN INC. et al) 07 March 2013 (07.03.2013) entire document	1-4
A	WO 2014/152089 A1 (GEORGETOWN UNIVERSITY) 25 September 2014 (25.09.2014) entire document	1-4
A	US 2005/0250684 A1 (HEUER et al) 10 November 2005 (10.11.2005) entire document	1-4
A	LIN et al. "Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice," Cell Metabolism, 07 May 2013 (07.05.2013), Vol. 17, Pgs. 779-789. entire document	1-4

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 December 2016

Date of mailing of the international search report

24 JAN 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, VA 22313 1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774